



Chicago Fall Group Meeting

SEPTEMBER 18-20, 2025

A Welcome, and a Farewell

This is my 26th – and final – chair’s Group Meeting welcome message.

Much has changed since I became SWOG Group Chair in the spring of 2013, and change is a major theme of this fall’s meeting – as demonstrated in our plenary presentations, and as seen in the impact of recent federal mandates on session content and priorities.

Thursday morning, our Leadership Council on Representation will hold an open forum, where implications of some of the more recent changes in our research environment will be discussed. Friday’s plenary will include perspectives on a dozen years of evolution in clinical and translational oncology research and in the NCI’s cooperative group network itself.

Like change itself, our drive to carry out research that improves patients’ lives is widespread and unrelenting (in a good way!), which is why on Friday we’ll hold kickoff sessions for two of our newest trials: our S2427 bladder preservation study (the BRIGHT trial) and the Triple Switch study in prostate cancer, a SWOG joint endeavor with the Canadian Cancer Trials Group.

And, despite the fact accrual to NCI trials has undergone a federally mandated

pause at most of our international sites, our SWOG Latin America Initiative Symposium *will* take place, Saturday morning, with a focus on breast cancer research.


In recognizing and embracing change, I want to welcome our incoming group chairs, Drs. Primo Lara and Dawn Hershman, and wish them huge success. I can’t imagine more capable hands to pass the leadership baton to.

As I did in closing my first chair’s welcome message in April 2013, I again “invite you to join me in making this an intensely productive and enjoyable group meeting!” We had a few in between 2013 and now, and I don’t expect things to change as we cross my finish line together.

Plus ça change, ...!



Charles D. Blanke, MD
SWOG Group Chair



Group Meeting Index

Chair's Welcome Message	2
Schedule of Events	4-6
Plenary Session	7
Top Accruals & Top Performing Sites	8-9
Funding & Career Development Opportunities	10
SWOG Leadership Council on Representation	11
Clinical Trials Partnership (CTP) Update Forum	12
Take Action Symposium	13 & 25
Lung-MAP Update Forum	14 & 23
Geriatric Assessment Workshop	15
NCORP Research Base Clinical Trials Workshop	16
S2427 (BRIGHT Trial) Kickoff	17
Triple Switch Prostate Trial Kickoff	18
Group Meeting App & CME Credit Information	19-20
SWOG Administrative & Research Support Committees	21
Future Meeting Dates	21
Adolescent and Young Adults Committee	22
Pharmaceutical Sciences & Drug Information Joint Meeting	24
Jeri & Noboru Oishi Symposium	26
SWOG Latin America Initiative Symposium	27
ORP Site Operations	28
VA Committee	29
Committee Agendas and Accrual Reports	
Barlogie-Salmon Myeloma Committee	30-33
Breast Committee	34-40
Cancer Control & Prevention Committee Leadership	41
Cancer Care Delivery Committee	42-44
Early Therapeutics & Rare Cancers Committee	56-59
Gastrointestinal Committee	60-69
Genitourinary Committee	70-79
Immunotherapeutics Committee	80-81
Leukemia Committee	82-86
Lung Committee	87-94
Lymphoma Committee	95-98
Melanoma Committee	99-101
Palliative Care Committee	45-46
Prevention, Screening, and Surveillance Committee	47-49
Radiation Oncology Committee	102
Symptom Management and Survivorship Committee	50-55
SWOG Publications	103-107

SWOG 2025 Fall Programs

Ballroom Level ■ | Concourse Level ■ | Lobby Level ■

FALL PROGRAM-AT-A-GLANCE

REGISTRATION & INFORMATION DESK:

REGENCY FOYER, BALLROOM LEVEL, WEST TOWER ■

WEDNESDAY: 3:30 PM - 6:00 PM

THURSDAY-FRIDAY: 6:30 AM - 5:00 PM

SATURDAY: 7:00 AM - 12:00 PM

HOPE FOUNDATION INFORMATION DESK:

REGENCY FOYER, BALLROOM LEVEL, WEST TOWER ■

THURSDAY-FRIDAY: 8:00 AM - 5:00 PM

SATURDAY: 8:00 - 11:00 AM

EXHIBITS

REGENCY FOYER, BALLROOM LEVEL, WEST TOWER ■



THURSDAY-FRIDAY:
8:00 AM - 5:00 PM

GO TO MEETING APP ONLINE,
[SWOG.ORG/MEETINGAPPF25](https://swog.org/meetingappf25)

MEETING
ROOM/
LEVEL

WEDNESDAY, SEPTEMBER 17, 2025

4:00 PM-6:00 PM:	Quality Initiative Meeting (Closed Business Meeting)	TORONTO ■
4:30 PM-6:00 PM:	Hope Foundation Board Meeting (Hope Board Members Only)	SOLDIER FIELD ■
6:00 PM-8:30 PM:	NCORP Research Base Executive Committee (Committee Members Only)	ACAPULCO ■

THURSDAY, SEPTEMBER 18, 2025

7:30 AM-8:00 AM:	NCORP Research Base Clinical Trials Workshop Check-In	REGENCY D FOYER ■
------------------	---	-------------------

7:30 AM-8:30 AM:	Leadership Council on Representation Open Forum (All members welcome)	COMISKEY ■
8:00 AM-9:00 AM:	VA Liaison Meeting (Closed Business Meeting)	HAYMARKET ■
8:00 AM-11:00 AM:	SWOG NCORP Research Base Clinical Trials Workshop	REGENCY D ■
8:30 AM-10:30 AM:	Advocates Committee (Committee Members Only)	ACAPULCO ■
11:00 AM-1:30 PM:	Early Therapeutics and Rare Cancers Committee	REGENCY C ■
11:30 AM-1:30 PM:	Cancer Care Delivery Committee	REGENCY A ■
12:00 PM-2:00 PM:	Lymphoma Working Group (Working Group Members Only)	ACAPULCO ■
1:00 PM-2:30 PM:	Site Operations	REGENCY D ■
2:00 PM-3:30 PM:	SWOG Tissue Banking Meeting (Closed Business Meeting)	GOLD COAST ■
2:00 PM-3:30 PM:	Bone Marrow & Stem Cell Transplantation Committee	COMISKEY ■
2:00 PM-4:00 PM:	Prevention, Screening, and Surveillance Committee	REGENCY A ■
2:30 PM-4:00 PM:	Professional Review Cmte (Closed Business Meeting)	SOLDIER FIELD ■
2:30 PM-4:30 PM:	Take Action Symposium presented by the SWOG Recruitment & Retention Cmte	REGENCY B ■
2:30 PM-4:30 PM:	Lung Radiation/ Surgery Subcommittee (Committee Members Only)	SAN FRANCISCO ■
3:00 PM-5:00 PM:	Sarcoma Working Group of the Early Therapeutics Committee	ACAPULCO ■
4:00 PM-5:00 PM:	Clinical Trials Partnerships Update Forum	REGENCY D ■
4:00 PM-6:00 PM:	Radiation Oncology Committee	COMISKEY ■
4:30 PM-6:30 PM:	Symptom Management and Survivorship Committee	REGENCY A ■
5:00 PM-6:00 PM:	Conflict Mgmt Committee (Closed Business Meeting)	SOLDIER FIELD ■

SWOG 2025 Fall Programs

THURSDAY, SEPTEMBER 18, 2025 | CONTINUED

5:00 PM–6:30 PM:	VA Committee	WATER TOWER ■
5:00 PM–7:00 PM:	Lymphoma Committee	REGENCY C ■
5:00 PM–7:00 PM:	Lung Working Group (Working Group Members Only)	TORONTO ■
6:00 PM–7:30 PM:	Early Therapeutics and Rare Cancers Working Group Dinner Retreat (Invitation Only)	GOLD COAST ■
6:30 PM–8:30 PM:	Breast Committee Social (Invitation Only)	WRIGLEY ■

FRIDAY, SEPTEMBER 19, 2025

7:00 AM–8:00 AM:	NCORP/MU-NCORP Site PI Meeting	WATER TOWER ■
7:00 AM–8:00 AM:	Imaging Committee (Committee Members Only)	SAN FRANCISCO ■
7:00 AM–8:00 AM:	Lung-MAP Administrative Meeting (Committee Members Only)	ACAPULCO ■
7:30 AM–8:30 AM:	Clinical Trials Partnerships Scientific Advisory Board (Closed Business Meeting)	SOLDIER FIELD ■
7:30 AM–9:30 AM:	SWOG Data and Safety Monitoring Committee (Closed Business Meeting)	GOLD COAST ■
8:00 AM–9:30 AM:	Surgery Committee	COMISKEY ■
8:00 AM–10:00 AM:	Palliative Care Committee	REGENCY A ■
8:15 AM–9:45 AM:	Lung-MAP Site Coordinators Meeting (Committee Members Only)	ACAPULCO ■
8:30 AM–9:00 AM:	Jeri & Noboru Oishi Symposium Check-In	REGENCY B FOYER ■
8:30 AM–12:00 PM:	Breast Committee and Translational Medicine Working Group (Working Group Members Only)	TORONTO ■
8:30 AM–12:30 PM:	GU Working Group (Committee Members Only)	REGENCY D ■

9:00 AM–10:00 AM:	Lung Community Engagement Subcommittee (Committee Members Only)	SAN FRANCISCO ■
9:00 AM–11:00 AM:	Immunotherapeutics Committee	WATER TOWER ■
9:00 AM–11:30 AM:	Jeri & Noboru Oishi Symposium	REGENCY B ■
9:15 AM–11:15 AM:	Pharmaceutical Sciences Committee and Drug Information Subcommittee	SOLDIER FIELD ■
10:00 AM–11:30 AM:	Hands-On Geriatric Assessment: Practical Tools for Age-Inclusive Cancer Research	CRYSTAL A ■
10:00 AM–1:30 PM:	GI Committee and Translational Medicine Working Group (Working Group Members Only)	COMISKEY ■
10:30 AM–12:30 PM:	Leukemia Working Group (Working Group Members Only)	ACAPULCO ■
11:30 AM–1:30 PM:	Nursing Research and Advanced Practice Provider Subcommittee (Invitation Only)	GOLD COAST ■
11:30 AM–1:30 PM:	Lung Committee	REGENCY A ■
12:00 PM–1:30 PM:	Oncology Research Professionals (ORP) Open Forum	CRYSTAL B ■
1:00 PM–2:00 PM:	Plenary Reception (Light Hors D'oeuvres)	REGENCY FOYER ■
2:00 PM–4:00 PM:	Plenary Session	REGENCY BC ■
4:15 PM–5:15 PM:	S2427 GU Kick Off Meeting	COMISKEY ■
4:15 PM–5:45 PM:	Lung-MAP Update Forum	CRYSTAL A ■
4:15 PM–5:45 PM:	Adolescent and Young Adult (AYA) Committee	TORONTO ■
4:15 PM–6:15 PM:	Breast Committee	REGENCY A ■
4:30 PM–6:30 PM:	GI Committee	REGENCY D ■
4:30 PM–6:30 PM:	Leukemia Committee	WATER TOWER ■
5:30 PM–6:30 PM:	Triple Switch (CCTG-PR26) GU Kick Off Meeting	COMISKEY ■

SWOG 2025 Fall Programs

FRIDAY, SEPTEMBER 19, 2025 | CONTINUED

6:00 PM–7:00 PM: Executive Reception
(Invitation Only)

6:45 PM–8:30 PM: Group Reception

CRYSTAL BALLROOM ■

SATURDAY, SEPTEMBER 20, 2025

7:00 AM–7:45 AM: Board of Governors
(Board Members Only)

REGENCY A ■

8:00 AM–9:00 AM: Committee Chairs
(Committee Chairs Only)

REGENCY A ■

8:00 AM–10:00 AM: Mentoring APPs
(Invitation Only)

GOLD COAST ■

9:00 AM–10:30 AM: SWOG Latin America
Initiative Symposium

REGENCY D ■

9:15 AM–10:45 AM: Quality Assurance
Committee (Committee
Members Only)

SAN FRANCISCO ■

9:15 AM–11:15 AM: GU Committee

REGENCY A ■

9:15 AM–11:15 AM: Melanoma Working
Group (Working Group
Members Only)

COMISKEY ■

9:30 AM–11:30 AM: Myeloma Working
Group (Working Group
Members Only)

ACAPULCO ■

11:30 AM–1:30 PM: Melanoma Committee

REGENCY D ■

12:00 PM–2:00 PM: Barlogie-Salmon Myeloma
Committee

COMISKEY ■

Make a Will, Make a Way

The Hope Foundation has a partnership with FreeWill, an easy online resource that more than 100 Hope supporters in 12 different states have used to create their wills and leave a gift to Hope. You can make a will in as little as 20 minutes, at no cost, and get peace of mind for the future.



CREATE A LEGACY WITH THE
CAUSES YOU CARE ABOUT MOST.
THEHOPEFOUNDATION.ORG/DONATE



THE HOPE
FOUNDATION
FOR CANCER RESEARCH



Run for
a Cause
with Hope
– Make
Miles
Mean
More and
Advance
SWOG's
Mission!

Starting in 2026, The Hope Foundation is partnering to engage with marathons in Miami, Dublin, Rome, and Washington, DC, to raise awareness and funding for SWOG. Whether a marathon is a bucket-list goal you've been contemplating or a part of your regular running practice, we'd love to help you get there with a Hope-sponsored bib!

Visit us at The Hope Foundation table near registration to learn more.

Plenary

13 Years of SWOG Plenaries: The More Things Change, ... the More Things Change!

As we move toward another SWOG leadership transition, we will look at how the field of oncology research has evolved since SWOG's last group leadership change. That transition coincided with the remodeling of the former cooperative group system to the current NCI National Clinical Trials Network. How have oncology research and the NCTN evolved and adapted since 2012?

FRIDAY, SEPT 19 · 2 – 4 PM CT · REGENCY BC (BALLROOM LEVEL) / HYBRID



Chair's Welcome and Update

Charles D. Blanke, MD

SWOG Group Chair

Knight Cancer Institute, Oregon Health & Science University



Translational Medicine: Introduction

Lee M. Ellis, MD

SWOG Vice-Chair for Translational Medicine

Florida Atlantic University



Breaking Barriers in SCLC: A Hope Foundation–Supported Clinical Trial to Reverse Immunotherapy Resistance in SCLC

Sonam Puri, MD

Moffitt Cancer Center



From Bench to Bedside to Breakthrough: AI-Accelerated Advances in Oncology and SWOG

Sandip Patel, MD

University of California – San Diego



General Plenary: 13 Years of SWOG Plenaries: The More Things Change, ... The More Things Change!

Charles D. Blanke, MD

SWOG Group Chair

Knight Cancer Institute, Oregon Health & Science University



Advances in Clinical Cancer Research 2012 to 2025: NSCLC as a Model

David Gandara, MD

University of California – Davis



Changes in Oncology TM Research

James Rae, PhD

SWOG Executive Officer for Translational Medicine
University of Michigan



The NCI and the NCTN: A Long and Winding Road

Richard L. Schilsky, MD

University of Chicago & Past Chair, Cancer and Leukemia Group B

THANKS TO Our Top Accruers

Patient volunteers power our trials —
and SWOG members connect us to them.

**SWOG-Credited Registrations to SWOG-Managed Trials
January 1 through June 30, 2025**



- Instituto Nacional De Cancerologia de Mexico
- Yale University - Yale Cancer Center LAPS
- Northwestern University LAPS
- University of Texas Health Science Center at San Antonio
- Moffitt Cancer Center



- Southeast Clinical Oncology Research Consortium NCORP
- Michigan Cancer Research Consortium NCORP
- Heartland Cancer Research NCORP
- Kaiser Permanente NCI Community Oncology Research Program
- University of Kansas Cancer Center - MCA Rural MU NCORP
- Cancer Research of Wisconsin and Northern Michigan Consortium



THANKS TO

Our Top Performing Sites

To help our data management sites track their performance relative to that of others, we have developed a new metric based on the quality and timeliness of data and biospecimen submissions. Data management institutions with at least 10 SWOG accruals in the prior 13 months are scored on this scale.

The members below are SWOG's top-performing sites for the period of January 1, 2025 to June 30, 2025



Lahey Hospital and Medical Center

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Cancer Research for the Ozarks NCORP

Instituto Nacional de Enfermedades Neoplásicas

Massachusetts Veterans Epidemiology Research and Information Center

Sutter Cancer Research Consortium

The West Clinic - Wolf River

Oregon Health and Science University

University of Kentucky/Markey Cancer Center

Cancer Research Consortium of West Michigan NCORP

Case Western Reserve University

Upcoming Funding & Career Development Opportunities

- Meyskens Lectureship:
November 1
- APP Mentorship Program:
November 21
- Impact Award LOIs:
January 15
- Vogelzang Scholars Program:
January 15
- CRA/Nurse Travel Support:
January 15

See all Hope Foundation programs at
thehopefoundation.org/funding-opportunities

THE **HOPE**
FOUNDATION
FOR CANCER RESEARCH

SWOG Leadership Council on Representation

OPEN FORUM

THURSDAY, SEPT 18, 7:30 – 8:30 AM CT – COMISKEY (CONCOURSE LEVEL)

All are invited!

The forum will be a chance to learn about the Council's work and to ask questions and have your voice heard.

“Forward-Looking Language Strategies to Broaden Membership and Clinical Trial Participation”

KEYNOTE BY:

Carolyn Reyes-Guzman, PhD, MPH

Program Director and Epidemiologist
Tobacco Control Research Branch,
Behavioral Research Program,
Division of Cancer Control & Population Sciences,
National Cancer Institute



SWOG Clinical Trials Partnerships (CTP)

HOW SWOG PARTNERS WITH INDUSTRY TO CONDUCT CANCER CLINICAL TRIALS

SWOG CTP Update Forum

THURSDAY, SEPT 18 • 4 – 5 PM CT • REGENCY D (BALLROOM LEVEL) / HYBRID

- **SWOG CTP overview**
 - Joint study development process
 - Scientific areas of interest
 - Types of trials
- **Site logistics: operations & data management**
 - Feasibility survey outreach and site selection
 - Site funding and contracts
- **Updates from behind the scenes**
 - From Group Statistician Michael LeBlanc, PhD
 - From the trenches – site ORP report
- **SWOG CTP trials in development:**
 - **21CTP.Breast01 (MONITOR):** Phase II platform trial using circulating tumor DNA to monitor treatment response in HR+, HER2- metastatic breast cancer
 - **25CTP.Breast02 (SAVE):** Randomized trial of second line adjuvant therapy for molecular relapse in stage I-III hormone receptor positive, HER2 negative breast cancer
 - **26CTP.Leuk02:** Randomized phase IV trial for treatment-naïve, cytopenic myelofibrosis

• **SWOG CTP active trials**

- **21CTP.Leuk01:** Phase II trial for patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
- **21CTP.HN01 (CAPT-HN):** Phase II study in recurrent metastatic head and neck cancer with cohorts defined by type of and/or response to prior systemic therapies



To apply to open either study, complete its feasibility survey at swogctp.org/trials.

- Accrual completed: TROPION Breast 03 FDA registration trial
- Novel CTP projects and other collaborative opportunities

All are invited!

Learn more: swogctp.org

Email us: CTP@swog.org

THURSDAY, SEPT 18 • 2:30 – 4:30 PM CT • REGENCY B (BALLROOM LEVEL)

Take Action Symposium

MAKING THE CASE:

Bridging the Gap in Clinical Research for Rural Communities

Join us for an interactive discussion focused on clinical research in rural communities.

Presented by SWOG Recruitment & Retention Committee

OBJECTIVES:

- 1** *Increase understanding and enhance awareness of the unique challenges rural communities face when participating in research.*
- 2** *Explore solutions that can facilitate clinical research in rural settings.*
- 3** *Discuss strategies for engaging rural health systems, clinicians, and patients in clinical trials.*



TARGET AUDIENCE:

Investigators, research professionals, and patient advocates, NCORP and LAPS

SPEAKERS



Shellie Ellis, MA, PhD
University of Wisconsin



Raymond U. Osarogiagbon, MD
Baptist Memorial Health
Care/ Mid-South MU NCORP
SWOG Executive Officer for
Community Engagement



Courtney Chun
Hawaii MU NCORP



**Christa Braun-Inglis, DNP,
APRN, FNP-BC, AOCNP**
Hawaii MU NCORP

Lung-MAP Update Forum

FRIDAY, SEPT 19 • 4:15 – 5:45 PM CT • CRYSTAL A (LOBBY LEVEL)

The session will include presentations on

- Lung-MAP accomplishments, publications, and enrollment
- Lung-MAP accrual enhancement efforts and website updates
- Active studies
 - S1900G: screening patients for MET amplification
 - S1900J: NSCLC with MET amplification
 - S1900K: NSCLC with METex14-skipping mutation
 - S1800E: acquired resistance to chemo & IO (non-match)
- Studies in development
- Engaging with Lung-MAP
 - Through the Drug Selection Committee
 - Through the Translational Medicine Committee

The Lung-MAP leadership encourages all who work with lung cancer research to attend!

Generation 3 of the Lung-MAP protocol is testing new treatments for patients with advanced non-small cell lung cancer

Lung-MAP 3.0 allows sites to enroll patients using prior tissue test results from most CLIA-certified next-generation sequencing platforms. Those results can be used to assign a patient to a Lung-MAP sub-study at time of progression.

A regularly updated list of dozens of accepted commercial and academic tests is linked from swog.org/lung-map-resources.

Lung-MAP 3.0 is bringing more new NSCLC treatments to more patients at more sites.



Geriatric Assessment Workshop

Hands-On Geriatric Assessment: Practical Tools for Age-Inclusive Cancer Research

FRIDAY, SEPT 19 • 10 – 11:30 AM CT • CRYSTAL A (LOBBY LEVEL)

This interactive workshop will introduce you to the principles and application of the geriatric assessment (GA) and demonstrate how it can be included in the workflow of cancer clinical trials.

Using a case-based format, you will gain hands-on experience with validated tools to assess key geriatric domains relevant to oncology research, including



**functional
status**



nutrition



social support



cognition



**chemotherapy
toxicity risk**

By the end of the session, you will understand which tools are most appropriate for use in clinical trials and how geriatric assessment can help ensure that studies are more inclusive of older adults.

The workshop is open to anyone interested in improving the representation of older adults in cancer research. We welcome participation from physicians, nurses, advanced practice providers (APPs), physician assistants (PAs), and research team members across all disease sites.

Whether you are new to geriatric oncology or looking to strengthen your approach to age-inclusive trial design, this session will provide practical tools and hands-on experience to support your work.

WORKSHOP FACULTY



Sukeshi Patel
Arora, MD



Efrat Dotan,
MD



Kristen Haase,
PhD




Elizabeth
Kessler, MD



Jyotsana
Parajuli,
PhD, MGS, RN



Mina S. Sedrak,
MD, MS



Enrique Soto
Pérez de Celis,
MD, PhD –
Organizer

NCORP Research Base Clinical Trials Workshop

THURSDAY, SEPT 18 • 8 – 11 AM CT • REGENCY D (BALLROOM LEVEL)

(CHECK-IN BEGINS 7:30 AM)

SWOG members, oncology research professionals, and investigators at NCORP and NCTN institutions are encouraged to attend the informative presentations and breakout session discussions.

PRESENTATION SESSION: in-person & virtual (hybrid)

BREAKOUT SESSIONS: in-person only

The workshop provides information on conducting clinical trials in the following four SWOG committees:

Cancer Care
Delivery



Palliative
Care



Prevention,
Screening, and
Surveillance



Symptom
Management and
Survivorship



This is an opportunity for information sharing between attendees, SWOG NCORP research staff, study chairs, the NCI, and other subject matter experts.

Society of Clinical Research Associates (SOCRA) continuing education credit is available.



A program of the National Cancer Institute
of the National Institutes of Health



S2427 (BRIGHT Trial) Kickoff

S2427 BRIGHT: The next stage in bladder preservation trials

If a patient's muscle-invasive bladder cancer responds completely to neoadjuvant therapy, can radiation therapy plus immunotherapy help them keep their bladder?

FRIDAY, SEPT 19 • 4:15 – 5:15 PM CT • COMISKEY (CONCOURSE LEVEL)

Pre-registration, patients get standard-of-care neoadjuvant therapy followed by TURBT with systematic biopsies. Patients with cT0 or cT1 disease at that time may be eligible to enroll.

S2427 participants get radiation therapy plus 12 months of pembrolizumab

Primary endpoint: 3-year bladder-intact event-free survival (BI-EFS)

S2427 BRIGHT activates in early September! Its enrollment goal is 111 patients.

WE NEED YOU AND YOUR INSTITUTION TO MAKE THIS TRIAL A SUCCESS!

Attend the S2427 Kickoff
to learn more and get answers to your questions.

STUDY CHAIR



*Leslie Ballas,
MD*



*Siamak
Daneshmand,
MD*



*Abhishek
Tripathi, MD*



*Daniel A.
Hamstra,
MD, PhD*



*James B. Yu,
MD, MHS*

CO-CHAIRS

BIostatisticians



Sam Callis, MS



*Catherine
Tangen, DrPH*

PATIENT ADVOCATE



*Darrell
Nakagawa*

Triple Switch Prostate Trial Kickoff

CCTG-PR.26: A Joint CCTG and SWOG Clinical Trial

FRIDAY, SEPT 19 • 5:30 – 6:30 PM CT • COMISKEY (CONCOURSE LEVEL)






CCTG-PR.26, A Randomized Phase III Clinical Trial for the Addition of Docetaxel to ARPI in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Suboptimal PSA Response


Triple Switch (CCTG-PR.26) was co-developed by Dr. Michael Ong (CCTG) and Dr. Alexandra Sokolova (SWOG) and is co-led by SWOG and CCTG.

The trial enrolls patients with mCSPC at a unique time point in their journey – 6 to 12 months after starting therapy, before disease progression.

This kickoff session will educate members on how to approach the enrollment challenges posed by this unusual registration timing.

Drs. Ong and Sokolova will also

-  **discuss**
 how they have been successful in identifying patients
-  **share**
 study rationale data that can be used when presenting Triple Switch to patients
-  **share**
 the experience of the first patient enrolled
-  **discuss**
 unique features of the protocol
-  **answer**
 questions about the protocol, data forms, and more



STUDY CHAIRS

Alexandra Sokolova, MD




Michael Ong, MD

Continuing Medical Education (CME) credits will not be offered



We apologize for any inconvenience this may cause. We remain committed to presenting the highest quality meeting content and to supporting valuable professional learning and networking. We will continue to broadcast many sessions virtually, as we understand the value of sharing SWOG work as widely as possible.

Please direct questions to info@thehopefoundation.org.



SWOG.ORG UPDATE

To help members find tools and resources more quickly, we have consolidated the site's role-based Workbenches into a new drop-down menu.

SWOG Group Meeting App

The SWOG group meeting mobile app is your pocket guide to the meeting.

With key features in an easily accessible format, the app not only replaces the agenda book as your on-site companion, it contains the agenda book – as a PDF you can flip through on your phone.

WITH THE APP, YOU CAN

1 create your schedule, annotate sessions, and add them to your calendar

3 access zoom links for hybrid sessions

2 access a directory of presenters and session leaders, along with other attendees who have opted in

The app also offers a single go-to source for speakers and presenters:

- find travel and lodging information and links
- view speaker guidelines, update photo and bio

4 access individual meeting agendas

5 access the full agenda book itself as a PDF



swog.org/appleappf25



swog.org/googleappf25

DON'T HAVE THE APP YET?

Download the app with the appropriate QR code or URL at left

DON'T WANT TO INSTALL YET ANOTHER APP?

Access the web browser version with the QR code or URL at right.



swog.org/meetingappf25



Committees

Administrative Committees

Board of Governors

Charles D. Blanke, MD

Publications

Hagen F. Kennecke, MD

Conflict Management

Paul Okunieff, MD

Professional Review

Paul Hesketh, MD

Research Support Committees

Adolescent and Young Adult

Rebecca Johnson, MD

Pharmaceutical Sciences

Siu-Fun Wong, PharmD

Joyce Lee, PharmD

Bone Marrow and Stem Cell Transplantation

Patrick J. Stiff, MD

Radiation Oncology

Chul Ha, MD

Imaging

Lawrence H. Schwartz, MD

Recruitment and Retention

Allison Caban-Holt, PhD

Oncology Research Professionals

*Connie Szczepanek,
RN, BSN, CCRP*

Surgery

Syed A. Ahmad, MD

Veterans Affairs

Stephen D. Bartlett, RPh

Patient Advocates

Anne Marie Mercurio

Barbara Segarra-Vazquez, DHSc

Future Meeting Dates

2026

SPRING

April 29-May 2

San Francisco, CA

FALL

October 7-10

Chicago, IL

2027

SPRING

April 14-17

San Francisco, CA

FALL

October 13-16

Chicago, IL

Adolescent and Young Adult Committee

Friday, September 19 • 4:15 – 5:45 PM CT
Toronto (Ballroom Level)

Agenda

- A. Welcome**
Becky Johnson, MD
- B. ALTE213: Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults with Cancer**
Becky Johnson, MD
- C. AREN1721, a Randomized Phase 2 Trial of Axitinib+Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/translocation Renal Cell Carcinoma (tRCC) Across All Age Groups**
Mamta Parikh, MD
- D. ACCL1931: A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy**
Etan Orgel, MD
- E. Addressing Financial Toxicity in AYAs with Cancer**
Melissa Beauchemin, PhD
- F. Patient Advocate Perspectives: Life with advanced cancer**
JJ Singleton & Valerie Fraser
- G. Goals of Care at End of Life for AYAs with Cancer**
Rosemarie Mastropolo, MD
- H. Q&A and Discussion**

Lung-MAP Update Forum

Friday, September 19 • 4:15-5:45 PM CT • Crystal A (Lobby Level)

Agenda

4:15 p.m.	Welcome, Introductions, Lung-MAP Accomplishments	Karen Reckamp & Saïama Waqar
4:20 p.m.	Manuscript and Accrual Updates	Mary Redman
4:25 p.m.	Accrual Enhancement Committee Updates and Lung-MAP Website Updates	Frank DeSanto
Active Study Updates		
4:40 p.m.	S1900G	Sarah Goldberg
4:45 p.m.	S1900J	Christian Rolfo
4:50 p.m.	S1900K	Paul K. Paik
4:55 p.m.	S1800E	Saïama Waqar
5:00 p.m.	Q&A	Karen Reckamp
Developing Study Updates		
5:15 p.m.	S1900N	Jonathan Riess
Engaging with Lung-MAP		
5:20 p.m.	How to Engage with Lung-MAP Through the Drug Selection Committee	Konstantin Dragnev
5:25 p.m.	How to Engage with Lung-MAP Through the Translational Medicine Committee	Joel Neal
5:30 p.m.	Q&A	Karen Reckamp

Pharmaceutical Sciences Committee and Drug Information Subcommittee Joint Meeting (Hybrid)

Friday, September 19 • 9:15 – 11:15 AM CT •

Soldier Field (Concourse Level)

Agenda

Committee Reports:

1. Committee Administrative Reports – Joyce Lee/Siu Fun Wong

- Introduction of new members
- Review of PSC Member Roster
- Summary report of committee activities
 - NCI CTEP Policy Advanced Practice Providers (APP) Task Force
 - Pharmaceutical-related events and inquiries
 - NCTN grant renewal

2. Remarks from Outgoing Chair – Siu Fun Wong

3. Drug Information Sub-Committee Report – Vy Bui

- Updates from the Chair – Vy Bui
 - Workload summary of drug section requests
 - Introduction of resident and fellow writers for 2025-2026 academic year
 - Updates on Section 3 development process and participants
- Protocol review activities – Holly Chan/Jorge Avila
- Aurora roll-out updates – Matt Boron

4. APP Initial Order Build Focus Group – Siu Fun Wong/Joyce Lee

Members: Holly Chan, Safae Chouraichi, Dawud Ellayan, Joyce Lee, Jane Rogers, Christa Braun-Inglis, Maggie Ryan, Dana Reeves

- Program development updates

5. Pharmacist Liaison Reports – All

- Review of Pharmacist Liaison Assignment List
- Disease Committee Liaison Pharmacist Reports – Open

6. Open Agenda – All

TAKE ACTION SYMPOSIUM: Making the Case: Bridging the Gap in Clinical Research for Rural Communities

PRESENTED BY
SWOG Recruitment & Retention Committee

THURSDAY, SEPTEMBER 18 · 2:30 – 4:30PM CT · REGENCY B (BALLROOM LEVEL)

Target Audience: Investigators, research professionals, and patient advocates, NCORP and LAPS

Objectives:

1. Increase understanding and enhance awareness of the unique challenges rural communities face when participating in research.
2. Explore solutions that can facilitate clinical research in rural settings.
3. Discuss strategies for engaging rural health systems, clinicians, and patients in clinical trials.

MODERATOR AND SPEAKER/PANELIST OUTLINE

<i>Time</i>	<i>Topic</i>	<i>Presenter</i>
2:30 - 2:35	Welcome & Announcements	<i>Allison Caban-Holt, PhD, RRC Chair</i>
2:35 - 3:00	<i>Unique challenges rural communities face when participating in research</i>	<i>Shellie Ellis, MA, PhD University of Wisconsin</i>
3:00 - 3:25	<i>Solutions to facilitate clinical research in a rural setting</i>	<i>Raymond U. Osarogiagbon, MD, Baptist Memorial Health Care/ Mid-South MU NCORP</i>
3:25 - 3:50	<i>Strategies to engage rural health systems, clinicians, and patients in clinical trials</i>	<i>Courtney Chun & Christa Braun-Inglis, DNP Hawaii MU NCORP</i>
3:50 - 4:25	Panel Discussions/Questions & Answers	<i>All Panelists</i>
4:25 - 4:30	Session Evaluation and Wrap Up	<i>Allison Caban-Holt, PhD, RRC Chair</i>

ORP Jeri & Noboru Oishi Symposium

FRIDAY, SEPTEMBER 19 • 9:00 – 11:30 AM CT • REGENCY B (BALLROOM LEVEL)

<i>Time</i>	<i>Topic</i>	<i>Speaker</i>
8:30 – 9:00 am	Registration	Connie Szczepanek, RN, BSN Joyce Nancarrow Tull, RN, MSN
9:00 – 9:10 am	Opening Remarks & Announcements	Connie Szczepanek, RN, BSN Joyce Nancarrow Tull, RN, MSN
9:10 - 9:40 am	CTSU	Krishna Chothwani
9:40 - 10:00 am	QA	Laura Gonzales, RN, BSN SWOG QA Manager
10:00 -10:30 am	SWOG Communications: • Plain Language Initiative • Patient Summaries	Andrea Mongler and Frank DeSanto SWOG Communications
10:30 – 11:10 am	Cancer Research in the Community	Raymond Osarogiagbon, MD Baptist Medical Group, Baptist Cancer Center, Memphis, TN
11:10 – 11:30 am	Panel Presentation: Community Engagement in our Various Sites	Raymond Osarogiagbon, MD Baptist Cancer Center, Memphis, TN Christina Weiss Yale Cancer Center Amy Jo Koffarnus Crown Cancer Consortium Joyce Nancarrow Tull, RN, MSN UCSD Moores Cancer Center

PLEASE KEEP THIS AGENDA AND USE THE FILLABLE STATEMENT BELOW TO DOCUMENT YOUR EDUCATIONAL CREDITS.

I certify that I attended _____ hours of this meeting. The topics of the meeting contribute to my education and professional advancement in clinical research.

Signature _____ Date _____

Oishi Education Sub-Committee Co-Chairs:

Kira Pavlik, MPH, CCRP – kira.pavlik@yale.edu

Joyce Nancarrow Tull, MSN, RN – jtull@health.ucsd.edu

SWOG Latin America Initiative Symposium

Saturday, September 20 • 9:00 – 10:30 AM CT

Regency D (Ballroom Level)

Agenda

Introductory Remarks, *Drs. Mariana Chávez MacGregor and Paula Cabrera Galeana*

Part 1: Breast Cancer Collaborations

*High-Risk Breast Cancer Research in Latin America: Trends, Gaps, and Opportunities, **Dr. Paula Cabrera Galeana***

*Breast Committee Opportunities in the NCTN Network, **Dr. Lajos Pusztai***

*Breast Cancer Research beyond the Breast Committee: The Role of NCORP, **Dr. Lynn Henry***

Part 2: Round Table Discussion about Collaborations

Open discussion about areas of current and future breast cancer collaborations

Part 3: Site Focus: SLAI Activities and Breast Patient Overview by Country

*Focus: SWOG in Peru, **Dr. Tatiana Vidaurre***

*SLAI activities and breast cancer patient overview by country, **all SLAI sites***

Closing Remarks, *Drs. Mariana Chávez MacGregor and Paula Cabrera Galeana*



ORP Site Operations Committee **Thursday, September 18 • 1:00 – 2:30 PM CT** **Regency D (Ballroom Level)**

<i>Fall 2025 SWOG Site Operations Meeting Agenda</i>		
<i>Open, Welcome, and Announcements</i>		<i>Site Operations Committee</i>
<i>SWOG Updates</i>		
<i>SWOG Network Operations Center</i>	<i>Administration & Study Funding</i>	<i>Pat Mize</i>
	<i>Quality Assurance (QA)</i>	<i>Laura Gonzales</i>
	<i>Information Systems</i>	<i>Cara Laubach</i>
<i>Statistics & Data Management Center (SDMC)</i>		<i>Kari Chansky</i>
<i>General Updates</i>		
<i>NCI Community Oncology Research Program (NCORP)</i>		<i>Brandy Heckman-Stoddard</i>
<i>Pharmaceutical Management Branch (PMB)</i>		<i>Matt Boron</i>
<i>Closing Remarks</i>		<i>Site Operations Committee</i>

VA Committee

Thursday, September 18 • 5:00 - 6:30 PM CT • Water Tower (Concourse Level)

Agenda

A. Introductions and Opening Comments - [Stephen Bartlett, RPh, MSPH](#)

B. Active Studies for VA Consideration

1. S2114, "A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma" - [Dr. Helen Ma, Tibor Rubin VA Medical Center, VA Liaison, Lymphoma Committee](#)
2. S2207, "A Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma" [Dr. Helen Ma, Tibor Rubin VA Medical Center, VA Liaison, Lymphoma Committee](#)

C. VA Disease Committee Liaisons

1. Updates, Ongoing Goals

- New VA Liaison; In-person VA Liaison meeting
[Dr. Jessica D. McDermott, Rocky Mountain Regional VA Medical Ctr](#)

2. Open Committee Roles

Cancer Care Delivery
Melanoma

Immunotherapeutics
Palliative Care

Lung
Prevention, Screening, & Surveillance

How to Apply - vamember@swog.org

D. Current VA Stats

Accrual/sites – SWOG Report

E. Other

1. 'All-call' -- seeking interested parties for VA Committee Co-Chair position!
2. "Close to Me" – funded program that provides cancer care/chemo infusions at several VA community clinics
3. Centralization of required VA reviews

F. Future Meetings

- 1st Qtr. 2026 Virtual VA Committee Meeting – February 10, 2026, 2:00-3:00pm CT
- SWOG Spring 2026 Group Meeting - April 30-May 2, 2026, San Francisco, CA

Barlogie-Salmon Myeloma Committee

Leadership

Chair: Robert Z. Orlowski, MD, PhD
 Vice-Chair: Sikander Ailawadhi, MD
 Vice-Chair: Jing Christine Ye, MD, MSc
 Executive Officer: Susan M. O'Brien, MD
 Statisticians: Antje Hoering, PhD
 Rachael Sexton, MS
 Adam Rosenthal, MS
 Sara Threlkel, BS

Scientific Leadership

Translational Medicine: Brian A. Walker, BSc, PhD
 Radiation: Chelsea Camille Pinnix, MD, PhD
 Surgery: TBD
 Imaging: Eric M. Rohren, MD, PhD
 Pathology: Pei Lin, MD
 Early Therapeutics: Frits van Rhee, MD, PhD

Designates

NCORP Representative: Charles S. Kuzma, MD
 Veterans Affairs: Thomas R. Chauncey, MD, PhD
 Data Coordinators: Aubrey Gilmore, BA
 Daria Chugina, MD, CCRPS
 Pasarlai Ahmadzai, MD, MPH
 Oncology Research Professionals:
 CRA: Brandon Richard Labadie, CCRP
 Nurse: TBD
 Patient Advocate: Paul Gater, MPhil
 Pharmaceutical Science: Craig Elg, PharmD
 Ila M. Saunders, PharmD
 Protocol Project Manager: Amy Doyle
 Clinical Trials Program Manager: Sharon Palmer

Time/Location

Saturday, September 20, 2025 12:00 p.m. - 2:00 p.m.
 Room: Comiskey (Concourse Level, West Tower)

Active Studies

S2005, "A Phase II Randomized Study Comparing Ibrutinib and Rituximab vs. Venetoclax and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) /Lymphoplasmacytic Lymphoma (LPL)" Drs. S. Ailawadhi and D. Bhutani. Activated: 6/24/21; Closed: 4/8/22; Re-activated: 2/15/24.

S2209, "A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or Ineligible for Stem

Cell Transplant Comparing Upfront Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd)." Drs. S. Ailawadhi, J.C. Ye, B. Lipe, T. Chauncey, and K. Gowin. Activated 5/30/23.

S2213, "Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCD) Induction Followed by Autologous Stem Cell Transplant or D-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis." Drs. P. Hagen, T. Parker, and S. Sidana. Activated 12/1/23.

A062102, "Randomized Phase II Study of Ixerdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients." Dr. R. Banerjee. Activated: 4/4/24.

EEA173, "Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma." Dr. E. Manasanch. Activated: 4/30/19.

EEA181, "Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial." Dr. K. Gowin. Activated: 10/27/20.

Developing Studies

S2508, "A Phase II Study of Optimal Induction and MRD Driven Maintenance Therapy for Patients with Newly Diagnosed High-Risk Multiple Myeloma (HRMM)." Drs. B. Lipe, J.C. Ye, and A. Cowan.

Closed Studies

S1803, "Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Drs. A. Krishnan and S. Chhabra. Activated: 6/27/19. Registration Step 1 Closed to Accrual: 1/15/25.

S1211, "A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)." Drs. S. Usmani, S. Ailawadhi, and B. Lipe. Activated: 11/9/12. Closed: 6/2/16.

S1702, "A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis." Drs. T. Parker and V. Sanchorawala. Activated: 3/8/18; Closed: 9/30/19.

S1304, "A Phase II Randomized Study Comparing Two Doses of Carfilzomib with Dexamethasone for Relapse/Refractory Multiple Myeloma." Dr. S.

Barlogie-Salmon Myeloma Committee

Ailawadhi. Activated: 10/18/13. Closed: 11/6/15; Complete: 1/17/25.

SXXXX, "Developing Smoldering Multiple Myeloma Concept." Drs. P. Hagen and A. Cowan.

S0777, "Frontline Phase III Rev/Dex +/- Vel, no upfront transplant." Dr. B. Durie. Activated: 4/1/18. Closed: 2/2/12.

S0120, "A prospective Observational Biologic Study of Asymptomatic Patients with Monoclonal Gammopathy and Plasmaproliferative Disorders." Dr. M. Dhodapkar. Activated: 6/1/02. Closed: 4/1/11.

CTN 0702, "Single Autologous Transplant with or without RVD Consolidation versus Tandem Transplant and Maintenance Therapy." Dr. G. Somlo. Activated: 2/15/11. Closed: 11/15/13.

A061402, "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone." Dr. A. Kuman Mahindra. Activated: 12/23/15. Closed: 8/15/19.

E1A11, "Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)." Drs. S. Kumar, A. Cohen, and J. Zonder. Activated: 11/22/13. Closed: 1/29/19.

E3A06 (was S0909), "High-risk AMM – Revlimid." Dr. M. Dhodopkar. Activated: 1/17/11. Closed: 7/14/17.

A061402, "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone." Dr. A. Kumar Mahindra. Activated: 12/23/15. Closed: 8/15/19.

EAA171, "Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM)." Dr. S. Kumar. Activated: 6/1/21. Closed 3/3/23.

Proposed Studies-Pre-Triage/On Hold

SXXXX, "A Phase III Study for Evaluation of Maintenance Cessation in Patients with Standard Risk Myeloma Achieving Minimal Residual Disease Negativity." Dr. M. Mohyuddin.

SXXXX, "A Phase II Trial of BCMA Bi-Specific T-Cell Engager (BiTE) Teclistamab in Patients with Systemic Light Chain (AL) Amyloidosis." Drs. D. Bhutani and K. Dorritie.

SXXXX, "An Open-Label Randomized Phase 2 Trial to Incorporate Venetoclax in Early Relapsed t(11;14) Multiple Myeloma." Dr. R. Chakraborty.

Barlogie-Salmon Myeloma Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	<i>S1803</i>	<i>S2005</i>	<i>S2209</i>	<i>S2213</i>	<i>EAA173</i>	<i>EAA181</i>
AdventHealth Parker	2	-	-	-	-	-
Banner University Medical Center - Tucson	12	-	-	-	-	5
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	2	-	-	-
Boston Medical Center	5	-	-	2	-	-
CWRU Case Comprehensive Cancer Center LAPS	28	-	-	-	8	-
Cancer Research for the Ozarks NCORP	2	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	5	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	2	-	-	-
Cedars-Sinai Medical Center	6	-	-	-	-	-
City of Hope Comprehensive Cancer Center	118	-	3	-	-	-
Columbia University Minority Underserved NCORP	-	-	1	3	-	-
Columbus NCI Community Oncology Research Program	5	-	-	-	-	-
CommonSpirit Health Research Institute	1	-	3	-	-	-
Dayton NCI Community Oncology Research Program	5	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	3	-	-	2	-	-
Essentia Health NCI Community Oncology Research Program	-	-	1	-	-	-
Fred Hutchinson Cancer Research Center LAPS	7	-	-	-	8	-
Froedtert and the Medical College of Wisconsin LAPS	12	-	-	-	-	-
Georgia NCI Community Oncology Research Program	21	-	-	-	-	-
Gulf South Minority Underserved NCORP	4	-	-	-	-	-
Heartland Cancer Research NCORP	12	-	4	-	-	-
Henry Ford Health Providence Southfield Hospital	2	-	-	-	1	1
Henry Ford Hospital	-	-	-	-	2	-
Houston Methodist Hospital	13	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	60	-	7	-	-	-
Kansas City Veterans Affairs Medical Center	-	-	4	-	-	-
Lahey Hospital and Medical Center	3	-	-	-	-	-
Loyola University Medical Center	26	-	-	-	3	3
MU Health Care Goldschmidt Cancer Center	3	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	1	-	-	2
Medical University of South Carolina Minority Underserved NCORP	60	-	-	-	1	1
Mercy Medical Center - Des Moines	1	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	13	-	1	-	-	-
Moffitt Cancer Center	48	-	-	-	-	-

Barlogie-Salmon Myeloma Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	<i>S1803</i>	<i>S2005</i>	<i>S2209</i>	<i>S2213</i>	<i>EAA173</i>	<i>EAA181</i>
Montana Cancer Consortium NCORP	1	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	2	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	1	-
New Mexico Minority Underserved NCORP	15	-	4	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	5	-	-	-	-	-
Oregon Health and Science University	33	-	1	-	3	9
Pacific Cancer Research Consortium NCORP	18	-	6	1	-	-
Regents of the University of Michigan	16	-	-	-	-	-
Riverside Methodist Hospital	3	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	3	-	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	2	-	-	-
Tulane University School of Medicine	-	-	-	-	2	-
UC Davis Comprehensive Cancer Center LAPS	27	-	7	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	19	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	4	-	-	5
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	2
University of Kansas Cancer Center - MCA Rural MU NCORP	35	-	-	1	-	-
University of Kentucky/Markey Cancer Center	4	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	3	-	-	-	-	-
University of Rochester LAPS	15	2	2	-	-	3
University of Texas Health Science Center at San Antonio	23	1	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	27	-	1	1	-	-
University of Utah - Huntsman Cancer Institute LAPS	16	-	-	-	4	2
Upstate Carolina Consortium Community Oncology Research Program	4	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	1	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	18	-	2	-	-	-
Wisconsin NCI Community Oncology Research Program	23	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	4	1	4	8
ALLIANCE	226	2	10	2	-	-
CCTG	21	-	-	-	-	-
ECOG-ACRIN	188	9	6	1	-	-
NRG	116	1	5	-	-	-
Total	1,337	15	85	14	37	41

Breast Committee

Leadership

Chair: Lajos Pusztai, MD, PhD
 Vice-Chair: Priyanka Sharma, MD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Allison Meisner, PhD
 Shay Bellasea, MS
 Danika Lew, MA
 Matt Chansky, BS

Scientific Leadership

Translational Medicine: Alastair M. Thompson, MD
 Andrew K. Godwin, PhD
 Radiation Oncology: Reshma Jagsi, MD
 Surgery: Joshua M.V. Mammen, MD, PhD
 Imaging: TBD
 Pathology: David L. Rimm, MD, PhD
 Early Therapeutics: Stephanie L. Graff, MD

Designates

Adolescent & Young Adults: Erin Elizabeth Roesch, MD
 Cancer Control Liaisons: Mariya Rozenblit, MD (Survivorship)
 Dawn L. Hershman, MD (Cancer Care Delivery)
 Banu Arun, MD (Prevention)
 Helen K. Chew, MD (Symptom Management)
 NCORP Representative: Philip E. Lammers, MD
 Veterans Affairs: Sarah V. Colonna, MD
 Data Coordinators: Aubrey Gilmore, BA
 Gabi Herbert, MS, BS
 Larry G. Kaye
 Kevin Moralda, BS
 Oncology Research Professionals:
 CRAs: Karyn N. Hart, CCRP
 Nurse: Cameo Windham, BSN, RN
 Patient Advocates: Roberta A. Albany
 Ginny Mason, RN, BSN
 Pharmaceutical Science: Jorge G. Avila, PharmD
 Dawud Nael Dawud Ellayan, Pharm D
 Protocol Project Manager: Chris Kippola, BS
 Clinical Trials Program Manager: Sharon Palmer

Time/Location

Friday, September 19, 2025 4:15 p.m. - 6:15 p.m.
 Room: Regency A (Ballroom Level, West Tower)

Agenda

4:15 - 4:20 pm Welcome and Introductions - Lajos Pusztai, MD, DPhil (Chair) and Priyanka Sharma, MD (Vice-chair)

Educational Session

De-Novo Stage IV Breast Cancer: Time to Reconsider Treatment Paradigms?

4:20 - 4:35 pm Update on staging and evolving clinical presentation - Jennifer Plichta, MD, MS, Duke Cancer Institute

4:35 - 4:50 pm Optimization of systemic and local therapy for De-novo stage IV breast cancer - Mariya Rozenblit, MD, Yale School of Medicine

4:50 - 5:05 pm Q&A

Committee Business and Updates

5:05 - 5:15 pm Publication update – Allison Meisner, PhD

5:15 - 5:25 pm Patient Advocate update – Ginny Mason and Roberta Albany

5:25 - 5:35 pm Translational Medicine Sub-Committee update - Alastair Thompson, MD and Andrew K. Godwin, PhD

5:35 - 6:05 pm Review of open CTSU trials

6:05 - 6:15 pm Reports from Committee Liaisons

NCORP: Philip Lammers, MD
 Symptom Management: Lynn Henry, MD, PhD
 Radiotherapy: Reshma Jagsi, MD, PhD
 Surgery: Joshua Mammen, MD
 Cancer Care Delivery: Dawn Hershman, MD
 Prevention: Banu Arun, MD
 Theranostics Subcommittee: Shane Stecklein, MD, PhD & Joanne Mortimer, MD
 Early Therapeutics: Stephanie Graff, MD

6:15 pm Closing Comments and Adjourn

Concepts in Development

S2511, "Randomized Phase III trial of multimodality therapy versus standard of care systemic therapy in HER2 positive (HER2+) de novo (AJCC stage IV) oligometastatic breast cancer with response to initial chemotherapy." Submitted: 5/16/25

Breast Committee

S2512, "ARIA: A Randomized Phase III Trial of Two vs. Three Years of Adjuvant Ribociclib In the Treatment of High-Risk, Hormone Receptor-Positive EARLY-Stage Breast Cancer" Submitted: 6/13/25

S2602, "A Phase II Trial Treating Molecular Relapse in Early Stage Triple Negative Breast Cancer (DETECT-Pilot)" Submitted: TBD

Active Studies

S2206, "Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer." Drs. Cobain and Pusztai. Activated: 10/30/23.

S2212, "Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study." Drs. Sharma and Mitri. Activated: 7/21/23.

CTSU/A011801, "The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib." Dr. O'Sullivan. SWOG Champion: Dr. Murthy. Activated: 1/6/21.

CTSU/CCTG MA.39, "Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer." Dr. Whelan. SWOG Champion: Dr. Jagsi. Activated: 5/30/18.

CTSU/NRG-BR007, "A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)." Dr. White. SWOG Champion: Dr. Shumway. Activated: 6/7/21.

Closed Studies

S1418, "A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy." Drs. Pusztai and Mammen. Activated: 11/15/16; Permanently closed: 6/30/21.

S1207, "Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy." Drs. Chavez-MacGregor and Pusztai. Activated: 9/4/13; Permanently closed: 5/1/19.

S1706, "A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer." Drs. Jagsi and Chalasani. Activated: 9/12/18. Permanently closed: 7/1/24.

S2007, "A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases." Drs. Brenner and Kaklamani. Activated: 12/15/20. Permanently closed: 4/7/25.

CTSU/A011202, "A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy." Dr. Boughey. SWOG Champion: Dr. Mammen. Activated: 2/7/14; Permanently closed: 7/1/22.

CTSU/EA1181, "(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer)" Dr. Tung. SWOG Champions: Breast Committee: Dr. Tang, Imaging Committee: Dr. Lu. Activated: 2/11/20; Permanently closed: 10/19/23.

CTSU/EA1183, "FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE." Dr. Specht. SWOG Champions: Breast Committee: Dr. Linden, Imaging Committee: Dr. Wright. Activated: 4/2/20; Permanently closed: 12/22/23.

CTSU/NRG-BR002, "A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer." Drs. Chmura and White. SWOG Champion: Dr. Jagsi. Activated: 12/24/14; Permanently closed: 5/27/22.

CTSU/NRG-BR003, "A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer." Dr. Valero. SWOG Champion: Dr. Makhoul. Activated: 6/26/15; Permanently closed: 4/22/22.

CTSU/NRG-BR004, "A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer." Dr. Geyer. SWOG Champion: Dr. Cobain. Activated: 3/12/19; Permanently closed: 7/1/22.

Breast Committee

CTSU/NRG-BR005, “A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery.” Dr. Basik. SWOG Champion: Dr. Thompson. Activated: 4/13/17; Permanently closed: 12/2/22.

Active Cancer Survivorship Study

S1501, “Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III.” Drs. Floyd and Leja. Activated: 9/15/17. Arms 1 and 2 permanently closed to accrual: 11/1/24.

Closed Symptom Control and Quality of Life Studies

S1614, “A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors.” Drs. Hwang and Lok. Activated: 2/21/19; Permanently closed: 11/15/22.

S1714, “A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients.” Drs. Trivedi and Hershman. Activated 3/1/19; Permanently closed: 11/15/21.

Active Cancer Care Delivery Studies

S1703, “Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer.” Drs. Accordini and Hershman. Activated: 7/16/18.

Closed Cancer Prevention Study

S1904, “Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE).” Drs. Crew, and Kukafka. Activated: 9/1/20. Permanently closed: 6/14/24.

CTSU/EA1151, “Tomosynthesis Mammographic Imaging Screening Trial (TMIST).” Dr. Pisano. SWOG Champion: Dr. Arun. Activated: 7/6/17. Closed to accrual: 12/20/24.

Closed Early Therapeutics and Rare Cancers Studies

S1609, “DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors.” Drs. Patel and Chae. Activated 1/13/17; Permanently closed: 3/15/23.

CTSU/EAY131, “Molecular Analysis for Therapy Choice (MATCH).” Dr. Flaherty. Activated 8/12/15; Permanently closed: 12/30/22.

Breast Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	S1706	S2007	S2206	S2212	A011801	A012103	A012301	EA1211	MA39	NRGBR007
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	-	-	-	-	-	1
Banner MD Anderson Cancer Center	-	-	-	-	12	-	-	-	-	-
Banner University Medical Center - Tucson	1	-	-	-	-	-	-	-	-	-
Baptist Mem Health Care/Mid South Minority Underserved NCORP	3	-	4	10	-	-	-	2	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	2	3	2	1	-	-	3	-
Boston Medical Center	-	-	-	1	6	1	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	1	-	-	-	-	-	-	2	-
Cancer Research Consortium of West Michigan NCORP	1	-	-	13	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	3	-	-	6	1	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	1	7	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	2	5	15	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	7	4	1	1	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	2	13	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	4	-	1	1	-	-	-	-	-	-
CommonSpirit Health Research Institute	2	-	1	9	-	-	-	-	2	-
Dayton NCI Community Oncology Research Program	-	1	-	-	-	-	-	-	-	-
Desert Regional Medical Center	1	-	-	-	-	-	-	-	1	-
Essentia Health NCI Community Oncology Research Program	-	-	1	2	1	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	5	-	-	4	-	6	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	1	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	2	-	2	8	-	1	-	-	-	-
Gulf South Minority Underserved NCORP	1	-	3	8	-	1	-	1	-	-
Hawaii Minority Underserved NCORP	-	-	-	5	-	-	-	1	-	1
Heartland Cancer Research NCORP	4	-	7	23	1	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	2	-	-	2	2	2	-	-	3	-
Henry Ford Hospital	-	-	3	5	-	3	-	-	-	-
Houston Methodist Hospital	-	-	-	-	2	2	-	-	3	1
Instituto Nacional De Cancerologia de Mexico	-	-	-	5	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	7	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	1	2	1	-	-	-	-	-
Loma Linda University Medical Center	-	-	-	4	-	-	-	-	-	-
Loyola University Medical Center	-	-	1	1	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	1	-	2	-	-	1	-	-	7	-
Michigan Cancer Research Consortium NCORP	4	-	4	15	-	-	-	-	-	-
Montana Cancer Consortium NCORP	1	-	-	6	-	-	1	-	-	-

Breast Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	S1706	S2007	S2206	S2212	A011801	A012103	A012301	EA1211	MA39	NRGBR007
Mount Sinai Hospital	-	-	2	-	-	-	-	-	-	-
MultiCare Tacoma General Hospital	-	-	4	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	5	8	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	6	1	-	-	-	1	-	-	-	-
Northwell Health NCORP	-	1	3	5	-	-	-	-	-	2
Northwestern University LAPS	1	2	-	26	1	1	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	3	-	-	7	-	-	-	-	-	-
Oregon Health and Science University	-	-	4	2	-	-	-	-	-	1
Pacific Cancer Research Consortium NCORP	2	-	9	19	-	-	-	-	4	-
Regents of the University of Michigan	3	-	3	2	2	3	-	-	14	-
Rhode Island Hospital	-	-	-	2	-	-	-	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	-	9	-	-	1	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	1	6	36	1	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	1	3	3	-	-	-	-	3
The Don and Sybil Harrington Cancer Center	3	-	-	-	3	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	20	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	7	-	-	-	-	3	4	-	-	1
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	1	2	-	2	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-	2	-
UPMC Hillman Cancer Center LAPS	1	-	3	4	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	1	-	-	-	4	-
U of Alabama at Birmingham / Deep South Research Consort LAPS	-	2	-	6	-	-	-	-	-	-
University of Arkansas for Medical Sciences	2	-	-	4	2	4	-	-	-	-
University of Colorado Cancer Center LAPS	1	-	1	3	1	-	-	-	2	3
University of Kansas Cancer Center - MCA Rural MU NCORP	4	-	8	11	1	2	-	-	5	3
University of Oklahoma Health Sciences Center LAPS	1	-	2	2	-	-	-	1	-	-
University of Rochester LAPS	1	-	-	-	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	4	6	-	-	-	-	-	-	7
University of Texas MD Anderson Cancer Center LAPS	1	2	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	5	-	-	-	2	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	2	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	2	10	2	-	-	4	3	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-	1	-
Wisconsin NCI Community Oncology Research Program	1	-	-	4	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	4	24	3	-	-	-	-	-
ALLIANCE	18	7	28	141	-	-	-	-	-	-
CCTG	6	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	11	3	34	111	-	-	-	-	-	-
NRG	48	-	19	82	-	-	-	-	-	-
Total	160	28	193	721	55	33	6	9	56	23

Breast Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	NRGBR008	NRGBR009
Arnot Ogden Medical Center/Falck Cancer Center	-	-
Banner MD Anderson Cancer Center	-	-
Banner University Medical Center - Tucson	-	-
Baptist Mem Health Care/Mid South Minority Underserved NCORP	1	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-
Boston Medical Center	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-
Cancer Research Consortium of West Michigan NCORP	-	-
Cancer Research for the Ozarks NCORP	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-
Cedars-Sinai Medical Center	-	-
City of Hope Comprehensive Cancer Center	-	-
Columbia University Minority Underserved NCORP	-	-
CommonSpirit Health Research Institute	-	-
Dayton NCI Community Oncology Research Program	-	-
Desert Regional Medical Center	-	-
Essentia Health NCI Community Oncology Research Program	-	-
Fred Hutchinson Cancer Research Center LAPS	-	3
Georgia Cares Minority Underserved NCORP	-	-
Georgia NCI Community Oncology Research Program	-	-
Gulf South Minority Underserved NCORP	-	-
Hawaii Minority Underserved NCORP	-	-
Heartland Cancer Research NCORP	-	1
Henry Ford Health Providence Southfield Hospital	-	2
Henry Ford Hospital	-	-
Houston Methodist Hospital	-	-
Instituto Nacional De Cancerologia de Mexico	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-
Lahey Hospital and Medical Center	-	-
Loma Linda University Medical Center	-	1
Loyola University Medical Center	-	1
Medical University of South Carolina Minority Underserved NCORP	-	-
Michigan Cancer Research Consortium NCORP	-	-
Montana Cancer Consortium NCORP	-	-
Mount Sinai Hospital	-	-
MultiCare Tacoma General Hospital	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-
New Mexico Minority Underserved NCORP	-	-

Breast Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	NRGBR008	NRGBR009
Northwell Health NCORP	-	-
Northwestern University LAPS	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-
Oregon Health and Science University	-	-
Pacific Cancer Research Consortium NCORP	-	-
Regents of the University of Michigan	-	-
Rhode Island Hospital	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-
Sutter Cancer Research Consortium	-	1
The Don and Sybil Harrington Cancer Center	-	3
The West Clinic - Wolf River	-	2
UC Davis Comprehensive Cancer Center LAPS	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-
UC San Diego Moores Cancer Center	-	-
UPMC Hillman Cancer Center LAPS	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-
University of Arkansas for Medical Sciences	-	-
University of Colorado Cancer Center LAPS	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-
University of Oklahoma Health Sciences Center LAPS	-	-
University of Rochester LAPS	-	-
University of Texas Health Science Center at San Antonio	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	1
Western States Cancer Research NCORP	-	-
Wisconsin NCI Community Oncology Research Program	-	-
Yale University - Yale Cancer Center LAPS	-	-
ALLIANCE	-	-
CCTG	-	-
ECOG-ACRIN	-	-
NRG	-	-
Total	1	15

Cancer Control & Prevention Committees

Leadership

Vice-Chair NCORP: Dawn L. Hershman, MD, MS
 Cancer Care Delivery Committee Co-Chairs: Veena Shankaran, MD
 Scott D. Ramsey, MD, PhD
 Palliative Care Committee Co-Chairs: Robert S. Krouse, MD, FACS
 Marie Bakitas, DNSc, CRNP
 Prevention, Screening & Surveillance
 Committee Co-Chairs: Banu Arun, MD
 Jason A. Zell, DO
 Symptom Management & Survivorship
 Committee Co-Chairs: Michael J. Fisch, MD, MPH
 Norah Lynn Henry, MD, PhD
 Executive Officers: Katherine D. Crew, MD (CCD, Prevention,
 Symptom Management)
 Virginia Sun, PhD, MSN, RN (Palliative)
 Senior Advisor: Frank L. Meyskens, Jr., MD
 Statisticians: Katherine Guthrie, PhD
 Cathy Tangen, DrPH
 Joseph M. Unger, PhD
 Kathryn B. Arnold, MS
 Amy K. Darke, MS
 Danika Lew, MA
 Sarah Colby, MS
 Cathee Till, MS
 Matt Chansky, BS
 Sara Threlkel, BS
 Administrative Lead
 Statistics & Data Management Center (SDMC): Monica Yee, CCRP

Scientific Leadership

NCORP Representative: Scott Edward Delacroix, Jr. MD
 Helen Heng-Shan Moon, MD
 Radiation Oncology Committee: Eileen P. Connolly, MD, PhD (CCD,
 Prevention)
 Kiri A. Cook, MD (Symptom Mgmt & Survivorship)
 Erin F. Gillespie, MD (Symptom Management)
 Surgery Committee: Robert S. Krouse, MD, FACS
 Translational Medicine: James (Jimmy) Rae, PhD

Liaisons

Barlogie-Salmon Myeloma Committee: Charles S. Kuzma, MD
 Breast Committee: Mariya Rozenblit, MD (Survivorship)
 Helen K. Chew, MD (Symptom Management)
 Dawn Hershman, MD, MS (CCD)
 Banu Arun, MD (Prevention)
 Philip Lammers, MD

Early Therapeutics & Rare Cancers: Lara E. Davis, MD (Survivorship)
 Jason M. Prosek, MD
 Gastrointestinal Committee: Jason A. Zell, DO (Prevention)
 Vincent Chung, MD (Palliative)
 Genitourinary Committee: Clara Hwang, MD
 Sarah P. Psutka, MD
 International Liaison: Kathy S. Albain, MD
 Leukemia Committee: Stephanie B. Tsai, MD
 Lung Committee: Gary E. Goodman, MD
 Lymphoma Committee: TBD
 Melanoma Committee: Sancy Leachman, MD, PhD (Prevention)
 Recruitment and Retention: Allison M. Caban-Holt, PhD
 Veterans Affairs: Yeun-Hee Anna Park, MD (Symptom Management)
 Jacqueline Ann Gesek, BSN, RN (Nursing)

Designates

Oncology Research Professionals

CRAs: Amanda R. Dinsdale, MHA, CCRC
 Amy Jo Koffarnus, BS, CCRP
 Racheal Odom, MPH
 Melina D. Rodriguez, BS
 Shirley S. Sui, BS
 Samantha Wright, MS, CCRP
 Nurses: Connie Szczepanek, RN, BSN
 Rachel C. Dooley, BSN, RN, OCN
 Melissa Maria Crane, BSN, RN

Pharmaceutical Sciences Committee: Kimberly McConnell, PharmD
 Data Coordinators: Kim Carvalho, BA
 Sam Dzingle, BA
 Mathew Eng, PharmD
 Manny Kharbanda, BA
 Diane Liggett, BS, CCRP
 Roxanne Topacio, CCRP
 Monica Yee, BA, CCRP
 Recruitment and Retention Specialist: Jamie Sundstrom, BS
 Patient Advocates: Barbara Segarra-Vazquez, DHSc (CCD)
 Hartley "Lee" M. Jones, MBA (Survivorship)
 Cheryl L. Jernigan, CPA (Prevention)
 Valerie Fraser (Palliative)

Sr. Protocol Project Manager (Cancer Care Delivery;
 Prevention): Patricia O'Kane
 Protocol Project Manager (Symptom Management): Elsie Duran
 Protocol Project Manager (Palliative Care): Andrea Garcia
 Clinical Trials Program Manager (Palliative Care): Laura Gildner, MS
 Clinical Trials Program Manager (CCD; Prevention;
 Symptom Management): Sarah Cantu

Cancer Care Delivery (CCD) Committee

Leadership

Co-Chairs: Scott D. Ramsey, MD, PhD
 Veena Shankaran, MD, MS

Time/Location

Thursday, September 18, 2025 11:30 a.m. - 1:30 p.m.

Room: Regency A (Ballroom Level, West Tower)

Agenda

NCORP Grant Renewal Updates – Dawn Hershman, MD, MS, Scott Ramsey, MD, PhD, and Veena Shankaran, MD, MS

Patient Advocate Updates – Barbara Segarra-Vazquez

Presentations:

“Common Sense Oncology: Outcomes That Matter,” Christopher Booth, MD, Queen’s University and Kingston Health Sciences Center, Kingston, Canada

“Impact of Primary Prophylactic Colony Stimulating Factor Delivery Method on Febrile Neutropenia. A Secondary Analysis of the TrACER study,” Lauren Shih MD, Fred Hutch

Panel Discussion

Signing Up and Recruiting for a New CCD Study

Active Studies

S2417CD, A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention to Promote Guideline-Concordant Colorectal Cancer Surveillance – Dr. Christine Veenstra, M.D., University of Michigan, Sarah Hawley, Ph.D., University of Michigan

S1703, “Randomized Non-inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Breast Cancer,” Dr. Melissa Accordini, M.D., Columbia University Irving Medical Center Activated 7/16/18.

Developing Studies

S2424CD, Lay Health Worker-led Intervention to Promote Goals of Care Communication – Manali Patel, MD, MPH, MS, Stanford University; Ravi Parikh, MD, Emory University; Christopher Manz, MD, Dana Farber Cancer Institute

Patient-centered Video Education Intervention to Improve Rural Cancer Care Delivery – Randall Holcombe, M.D., MBA, Izumi Okado, Ph.D., University of Hawaii

Patient, Provider, and Care Delivery Impacts of Immediate Release of Radiology Reports in Advanced Cancer – Dr. Veena Shankaran, M.D., University of Washington.

Recently Completed Accrual Studies

S1912CD, “A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT).” Dr. Veena Shankaran, M.D., University of Washington. Activated 7/26/21.

S2108CD, “Randomized Comparison of an Educationally Enhanced Genomic Tumor Board (eGTB) Intervention to Usual Practice of Incorporating Genomic Test Results into Clinical Care.” Dr. Jens Rueter, M.D., Maine Cancer Genomics Initiative; Dr. Meghna Trivedi, M.D., Columbia University Irving Medical Center

S1904, “Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE).” Dr. K. Crew. Activated: 9/1/20. (Committee: Prevention/Epidemiology). Closed: 6/14/24.

Closed Studies

S1415CD, “A Pragmatic Trial To Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing, Effectiveness and Risk (TrACER).” Drs. S. Ramsey, D. Hershman, G. Lyman, et al. Activated: 10/7/16. Closed: 4/15/20.

S1417CD, “Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer.” Dr. V. Shankaran. Activated: 4/15/16. Closed: 2/1/19.

Substudies (Economic Analyses / Cost Effectiveness from NCTN trials)

S1806, Healthcare Cost Comparison of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle-invasive Bladder Cancer, Dr. R. Vaidya, Dr. J. Unger

Cancer Care Delivery (CCD) Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	S1703	S1912CD	S2108CD	A191901	A231901CD	EAQ221CD	EAQ222CD	NHLBIMDS
Banner University Medical Center - Tucson	1	-	-	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-	-	1	-	-	3
Bay Area Tumor Institute NCORP	-	1	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	31	-	-	-	-	-	-	5
Cancer Research Consortium of West Michigan NCORP	-	9	-	-	1	-	-	-
Cancer Research for the Ozarks NCORP	-	11	44	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	17	19	61	1	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	11	2	132	-	-	-	-	1
Columbia University Minority Underserved NCORP	28	10	-	-	-	-	-	24
Columbus NCI Community Oncology Research Program	4	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	12	2	54	-	-	-	-	-
Corewell Health William Beaumont University Hospital	-	-	-	-	-	-	-	2
Cotton O'Neil Cancer Center / Stormont Vail Health	1	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	3	1	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	132	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	-	23
Georgia Cares Minority Underserved NCORP	-	12	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	3	-	31	-	-	-	-	-
Gulf South Minority Underserved NCORP	7	3	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	12	14	100	-	-	-	19	5
Heartland Cancer Research NCORP	26	7	237	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	-	4	-	-	-	1
Instituto Nacional De Cancerologia de Mexico	1	-	-	-	-	-	-	-
Instituto Nacional de Enfermedades Neoplasicas	5	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	5	17	-	-	-	3	-	9
Kansas City Veterans Affairs Medical Center	-	-	-	-	-	-	-	4
Kansas Institute of Medicine Cancer and Blood Center	-	-	-	-	-	-	-	2
Lahey Hospital and Medical Center	4	-	-	-	-	-	-	-
Loyola University Medical Center	4	-	-	8	-	-	-	-
Malcom Randall Veterans Administration Medical Center	-	-	-	-	-	-	-	6
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	-	-	-	-	35

Cancer Care Delivery (CCD) Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	S1703	S1912CD	S2108CD	A191901	A231901CD	EAQ221CD	EAQ222CD	NHLBIMDS
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	5
Michigan Cancer Research Consortium NCORP	24	21	94	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	-	8
Montana Cancer Consortium NCORP	5	7	69	-	-	-	-	-
Mount Sinai Hospital	9	-	-	-	-	-	-	-
MultiCare Tacoma General Hospital	-	-	-	22	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	6	2	-	-	-	-	-	2
Nevada Cancer Research Foundation NCORP	2	2	-	1	-	-	-	-
New Mexico Minority Underserved NCORP	16	28	-	-	-	-	-	-
Northwell Health NCORP	-	3	-	-	-	-	-	18
Oregon Health and Science University	-	-	-	-	-	-	-	12
Pacific Cancer Research Consortium NCORP	12	30	-	-	-	-	-	-
Riverside Methodist Hospital	2	-	-	-	-	-	-	-
Salem Hospital	3	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	6	37	18	-	-	-	1	-
UC Davis Comprehensive Cancer Center LAPS	2	-	-	3	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	-	-	27
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	34
Universidad de la Republica - Facultad de Medicina	2	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	5	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	-	-	-	-	16
University of Kansas Cancer Center - MCA Rural MU NCORP	11	11	95	-	-	-	-	-
University of Rochester LAPS	4	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	2	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	10	73	-	-	-	-	-
Western States Cancer Research NCORP	-	2	-	1	-	-	1	-
Wisconsin NCI Community Oncology Research Program	8	4	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	52	-	-	-	-	-	-	7
ALLIANCE	18	19	81	-	-	-	-	-
ECOG-ACRIN	30	31	63	-	-	-	-	-
NRG	20	16	-	-	-	-	-	-
Total	412	331	1,284	42	2	3	21	249

Palliative Care Committee

Leadership

Co-Chairs: Robert S. Krouse, MD
 Marie Bakitas, DNSc, CRNP

Time/Location

Friday, September 19, 2025 8:00 a.m. - 10:00 a.m.

Room: Regency A (Ballroom Level, West Tower)

Agenda

1. Welcome and Introductions: Drs. Krouse and Bakitas

2. Committee Liaison Updates:

- Executive Officer: Dr. Virginia Sun
- Patient Advocates: Valerie Fraser, Carole Seigel, Lee Jones
- ORP Liaison: Shirley Sui
- GI Liaison: Dr. Vincent Chung, Discussion of the Request for Proposals: *Advancing Palliative Care Integration in Gastrointestinal Oncology Clinical Trials*

3. Updates on Studies:

Active Studies

S1501, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic Her-2+ Breast Cancer, Phase III." Reopened: 11/1/25. PI: Justin Floyd

S2408, "A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula." Activated: 2/14/25. PIs: Jonathan G Sham, Venu G. Pillarisetty

Developing Studies

S2415, "Acupuncture to Decrease Symptom Burden in Patients with Metastatic Breast Cancer." PI: Heather Greenlee

S2418, "Optimizing Distress Screening and Support of Family Caregivers of Persons with Advanced Cancer (FamilyStrong) using a SMART Design." PI: J. Nicholas Odom

S2422, "Phase III Trial of Telehealth Intervention for Personalized Self-Management (TIPS) for Eating after Gastroesophageal Cancer Surgery." PI: Jae Kim

Secondary Studies

S1316, "Prospective Comparative Effectiveness Trial for Malignant Bowel

Obstruction." PI: Robert S. Krouse, MD

Dr. Jyotsana Parajuli Project Updates

- Development and Initial Validation of a Palliative Care Readiness Tool for Older Adults with Cancer (NIH/NIA R15 AG081886-01A1)
- Participation of Older adults Belonging to Underrepresented Backgrounds in SWOG Clinical Trials, SWOG Scholars Program Project

4. Review and Discuss survey on Palliative Care Committee Mission and objectives

- Presentation of preliminary survey results from committee members and NCORP sites
- Open discussion on how well current activities align with the committee's stated mission
- Brainstorming on actionable steps or revisions to the mission, goals, or future focus areas

5. Closing Remarks and Next Steps

Other Developing Studies

S2424CD, "Randomized Controlled Trial Lay Health Worker-led Intervention to Promote Goals of Care Communication." Study Chairs: Drs. Parikh, Manz, Patel. NOA received February 2025. Grant start date is 3/1/25.

Closed Studies

S1820, "A Randomized Phase II Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors (AIMS-RC)." Dr. Virginia Sun. Activated: 12/9/19. Closed to Accrual as of 04/12/2022. Permanently Closed: 04/12/2022

S1316, "Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction." Dr. Robert Krouse. Activated: 3/9/15. Permanently Closed: 5/15/20

Palliative Care Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	<i>S1501</i>	<i>S2408</i>
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	7	-
CWRU Case Comprehensive Cancer Center LAPS	19	-
Cancer Research Consortium of West Michigan NCORP	-	2
Cancer Research for the Ozarks NCORP	11	-
City of Hope Comprehensive Cancer Center	51	-
Columbia University Minority Underserved NCORP	2	-
CommonSpirit Health Research Institute	1	-
Essentia Health NCI Community Oncology Research Program	-	1
Fred Hutchinson Cancer Research Center LAPS	4	-
Georgia NCI Community Oncology Research Program	14	-
Gulf South Minority Underserved NCORP	4	-
Heartland Cancer Research NCORP	17	-
Henry Ford Health Providence Southfield Hospital	4	-
Henry Ford Hospital	3	-
Instituto Nacional de Enfermedades Neoplasicas	1	-
Kaiser Permanente NCI Community Oncology Research Program	1	-
King Faisal Specialist Hospital and Research Centre	3	-
Lahey Hospital and Medical Center	6	-
Loyola University Medical Center	9	-
MU Health Care Goldschmidt Cancer Center	5	-
Medical University of South Carolina Minority Underserved NCORP	1	-
Michigan Cancer Research Consortium NCORP	4	-
Moffitt Cancer Center	33	-
Montana Cancer Consortium NCORP	1	-
NCORP of the Carolinas (Prisma Health NCORP)	2	-
National Cancer Center-Korea	2	-
New Mexico Minority Underserved NCORP	7	-
Oregon Health and Science University	1	-
Regents of the University of Michigan	10	-
UC Davis Comprehensive Cancer Center LAPS	2	-
USC Norris Comprehensive Cancer Center LAPS	4	-
University of Kansas Cancer Center - MCA Rural MU NCORP	7	-
Wayne State University - Karmanos Cancer Institute LAPS	6	-
Western States Cancer Research NCORP	2	-
ALLIANCE	30	-
ECOG-ACRIN	43	-
NRG	30	2
Total	347	5

Prevention, Screening, & Surveillance Committee

Leadership

Co-Chairs: Banu Arun, MD
 Jason A. Zell, DO

Time/Location

Thursday, September 18, 2025 2:00 p.m. - 4:00 p.m.
 Room: Regency A (Ballroom Level, West Tower)

Agenda

Welcome and Opening Comments: Dr. Jason Zell &
 Dr. Banu Arun

Presentation: Targeting Metabolic Perturbation to Improve Cancer Risk and Outcomes - Neil M. Iyengar, MD, Associate Professor, Winship Cancer Institute at Emory University

Closed Studies

S0820, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. J. Zell, P. Brown, M.P. Lance, et al. Activated: 3/1/13. Closed: 6/30/23.

S1823, "A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors". Drs. C. Nichols and L. Nappi. Activated: 6/1/20. Closed: 5/20/24.

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. K. Crew, R. Kukafka, et al. Activated 9/1/20. Closed 6/14/24.

Concepts in Development (not yet approved by Triage)

A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial of Finasteride to Prevent Recurrence in Patients with Low-Grade Intermediate-Risk NMIBC." Drs. S. Psutka and P. Hensley.

"Randomized Phase IIb Trial of Trifluridine/Tipiracil (FTD/TPI) and Irinotecan (IRI) For Molecular Residual Disease (MRD) Positive Colorectal Adenocarcinomas (CRC) Recurrent or Refractory to Standard Curative Intent Multimodality Treatment." Drs. F. Dayyani and J. Zell.

"Randomized trial of Radiation with or without HER2 targeted therapy (trastuzumab) in DCIS patients identified as Residual Risk by DCISionRT testing". Dr. E. Connolly.

"Decision-T app-based intervention for smoking cessation." Dr. I. Tami-Maury.

Patient Advocate Update: Cheryl Jernigan

Annual NCORP Meeting Update: Banu Arun
 Katherine Crew

Group Discussion

Other Group Prevention Studies with SWOG Study Champions

CTSU/EA8184, "A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers." Dr. R. Kopp. Activated: 5/10/21.

Other Group Screening Studies with SWOG Study Champions or SWOG Accrual

CTSU/NRG-CC005, "FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)". Dr. L. Kachnic. Activated: 10/6/21.

CTSU/NRG-CC008, "A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCK]." Activated: 6/23/20

CTSU/EA1151, "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)." Dr. Pisano. SWOG Champion: Dr. Arun. Activated: 7/6/17. Closed to accrual: 12/20/24.

CTSU A212102, "Blinded Reference Set for Multicancer Early Detection Blood Tests." Dr. J. McGuinness. Activated: 8/1/22.

CTSU/EA2185, "Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers"/ Activated: 1/16/20. Temporarily Closed to Accrual as of 3/1/24.

Prevention, Screening, and Surveillance Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	<i>S1823</i>	<i>S1904</i>	<i>A211801</i>	<i>A212102</i>	<i>EA1151</i>	<i>EA2185</i>	<i>EA8184</i>	<i>NRGCC005</i>	<i>NRGCC008</i>
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	263	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	51	-	-	4	2	-
Banner MD Anderson Cancer Center	5	-	-	-	1	-	-	-	-
Banner University Medical Center - Tucson	14	-	-	-	56	-	-	-	-
Baptist Mem Health Care/Mid South Minority Underserved NCORP	-	12	-	-	8	-	-	-	-
Bay Area Tumor Institute NCORP	1	-	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	-	-	3	-	-	5
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	2	290	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	2	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	5	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	6	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	5	26	-	-	2	-	-	-	-
City of Hope Comprehensive Cancer Center	-	20	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	42	-	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	7	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	5	-	-	-	100	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	105	-	-	-	-
Gulf South Minority Underserved NCORP	13	-	-	5	-	-	-	-	2
Hawaii Minority Underserved NCORP	3	21	-	-	80	-	-	-	-
Heartland Cancer Research NCORP	15	11	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	4	133	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	178	15	-	-	-	-	-	-	-
Kansas City Veterans Affairs Medical Center	-	-	-	5	-	-	-	10	-
Lahey Hospital and Medical Center	-	3	-	-	-	-	-	-	-
Loma Linda University Medical Center	8	-	-	-	-	-	-	-	-
Loyola University Medical Center	-	4	-	-	-	-	-	-	-
Malcom Randall Veterans Administration Medical Center	-	-	-	-	-	-	-	4	-
Massachusetts Vets Epidemiology Research & Information Center	-	-	-	27	-	8	-	35	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	2	4	-	4	-	-
Memorial Hermann Texas Medical Center	-	-	-	-	8	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	11	-	-	-	463	-	-	-	-
Nevada Cancer Research Foundation NCORP	1	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	12	-	-	-	-	-	-	-	-

Prevention, Screening, and Surveillance Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	<i>S1823</i>	<i>S1904</i>	<i>A211801</i>	<i>A212102</i>	<i>EA1151</i>	<i>EA2185</i>	<i>EA8184</i>	<i>NRGCC005</i>	<i>NRGCC008</i>
Northwell Health NCORP	11	-	-	-	-	-	-	-	1
Ohio State University Comprehensive Cancer Center LAPS	8	2	-	-	-	-	-	-	-
Oregon Health and Science University	17	-	-	-	-	3	3	13	3
Pacific Cancer Research Consortium NCORP	-	1	-	-	-	-	-	-	-
Regents of the University of Michigan	-	-	1	-	-	-	-	-	-
Riverside Methodist Hospital	3	-	-	-	-	-	-	-	-
Salem Hospital	3	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	2	-	-	-	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	5	-	-	-	-	-
Tulane University School of Medicine	-	-	-	-	2	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	1	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	4	-	-	91	-	-	-	-	-
UC San Diego Moores Cancer Center	24	-	-	-	-	1	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	30	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	33	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	389	3	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	6	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	26	-	-	5	2	-	-	13	-
University of Kentucky/Markey Cancer Center	-	-	-	-	9	-	-	-	-
University of Mississippi Medical Center	6	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	8	-	-	-	-	-	-	-	-
University of Rochester LAPS	20	-	-	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	-	-	20	-	-	-	-	1
University of Utah - Huntsman Cancer Institute LAPS	-	21	-	-	-	-	-	-	-
Upstate Carolina Consortium Comm Oncology Research Program	-	-	-	-	619	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	7	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	16	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	8	-	-	-	-
Western States Cancer Research NCORP	5	-	-	-	73	-	-	-	-
ALLIANCE	96	106	-	-	-	-	-	-	-
CCTG	217	-	-	-	-	-	-	-	-
ECOG-ACRIN	76	43	-	-	-	-	-	-	-
NRG	55	85	-	-	-	-	-	-	-
Total	964	412	1	217	2,615	19	12	77	12

Symptom Management & Survivorship Committee

Leadership

Co-Chairs: Michael J. Fisch, MD, MPH
 Norah Lynn Henry, MD, PhD

Time/Location

Thursday, September 18, 2025 4:30 p.m. - 6:30 p.m.

Room: Regency A (Ballroom Level, West Tower)

Agenda

Plenary Session: What Recent SMS Studies Have Taught Us -- And Next Steps

S1714: Drs. Meghna Trivedi

S1600: Dr. Jill Hamilton-Reeves

PROs Across SWOG: Dr. Joseph Unger

Patient Advocate Update: Lee Jones

Concepts in Development

1. App-delivered Coaching to Support Cancer Survivor Sleep Health (S2435). Dr. Rina Fox
2. Randomized trial of vaginal estrogen versus placebo in women with breast cancer for the treatment of genitourinary symptoms of menopause. Dr. Don Dizon
3. Use of GLP-1 agonists in early stage breast cancer survivors. Dr. Vidhya Nair
4. Exercise interventions focused on men with prostate cancer on ADT-based regimens. (Drs. Lisa Rogers and Dennis Kerrigan, Dr. Dong-Woo Kang)
5. Interventional study for cancer-related cognitive dysfunction in men with prostate cancer on ADT-based regimens. Dr. Clara Hwang
6. The Use of Memantine for the Prevention of Cancer-Related Cognitive Impairment (CRCI) in Young Adult (YA) Patients with Colorectal Cancer. Dr. Christopher Cann

Active Studies

S2013, "Immune Checkpoint Inhibitor Toxicity (I-Checkit): A Prospective Observational Study." Drs. Gunturu, Hershman, Kuderer, et al. Activated: 8/16/21.

S2205, "STOP CIPN: Randomized trial of Limb Cryocompression versus Continuous cOmpression versus Low Cyclic Compression for the Prevention of Taxane-Induced peripheral Neuropathy." Drs. Accordini,

Penington, Hershman, et al. Activated: 3/16/23.

Committee Business

1. What other studies are we planning?
2. What is happening with our open studies?
3. What other updates should we know about?

- Patient Advocate Update

- Statistical Center Update

Closed Studies

S1600, "A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes (SIMMune)." Drs. Hamilton-Reeves, Holzbeierlein, Kukreja, et al. Permanently closed 10/20/23.

S1614, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors." Drs. Hwang, Lok, Gehring, et al. Permanently closed 11/15/22.

S1714, "A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients." Drs. Trivedi, Hershman, Brannagan, et al. Activated: 3/1/19; Permanently closed 11/15/21.

S1706, "A Phase II Randomized, Double-Blinded, Placebo-Controlled Trial of Olaparib Administered Concurrently with Radiotherapy for Inflammatory Breast Cancer." Dr. Jaggi. Activated: 9/12/18; Closed to accrual: 7/1/24.

S1806, "Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer." Dr. Singh. Activated: 4/19/18; Closed to accrual: 4/1/24.

S1826, "A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age \geq 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma." Drs. Herrera, Friedberg. Activated: 7/19/19; Closed to accrual: 12/1/22.

S0820, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. Zell, Brown, Lance, et al. Activated: 3/1/13; Closed to accrual: 6/30/23.

Symptom Management & Survivorship Committee

S1904, "Cluster Randomized Controlled Trial of Patient and Provider

Decision Support To Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma in Situ - Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. Crew, Kukafka, Hershman, et al. Activated: 9/1/20; Closed to accrual: 6/14/24.

S2010, "A Randomized Phase III Trial Comparing Active Symptom

Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence with Endocrine Therapy in Young Women with Stage I-III Breast Cancer (ASPEN)." Drs. Henry, Hershman, and Skaar. Activated: 1/17/23; Closed to accrual: 1/15/25.

Other SWOG Studies with Symptom Control and QOL Component Cancer Care Delivery

S1703, "Randomized Non-Inferiority Trial Comparing Overall Survival

of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (Stmddm) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Her-2 Negative Breast Cancer." Drs. Accordino, Hershman, and Ramsey. Activated: 7/16/18.

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial

Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Drs. Shankaran, Carlos, Hershman, et al. Activated: 7/26/21.

S2108CD, "A Cluster Randomized Trial Comparing an Educationally

Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy." Drs. Reuter, Trivedi, Symington, et al. Activated: 8/22/22.

GU

S1802, "Phase III Randomized Trial of Standard Systemic Therapy (SST)

Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Dr. Chapin. Activated: 9/17/18.

Leukemia

S1925, "Randomized, Phase III Study of Early Intervention with Venetoclax

and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study." Drs. Stephens, Hill, Pagel, et al. Activated: 12/14/20.

Lung

S1914, "A Randomized Phase III Trial of Induction/Consolidation

Atezolizumab (NSC#783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activated: 3/25/20.

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and

Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Drs. Rusthoven, Brown, Wefel, et al. Activated: 1/10/20.

Lymphoma

S1918, "A Phase II/III Randomized Study of R-miniCHOP with or without

Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. Brem, Smith, Henry, et al. Activated: 3/19/21.

Myeloma

S1803, "Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) +

Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Drs. Krishnan, Chhabra, and Callander. Activated: 6/27/19.

NCTN Studies

CTSU/NRG-GI004, "Colorectal Cancer Metastatic dMMR Immunotherapy

(COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer." Dr. Overman. Activated: 11/7/17; Temporarily closed: 6/4/20; Reactivated: 1/29/21.

Symptom Management & Survivorship Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	S2010	S2013	S2205	A211901	A221805	A222004	ACCL1931	EAQ202
Audie L Murphy VA Hospital	-	26	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	1	-	-	-
Banner University Medical Center - Tucson	-	5	-	-	-	-	-	-
Baptist Mem Health Care/Mid S Minority Underserved NCORP	-	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	4	-	-	-
Cancer Research Consortium of West Michigan NCORP	2	-	1	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	12	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	4	150	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	19	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	26	38	35	-	-	1	-	-
Columbus NCI Community Oncology Research Program	-	35	-	-	-	-	-	-
CommonSpirit Health Research Institute	13	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	1	-	-	-
Georgia Cares Minority Underserved NCORP	-	29	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	20	71	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	9	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	4	25	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	9	7	28	-	-	-	-	-
Heartland Cancer Research NCORP	25	245	-	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	29	-	-	-	-	-	-
Henry Ford Hospital	-	-	4	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	27	13	-	-	-	-	-	-
Instituto Nacional de Enfermedades Neoplasicas	24	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	28	81	-	-	-	-	-	-
Lahey Hospital and Medical Center	12	63	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research & Information Center	-	63	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	9	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	20	7	-	-	-	-	-	-
Moffitt Cancer Center	10	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	7	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-	39
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	3	-	4

Symptom Management & Survivorship Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	S2010	S2013	S2205	A211901	A221805	A222004	ACCL1931	EAQ202
Audie L Murphy VA Hospital	-	26	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	1	-	-	-
Banner University Medical Center - Tucson	-	5	-	-	-	-	-	-
Baptist Mem Health Care/Mid S Minority Underserved NCORP	-	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	4	-	-	-
Cancer Research Consortium of West Michigan NCORP	2	-	1	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	12	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	4	150	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	19	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	26	38	35	-	-	1	-	-
Columbus NCI Community Oncology Research Program	-	35	-	-	-	-	-	-
CommonSpirit Health Research Institute	13	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	1	-	-	-
Georgia Cares Minority Underserved NCORP	-	29	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	20	71	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	9	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	4	25	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	9	7	28	-	-	-	-	-
Heartland Cancer Research NCORP	25	245	-	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	29	-	-	-	-	-	-
Henry Ford Hospital	-	-	4	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	27	13	-	-	-	-	-	-
Instituto Nacional de Enfermedades Neoplasicas	24	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	28	81	-	-	-	-	-	-
Lahey Hospital and Medical Center	12	63	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research & Information Center	-	63	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	9	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	20	7	-	-	-	-	-	-
Moffitt Cancer Center	10	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	7	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-	39
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	3	-	4

Symptom Management & Survivorship Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	NRGCC010	NRGCC011
Audie L Murphy VA Hospital	-	-
Banner MD Anderson Cancer Center	-	-
Banner University Medical Center - Tucson	-	-
Baptist Mem Health Care/Mid S Minority Underserved NCORP	-	2
CWRU Case Comprehensive Cancer Center LAPS	-	-
Cancer Research Consortium of West Michigan NCORP	-	-
Cancer Research for the Ozarks NCORP	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-
Columbia University Minority Underserved NCORP	-	-
Columbus NCI Community Oncology Research Program	-	-
CommonSpirit Health Research Institute	-	-
Dayton NCI Community Oncology Research Program	-	1
Georgia Cares Minority Underserved NCORP	-	-
Georgia NCI Community Oncology Research Program	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-
Gulf South Minority Underserved NCORP	13	-
Hawaii Minority Underserved NCORP	-	-
Heartland Cancer Research NCORP	-	-
Henry Ford Health Providence Southfield Hospital	-	-
Henry Ford Hospital	-	-
Instituto Nacional De Cancerologia de Mexico	-	-
Instituto Nacional de Enfermedades Neoplasicas	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-
Lahey Hospital and Medical Center	-	4
Massachusetts Veterans Epidemiology Research & Information Center	-	-
Mercy Medical Center - Des Moines	-	-
Michigan Cancer Research Consortium NCORP	-	-
Moffitt Cancer Center	-	-
Montana Cancer Consortium NCORP	-	-
Mount Sinai Hospital	-	1
NCORP of the Carolinas (Prisma Health NCORP)	-	-
Nevada Cancer Research Foundation NCORP	-	-

Symptom Management & Survivorship Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	NRGCC010	NRGCC011
New Mexico Minority Underserved NCORP	-	-
Northwestern University LAPS	-	-
Oregon Health and Science University	-	-
Pacific Cancer Research Consortium NCORP	-	-
Regents of the University of Michigan	-	-
Rhode Island Hospital	-	-
STCC at DHR Health Institute for Research and Development	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-
Salem Hospital	-	11
Southeast Clinical Oncology Research Consortium NCORP	-	-
Stanford Cancer Institute Palo Alto	-	-
The Don and Sybil Harrington Cancer Center	-	-
UC Davis Comprehensive Cancer Center LAPS	-	2
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-
UC San Diego Moores Cancer Center	-	-
UPMC Hillman Cancer Center LAPS	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-
Universidad de la Republica - Facultad de Medicina	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-
University of Arkansas for Medical Sciences	-	-
University of Colorado Cancer Center LAPS	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	11
University of Kentucky/Markey Cancer Center	-	3
University of Mississippi Medical Center	-	-
University of Oklahoma Health Sciences Center LAPS	2	-
University of Texas Health Science Center at San Antonio	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-
Western States Cancer Research NCORP	-	-
Wisconsin NCI Community Oncology Research Program	-	-
ALLIANCE	-	-
ECOG-ACRIN	-	-
NRG	-	-
Total	15	35

Early Therapeutics & Rare Cancers Committee

Leadership

Chair: Razelle Kurzrock, MD
 Vice-Chair: Young Kwang Chae, MD, MPH
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Megan Othus, PhD
 Anna B. Moseley, MS
 Sara Threlkel, BS

Designates

Data Coordinator: Christine Magner
 Veterans Affairs: Jimmy Ruiz, MD
 Oncology Research Professionals:
 CRAs: Adam Platt, BS
 Nurse: TBD
 Pharmaceutical Science: Craig Elg, PharmD
 Sun "Coco" Yang, PharmD, PhD
 Patient Advocate: Marcia K. Horn, JD
 Protocol Project Manager: Catrina De Los Santos-Mireles
 Clinical Trials Program Manager: Laura Gildner, MS

Early Therapeutics Liaisons

Breast Committee Liaison: Stephanie L. Graff, MD
 Cancer Control Liaison: Jason M. Prosek, MD
 Lara E. Davis, MD (Survivorship)
 Genitourinary Committee Liaison: Parminder Singh, MD
 Imaging: TBD
 Lung Committee Liaison: Shirish M. Gadgil, MD
 Lymphoma Committee Liaison: Nasheed Mohammad Hossain, MD
 Melanoma Committee Liaison: TBD
 Myeloma Committee Liaison: Frits van Rhee, MD, PhD

Time/Location

Thursday, September 18, 2025 11:00 a.m. - 1:30 p.m.

Room: Regency C (Ballroom Level, West Tower)

Agenda

11:00 - 11:10 am	Welcome and Introduction - Razelle Kurzrock, MD
11:10 - 11:35 am	ComboMATCH - James M. Ford, MD, FASCO
11:35 - 11:55 am	CNS Working Group and DART CNS Data - Manmeet Ahluwalia, MD
11:55 - 12:15 pm	S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas" - David Zhen, MD

12:15 - 12:40 pm	Overview of Clinical Outcomes of DART - Sandip Patel, MD
12:40 - 1:00 pm	Updates from Sarcoma Working Group - Lara Davis, MD
1:00 - 1:20 pm	Translational Studies for DART - Cara Haymaker, PhD
1:20 - 1:30 pm	Wrap Up - Razelle Kurzrock, MD

Active Studies

S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)." Drs. Zhen, Chiorean, Burgess, Swisher. Activated: 12/2/21.

CTSU/A071401, "Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2/CDK Pathway Mutations." Dr. Brastianos. SWOG Champion: Dr. Piccioni. Activated: 8/28/2015. New patient registration (Step 1) to the NF2, CDKN2A, CDK4, CDK6, CCND1, CCND2, CCND3, and CCNE1 Cohort (Abemaciclib Cohort) is closed to accrual as of 10/3/22.

CTSU/A092001, "Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or Without Immunotherapy for Peritoneal Mesothelioma". SWOG Champion: Dr. P.S.K. Raghav. Activated: 10/15/21.

CTSU/AGCT1531, "A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors" SWOG Champion: Dr. D'Souza Activated: 5/8/17. Stratum 2 is temporarily closed to accrual 12/17/24.

CTSU/AOST2031, "A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma" SWOG Champion: Dr. Hofstetter. Activated: 2/15/22

CTSU/AOST2032, "A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma" SWOG Champion: Dr. J. A. Livingston. Activated: 2/17/23 Temporarily Closed to Accrual as of 9/6/23

CTSU/ HN.11 (CCTG-HN11), "SPECT-CT Guided Elective Contralateral Neck Treatment (SELECT) for Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial SWOG" Champion: Dr. Paul Swiecicki. Activated: 9/29/22

Early Therapeutics & Rare Cancers Committee

Studies in Development

SN2426, "A Randomized Phase II Study of Amivantamab versus Cetuximab in Immunocompromised Patients with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma". Dr. Swiecicki. Anticipated activation date: 8/15/25

S2505, "Phase III Randomized Study Testing Non-Inferiority of Short-Course Ultra-Fractionated Radiation (UHRT-5) Versus Standard Fractionation (RT-25) for High-Risk, Resectable Soft Tissue Sarcoma. Dr. Harris

Closed Studies

CTSU/A071702, "A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hyper-mutated Recurrent Glioblastoma." SWOG Champion: Dr. M. Ahluwalia. Activated: 10/30/20. Pre-Registration is temporarily Closed to accrual 12/12/23. Closed: 6/2/25.

CTSU/EA2183, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma." Dr. Uboho. SWOG Champion: Dr. Saeed. Activated: 2/6/20. Closed: 5/23/25

CTSU/A071601, "Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas." Dr. Brastianos. SWOG Champion: Dr. Ahluwalia. Activated: 8/4/17. Temporarily Closed (Cohort A): 9/8/20. Closed: 5/10/24

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors." Drs. Patel, Chae, and Kurzrock. Activated: 1/13/17. Closed: 3/15/23.

CTSU/NRG-GY006, "A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer." Dr. Leath. SWOG Champion: Dr. Robinson. Activated: 1/15/16. Closed: 9/22/22

CTSU/NRG-GY020, "A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer." Dr. Backes. SWOG Champion: Dr. Robinson. Activated: 2/7/20. Closed: 8/29/22.

NCICOVID, "NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study." Dr. Karim. Activated: 5/21/20. Closed: 2/1/22.

CTSU/NRG-GY009, "A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus

Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer." Dr. O'Cearbhaill. SWOG Champion: Dr. Robinson. Activated: 5/12/17. Closed 10/14/21

CTSU/NRG-HN007, "An Open-Label, Phase III Study of Platinum-Gemcitabine with or without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma." Dr. Brigitte B. Y. Activated: 9/8/20; Closed: 10/28/21

CTSU/EAY131, "Molecular Analysis for Therapy Choice (MATCH)." Activated: 8/12/15. Closed: 12/23/22

CTSU/NRG-BN007, "A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma." Dr. Lassman. SWOG Champion: Dr. Ahluwalia. Activated: 8/6/20. Closed: 3/29/23.

CTSU/EA3163, "Phase II Randomized Trial of Neoadjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a (and Selected T4b) Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)." Dr. Saba. SWOG Champion: Dr. Swiecicki. Activated: 3/28/18. Closed: 11/7/23

Proposed Studies

NRG-BN1803, "NRG-COG Phase II Trial of Radiation Plus Concurrent and Adjuvant ONC201 for Newly Diagnosed, H3 K27M-Mutant Gliomas." SWOG Champion: Dr. Ahluwalia.

NRG-OV1821, "A Randomized Phase II Trial of Olaparib Versus Olaparib + Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer." Dr. Robinson.

NRG-BN1855, "A Randomized Phase II/III Open Label Study of Ipilimumab and Nivolumab Vs Te-mozolomide in Patients with Newly Unmethylated MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Glioblastoma." Dr. M. Ahluwalia.

NRG-HN1854, "An Open-label, Phase III Study of Platinum-Gemcitabine with or Without Nivolumab in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma." Dr. P. Swiecicki.

NRG-UC1805, "Randomized Phase III Trial of Radiation +/- Pembrolizumab for High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer." Dr. W. Robinson.

Early Therapeutics & Rare Cancers Committee

ComboMATCH

Proposed Studies

EAY191-S7, "A Phase 2 Study Investigating Safety and Efficacy of Trastuzumab Deruxtecan (DS8201/T-DXd) and ATR Inhibitor, Ceralasertib (AZD6738) in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Advanced Solid Tumors." Dr. K. Raghav.

Active Studies

EAY191-S3, "Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors." Study Chairs: Reva Basho, M.D., Haider Mahdi, M.

Clinical Trials Partnerships (CTP)

Developing Studies

21CTP.HN01, CAPT-HN, "A Phase II Study of Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer." Drs. Swiecicki, Rodriguez, and Brenner.

Early Therapeutics & Rare Cancers Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	EAY191-S3	S2012	A071401	AGCT1531	EAY191	EAY191A3	EAY191A6	EAY191E4
Cancer Research Consortium of West Michigan NCORP	-	1	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	2	-	-	-	-	-	-
Cedars-Sinai Medical Center	1	-	-	-	2	-	-	-
CommonSpirit Health Research Institute	-	1	1	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	1	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	11	-	-	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	1	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	2	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	1	-	-	1	-	1	-
Heartland Cancer Research NCORP	-	1	-	-	-	-	-	-
Henry Ford Hospital	-	2	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	5	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	1	4	-	-	-	-	-	-
Moffitt Cancer Center	-	8	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	1	-	-	-	-
Northwestern University LAPS	-	5	1	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	8	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	1	-	-	-	-	-	-	-
Regents of the University of Michigan	-	2	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	1	-	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	1	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	1	-	4	-	1	3
UC San Diego Moores Cancer Center	-	-	2	1	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	1	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	3	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	3	-	-	-	10	2	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	1	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	2	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	2	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	7	2	-	-	-	-	-
ALLIANCE	3	14	-	-	-	-	-	-
ECOG-ACRIN	8	11	-	-	-	-	-	-
NRG	4	10	-	-	-	-	-	-
Total	22	105	8	3	17	2	2	3

Gastrointestinal Committee

Leadership

Chair: Philip A. Philip, MD, PhD, FRCP
 Vice-Chair: Elena Gabriela Chiorean, MD, FASCO
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Katherine A. Guthrie, PhD
 Sarah Colby, MS
 Sara Threlkel, BS

Scientific Leadership

Gastroesophageal: Syma Iqbal, MD
 Zev A. Wainberg, MD
 Pancreatic: Davendra P.S. Sohal, MD
 Andrew M. Lowy, MD (Surgical representative)
 Hepatobiliary: Anthony B. El-Khoueiry, MD
 Rachna T. Shroff, MD
 Syed A. Ahmad, MD (Surgical representative)
 Colon: Marwan G. Fakih, MD
 Philip J. Gold, MD
 Sepideh Gholami, MD (Surgical representative)
 Neuroendocrine Tumors: Nageshwara Arvind Dasari, MD
 Aman Chauhan, MD
 Ano-Rectal: Lisa A. Kachnic, MD
 Hagen F. Kennecke, MD
 Imaging: Anthony F. Shields, MD, PhD
 Pathology: Mary Kay Washington, MD, PhD
 Radiation Oncology: Lisa A. Kachnic, MD
 Surgery: Stephen W. Behrman, MD
 Syed A. Ahmad, MD
 Flavio Rocha, MD
 Translational Medicine: Gabriel N. Duda, PhD, DMD
 Eric Collisson, MD
 HEARD: Rachel Safyan, MD
 Colmar Figueroa-Moseley, PhD, MPH

Designates

Cancer Control Liaisons: Jason A. Zell, DO (Prevention)
 Vincent Chung, MD (Palliative Care)
 Community Liaisons: Gary L. Buchsacher, MD, PhD (Medical Onc)
 Mohamed E. Salem, MD (Medical Oncology)
 Flavio Rocha, MD (Surgical)
 David Horowitz, MD (Radiation Oncology)
 AYA Committee Liason: Christopher Cann, MD
 Veterans Affairs: Rangaswamy Govindarajan, MD
 Data Coordinators: Christine Magner
 Alex Rangel
 Brian Zeller

Oncology Research Professionals:

CRA: Adriana Gamboa Guzman, BA
 Nurse: TBD
 Patient Advocate (Colon): Angela "Marielle" McLeod, MHA
 Patient Advocate (Pancreatic): Carole Seigel, MBA
 Pharmaceutical Science: Jane E. Rogers, PharmD
 Safae Chouraichi, PharmD
 Protocol Project Manager: Andrea Garcia
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Friday, September 19, 2025 4:30 p.m. - 6:30 p.m.

Room: Regency D (Ballroom Level, West Tower)

Agenda

1. Welcome
2. Announcements & Introductions Philip Philip
E. Gabriela Chiorean
3. HEARD Subcommittee Initiatives Rachel Safyan, Colmar Figueroa-
Moseley, Carole Seigel,
Marielle McLeod
4. Updates in Targeted Therapies for Metastatic Colorectal Cancer
Marwan Fakih
5. SWOG Led Active Trials
 a. S1922 Michael Overman
 b. S2001 Vincent Chung
 c. S2104 Heloisa Soares/S. Ahmad
 d. S2107 Van Morris
 e. S2012 David Zhen/E. Gabriela Chiorean
 f. S2303 Anwaar Saeed/Paul Oberstein
 g. S2408 Jonathan Sham/Venu Pillarisetty
 h. S2433 Rachael Safyan/E. Gabriela Chiorean
6. Gastroesophageal Syma Iqbal, Zev Wainberg
 a. Major recent clinical results
 b. NCTN trials update
 c. Future SWOG plans
7. Pancreatic Davendra Sohal, Andrew Lowy
 a. Major recent clinical results
 b. NCTN trials update
 c. Future SWOG plans

Gastrointestinal Committee

- | | |
|----------------------------------|---|
| 8. Colon | Marwan Fakih, Philip Gold,
Sepideh Gholami |
| a. Major recent clinical results | |
| b. NCTN trials update | |
| c. Future SWOG plans | |
| 9. Anal and Rectal | Hagen Kennecke, Lisa Kachnic |
| a. Major recent clinical results | |
| b. NCTN trials update | |
| c. Future SWOG plans | |
| 10. Hepatobiliary | Anthony El-Khoueiry
Rachna Shroff |
| a. Major recent clinical results | |
| b. NCTN trials update | |
| c. Future SWOG plans | |
| 11. Neuroendocrine | Arvind Dasari, Aman Chauhan |
| a. Major recent clinical results | |
| b. NCTN trials update | |
| c. Future SWOG plans | |
| 12. Discussion/Other business | |
| 13. Adjourn | |

Gastroesophageal

Active Studies

S2303, "Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS \geq 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)." Study Chairs: Dr. Saeed, and Dr. Oberstein. Activated: 5/6/24

A022102, "Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma." SWOG Champion: Dr. Oberstein. Activated: 1/17/19.

EA2174, "A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma." SWOG Champion: Dr. Kelly. Activated: 1/17/19. Temporarily Closed to Accrual as of 12/29/22.

EA2212, "A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer." SWOG Champion: Emerson Chen Temporarily Closed to Accrual as of 12/4/24

EA2183, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)." SWOG Champion: Dr. Horowitz. Activated: 2/6/20.

Closed Studies

A021302, "Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study." SWOG Champion: S. Iqbal. Activated by SWOG: 4/1/16.

Pancreatic

Developing Studies

S2433, "Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma." Study Chairs: R. Safyan, E. Chiorean, H. Singh

Active Studies

S2408, "A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula." Study Chairs: J. Sham, V. Pillarisetty, R. Krouse. Activated: 2/14/25

S2001, "Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations." Study Chair: Dr. Chung. Activated: 12/4/20.

A022106, "A Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/ Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)." SWOG Champion: G. Botta

A021804, "A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma." SWOG Champion: Dr. C. Lopez. Activated: 11/2/20.

A021806, "A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer." SWOG Champion: Dr. Noel. Activated: 7/1/20.

EA2192, "APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation." SWOG Champions: Drs. Chiorean and Philip. Activated: 4/29/21.

Gastrointestinal Committee

Closed Studies

EA2186, "A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)." Activated: 6/18/20. SWOG Champion: Dr. Zhen. Closed to Accrual as of 10/17/23

RTOG-0848, "Gemcitabine, with and without Erlotinib, Followed by a Second Randomization with and without Chemoradiation, as Adjuvant Treatment for Pancreatic Head Cancer: A Phase III RTOG/SWOG/NCIC/EORTC Study." SWOG Champion: P. Philip. Closed to accrual as of 1/18/19

A021501, "Preoperative Extended Chemotherapy vs Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas." SWOG Champion: S. Ahmad. Closed to accrual as of 5/6/19

EA2161, "A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)." 12/27/19: Closed to Accrual & Treatment

Neuroendocrine

Active Studies

S2104, "Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors." Study Chairs: Dr. Soares, S. Ahmad.. Activated: 10/14/21

S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)." Study Chairs: Drs. D. Zhen, E. Chiorean, E. Burgess, E. Swisher, L. Byers. Activated: 12/2/21

Closed Studies

A021602, "Randomized Double-Blinded Phase III Study of CABozantinib versus Placebo IN Advanced NEuroendocrine Tumors after Progression on Prior Therapy (CABINET)." SWOG Champion: Dr. Strosberg. Activated: 7/18/18. Closed to Accrual as of 9/8/23

EA2142, "Randomized Phase II Study of Platinum and Etoposide Versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas." SWOG Champion: H. Soares, Closed to Accrual & Treatment: 4/1/21

Hepatobiliary

Active Studies

NRG-GI003, "A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma." SWOG Champion: Dr. El-Khoueiry. Activated: 6/21/17.

EA2197, "Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial." SWOG Champion: Dr. Rocha. Activated: 12/22/20.

Closed Studies

S1815, "A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers." Study Chair: Dr. Shroff. Activated: 12/3/18. Permanently Closed: 2/15/21.

EA2187, "A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma." SWOG Champion: Dr. Stein. Activated: 1/31/20. Permanently Closed: 3/22/23.

RTOG-1112, "Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma." L. Dawson. SWOG Champion: T. Mitin

Colorectal

Active Studies

S1922, "Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma." Study Chair: M. Overman, Activated: 12/16/19

A021502, "Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC)." SWOG Champion: G. Lieu Closed to Accrual as of 1/17/23

A022101, "A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)." SWOG Champion: S. Gholami Activated: 1/10/23.

EA2222, "A Randomized Phase III Study of Systemic Therapy with or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial" Activated: 10/19/23. SWOG Champion: Skye C. Mayo, MD, MPH

Gastrointestinal Committee

NRG-GI008, "Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)," SWOG Champions: P. Philip & C. Eng
Activated: 3/10/22

NRG-GI004/ S1610, "Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer." SWOG Champion: Dr. Overman.
Activated: 11/7/17.

Closed Studies

S2107, "Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab for Patients with Microsatellite Stable, BRAFV600E Metastatic Colorectal Cancer." Study Chair: Dr. Morris. Study closed to accrual 10/1/24

S1613, "A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification." Study Chair: Dr. Raghav. Activated: 10/19/17. Step 3 permanently closed: 11/30/23

S0820, "A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Study Chair: Dr. Zell. Activated: 3/1/13. Permanently Closed: 6/30/23

A021502, "Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair." SWOG Champion: Dr. Lieu. Activated: 9/12/17. Permanently Closed: 1/17/23

A021703, "Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)." SWOG Champion: Dr. Cohen. Activated: 9/30/19. Permanently Closed: 12/15/22

E7208, "A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy." SWOG Champion: H. Hochster. Accrual target: 147 / Final accrual: 136

NRG-GI005, "Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)." SC: A. Scott. SWOG Champion: A. Scott Closed to Accrual as of 2/12/24

Anal

Active Studies

A022104, "The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer." SWOG Champion: A. Dasari, Activated: 11/9/22.

EA2176, "Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients." SWOG Champion: Dr. Morris. Activated: 10/15/20.

EA2182, "A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)." SWOG Champion: Dr. Murphy. Activated: 11/12/19.

EA2201, "A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma." SWOG Champion: Dr. Cho. Activated: 5/13/21.

Closed Studies

N1048, "A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision." SWOG Champion: C. Eng. Activated: 4/15/12. Accrual target: 1120 / Final accrual: 1194

InterAACT EA2133, "An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-Fluorouracil Versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease." SWOG Champion: V. Morris. Activated: 2/15/16. Accrual target: 80 / Final accrual: 12

NRG-GI002, "A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer." Activated: 10/12/16. Accrual target: 348/ SWOG accrual: 12 / Final accrual: 363. SWOG Champion: L. Kachnic

EA2165, "A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer." NCTN activated: 4/13/18. Accrual target: 344 / SWOG accrual: 38 / Final accrual: 383 SWOG Champion: V. Morris

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	<i>S1922</i>	<i>S2001</i>	<i>S2104</i>	<i>S2107</i>	<i>S2303</i>	<i>A021806</i>	<i>A022001</i>	<i>A022101</i>	<i>A022102</i>
Banner University Medical Center - Tucson	-	-	9	-	-	1	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	2	-	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
Boston Medical Center	-	-	-	-	-	1	-	-	3
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	2	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	2	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	1	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	1	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	1	2	2	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	1	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	6	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	1	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	2	3	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	2	-	-	2	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	3	-	-	-	1	-
Heartland Cancer Research NCORP	1	1	-	3	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	2	-	-	-	-	-	-	-
Henry Ford Hospital	-	2	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	1	-	-	6	3	-	-	-	-
Loma Linda University Medical Center	-	-	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	1	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	2	2	-	4	3	-	-	-	-
Moffitt Cancer Center	-	-	2	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	1	-	1	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	1	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	1	-	-	-
Northwestern University LAPS	1	-	1	-	-	1	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	1	-	-	-	-	-	-
Oregon Health and Science University	-	-	1	-	3	3	-	-	-

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	S1922	S2001	S2104	S2107	S2303	A021806	A022001	A022101	A022102
Pacific Cancer Research Consortium NCORP	1	2	3	2	1	-	-	-	-
Regents of the University of Michigan	4	3	2	-	-	4	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	2	4	4	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	-	1
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	2	-	-	-
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	2	-	4	-	-	-	-	7
UPMC Hillman Cancer Center LAPS	-	-	-	-	3	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	1	-	3	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-	-	-	-	-	1
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	1	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	3	-	9	-	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-	-	8
University of Kentucky/Markey Cancer Center	-	-	4	-	-	-	-	-	-
University of Nebraska Medical Center	-	-	-	-	1	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	2	-	-	-	-	-
University of Rochester LAPS	1	-	-	-	1	11	-	-	5
University of Texas Health Science Center at San Antonio	-	-	-	-	-	3	-	-	-
University of Texas MD Anderson Cancer Center LAPS	13	-	-	10	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	1	5	-	2	-	1	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	4	-	1	1	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	1	-	-	-	-	-	-	5
Wisconsin NCI Community Oncology Research Program	-	-	1	1	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	1	2	-	1	2	1	-	-
ALLIANCE	12	8	9	8	14	-	-	-	-
ECOG-ACRIN	2	16	8	14	1	-	-	-	-
NRG	3	9	8	10	2	-	-	-	-
Total	42	70	72	88	41	33	2	1	30

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	A022104	CCTGCO32	CCTGNE1	EA2174	EA2176	EA2182	EA2192	EA2197	EA2222
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	13	-	-	-	-	-	-	-	-
Boston Medical Center	6	-	-	2	-	2	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	2	-	4	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	2	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	8	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	-	-	1	2	-	-	-
Henry Ford Hospital	5	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	8	-	-	-	-
Loma Linda University Medical Center	-	-	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	1	-	-	-	1	-
Northwestern University LAPS	-	-	-	-	1	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	2	-	-	-	-	-	-
Oregon Health and Science University	-	1	-	-	4	1	4	6	1

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	A022104	CCTGC032	CCTGNE1	EA2174	EA2176	EA2182	EA2192	EA2197	EA2222
Pacific Cancer Research Consortium NCORP	-	1	-	-	-	-	-	-	-
Regents of the University of Michigan	1	-	-	-	-	-	-	-	1
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	2	-	-
The Don and Sybil Harrington Cancer Center	1	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	17	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	4	-	-	-	-	-	-	1	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	5	3	-	-	4	1	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	1	-	-	1	3	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	2	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	1	1	-	-	-
University of Colorado Cancer Center LAPS	-	-	2	-	-	2	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-	2
University of Nebraska Medical Center	-	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-	-	-
University of Rochester LAPS	22	-	-	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	8	-	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	10	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	9	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	7	-	-	-	-	-	-	1	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	1	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-
Total	107	7	4	6	34	14	6	9	4

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	NRGG1004	NRGG1005	NRGG1006	NRGG1008
Banner University Medical Center - Tucson	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	3	-	2
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	1
Boston Medical Center	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-
Dayton NCI Community Oncology Research Program	-	1	-	1
Fred Hutchinson Cancer Research Center LAPS	-	-	-	2
Gulf South Minority Underserved NCORP	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	5	-	1
Henry Ford Hospital	-	1	-	-
Houston Methodist Hospital	1	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	11	-	-
Loma Linda University Medical Center	-	-	-	1
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	1	-	-
Moffitt Cancer Center	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-
Northwell Health NCORP	-	1	-	1
Northwestern University LAPS	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-
Oregon Health and Science University	-	1	-	-

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	NRGG1004	NRGG1005	NRGG1006	NRGG1008
Pacific Cancer Research Consortium NCORP	-	-	-	-
Regents of the University of Michigan	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	1	-	1
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-
The West Clinic - Wolf River	-	-	-	4
UC Davis Comprehensive Cancer Center LAPS	-	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	1	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	6
University of Kansas Cancer Center - MCA Rural MU NCORP	-	2	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-
University of Nebraska Medical Center	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	1	1
University of Rochester LAPS	1	-	-	10
University of Texas Health Science Center at San Antonio	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	13	1	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	1	-	3
Virginia Mason Medical Center	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	4	-	-
ALLIANCE	-	-	-	-
ECOG-ACRIN	-	-	-	-
NRG	-	-	-	-
Total	15	35	1	34

Genitourinary Committee

Leadership

Chair: Seth P. Lerner, MD
 Vice-Chair: Daniel P. Petrylak, MD
 Chair Emeritus: Ian M. Thompson, Jr., MD
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Cathy M. Tangen, DrPH
 Melissa Plets, MS
 Sam Callis, MS
 Gabby Lopez, MS
 Sara Threlkel, BS

Scientific Leadership

Translational Medicine: Joshua J. Meeks, MD, PhD (GU Chair)
 Roger Li, MD (Bladder)
 Amir Goldkorn, MD (Prostate)
 Sumanta "Monty" K. Pal, MD (Renal)
 David McConkey, PhD (Advisor)
 Radiation Oncology: James B. Yu, MD
 Daniel A. Hamstra, MD
 Imaging: Evan Y. Yu, MD
 Hiram Shaish, MD
 John D. Hazle, PhD
 Theranostics: Andrei Iagaru, MD
 Yun Rose Li, MD, PhD
 Immunotherapeutics: Shuchi Gulati, MD (Medical Onc)
 Robert Svatek, MD (Urologic Onc)
 Pathology: M. Scott Lucia, MD
 Surgery: Kelly L. Stratton, MD
 Early Therapeutics: Parminder Singh, MD
 Bladder Organ Site Chairs: Siamak Daneshmand, MD (Localized)
 Thomas W. Flaig, MD (Advanced)
 Prostate Organ Site Chairs: Daniel W. Lin, MD (Localized)
 Tanya B. Dorff, MD (Advanced)
 Renal Organ Site Chairs: Brian Shuch, MD (Localized)
 Ulka N. Vaishampayan, MD (Advanced)
 Designates
 Cancer Control: Clara Hwang, MD
 Sarah P. Psutka, MD, MSC
 Accrual Champion: Jessica D. McDermott, MD
 International Liaison: Sumanta "Monty" K. Pal, MD
 NCORP: Scott Edward Delacroix, Jr., MD
 Helen Heng-Shan Moon, MD
 Veterans Affairs: Michael M. Goodman, MD
 Aihua Edward Yen, MD

Data Coordinators: Laura Wells, BA
 Tonya Johnson, BS
 Michele Counts, BS
 Oncology Research Professionals:
 CRAs: Abigail L. Cornette, MS
 Nurse: Gary Lee Duvall, RN
 Patient Advocates: Darrell Nakagawa (Bladder)
 Joël R. Pointon, MPH (Prostate)
 Laura B. Esfeller, MA (Renal)
 Rick Bangs, MBA (Emeritus)
 Pharmaceutical Science: TBD
 Senior Protocol Project Manager: Megan Keim
 Clinical Trials Program Manager: Sarah Cantu

Time/Location

Saturday, September 20, 2025 9:15 a.m. - 11:15 a.m.

Room: Regency A (Ballroom Level, West Tower)

Agenda

9:15 - 9:30 am: Chair's Welcome and Opening Remarks - Seth Lerner
 9:30 - 9:55 am: Cancer Control - Clara Hwang and Sarah Psutka
 9:55 - 11:15 am: Review of open approved trials - all organ site chairs

Prostate – Dan Lin and Tanya Dorff

Renal – Brian Shuch and Ulka Vaishampayan

Bladder – Sia Daneshmand and Tom Flaig

Cancer Control

Organ Site Chairs: Drs. Clara Hwang and Dr. Sarah Psutka

Active Studies

S1600, "A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes." Drs. J. Hamilton-Reeves and J. Holzbeierlein. Activated: 2/21/19.

S1823, "A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors", PI: Craig Nichols– Activated 6/1/20 GU Champions: Thomas Frye & Anishka D'Souza

S1931 (Companion Study): Examining Psychosocial and Emotional Issues for Metastatic Kidney Cancer. PI: Cristiane Bergerot.

Genitourinary Committee

S1937 (Companion Study): Assessment of Quality of Life for S1937: A Phase III Randomized Trial of Eribulin with or without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy. QoL Study Chair: Dr. Afsaneh Barzi. On hold until accrual picks up on S1937.

Prostate

Organ Site Chairs: Dr. Tonya Dorff (Advanced) and Dr. Daniel W. Lin (Local).

Priority Study

S2210, "Targeted neoadjuvant treatment for patients with localized prostate cancer and germline DNA repair deficiency." Dr. H. Cheng. Activated 8/14/23.

Active Studies

S2312, "A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature." Dr. Paul Corn. Activated 9/3/24.

S1802, "Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Drs. B. Chapin, A. Aparicio, and R. Valicenti. Activated: 9/17/18. Revision #5 released 8/15/24.

CTSU/A031102, "A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors." Dr. D. Quinn. Activated: 7/1/15.

CTSU/EA8171, "Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer." Dr. M. Liss. Activated: 7/9/18.

CTSU/EA8184, "A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers." Dr. R. Kopp. Activated: 5/10/21.

CTSU/NRG-GU002, "Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel." Dr. D. Raben. Activated: 12/30/16.

CTSU/NRG-GU008, "Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy." Dr. D. Lin. Activated: 3/5/20; Temporarily Closed: 6/24/21; Re-activated: 12/1/21.

CTSU/NRG-GU009, "Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)." Dr. S. Zhang. Activated: 10/15/20; Temporarily Closed: 6/24/21; Re-activated: 12/15/21.

Closed Studies

S1216, "A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer." Drs. N. Agarwal, A. Goldkorn, S. Gupta, et al. Activated: 3/6/13; Permanently Closed: 7/15/17. All participants off of treatment and follow up by 7/15/25.

CTSU/NRG-GU005, "Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer." Dr. A. Solanki. Activated: 11/16/17; Closed to accrual: 6/8/22.

CTSU/NRG-GU006, "A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer." Dr. J. Zeng. Activated: 4/27/18; Permanently Closed: 5/19/20.

CTSU/RT0G-0924, "Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial. Dr. T. Marshall. Activated: 7/7/11; Permanently Closed: 6/24/19.

CTSU/NRG-GU007, "Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen Deprivation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (With Initial Phase I)." Dr. D. VanderWeele. Activated: 6/3/19; Temporarily Closed: 5/5/21; Reactivated of dose level 2 (phase I) for 1 additional patient: 9/14/21; Temporarily closed to accrual for phase I dose level 2: 11/4/21; Re-activated to accrual for phase I/dose level 3: 12/6/21; Temporarily Closed: 7/11/22.

Genitourinary Committee

CTSU/EA8153, “Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHARTED2 Trial.” Dr. P. Corn. Activated: 2/8/18; Permanently Closed: 4/2/21; Tobacco use assessment sub-study permanently closed: 10/8/21.

CTSU/AGCT1531, “A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.” Dr. A. D’Souza. Activated: 5/8/17; PRO study Temporarily Closed: 2/12/21.

Renal

Organ Site Chairs: Dr. Ulka Vaishampayan (Advanced) and Dr. Brian Shuch (Local).

Priority Study

S1931, “Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial).” Drs. H. Kim and U. Vaishampayan. Activated: 11/16/20.

Concepts in Development

S2419, “Phase III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic CBM588, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial].” Drs. P. Barata and U. Vaishampayan. Submitted to CTEP for initial review on 6/20/25.

Active Studies

S2200, “A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)” Drs. B. Maughan and S. Pal. Activated 9/19/22.

CTSU/AREN1721, “A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups.” Dr. M. Parikh. Activated: 10/9/18; Temporarily Closed: 3/24/21; Re-activated: 2/7/22.

CTSU/A031704, “PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE].” Dr. T. Zhang. Activated: 5/9/19; Step 1 temporarily closed: 3/8/21; Step 1 re-activated: 3/26/21.

CTSU/A031801, “A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (Radical).” Dr. M. Parikh. Activated: 12/13/19.

CTSU/A031901, “Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A randomized Phase 3 non-Inferiority Trial.” Dr. D. Vaena. Activated: 12/10/20.

Closed Studies

S1500, “A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET).” Drs. S. Pal and P. Lara. Activated 4/5/16; Permanently closed: 12/15/19.

S0931, “EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study.” Drs. C. Ryan, E. Heath, P. Lara, et al. Activated: 4/1/11; Permanently Closed: 9/15/16.

CTSU/E2810, “Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy.” Dr. S. Pal. Activated: 8/8/12; Permanently closed: 7/25/17.

CTSU/A031501, “Phase III Randomized Adjuvant study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation.” Dr. G. Sonpavde. Activated: 9/21/17; Permanently Closed: 8/24/21.

CTSU/EA8143, “A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC).” Drs. P. Lara and B. Shuch. Activated: 2/2/17; Permanently Closed: 6/9/21.

Bladder

Organ Site Chairs: Dr. Thomas Flaig (Advanced) and Dr. Siamak Daneshmand (Local).

Priority Study

S1937, “A Phase III Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.” Drs. S. Sadeghi and P. Lara. Activated: 2/16/21. Temporary Closure: 5/30/23. Re-opened Arms 1&3 to accrual and permanently closed Arm 2 on 2/15/24. Revision #4 had Sacituzumab govitecan removed as a treatment option on 2/3/25.

Concepts in Development

S2427, “Bladder preservation with chemoradiotherapy or immunoradiotherapy after a good response to neoadjuvant chemotherapy in patients with muscle invasive bladder cancer

Genitourinary Committee

(BRIGHT).” Dr. L. Ballas. PRC call occurred 1/29/25. Submitted to CTEP 3/5/25, Approval on hold received 6/26/25. CIRB review scheduled for 7/17/25.

Active Studies

S1806, “Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.” Drs. P. Singh, S. Lerner, J. Efstathiou, et al. Activated: 4/19/19. Step 1 accrual closed 3/1/24. Revision #10 submitted to CTEP on 5/29, pending review.

CTSU/A031701, “A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations.” Drs. A. Gupta and S. Gupta. Activated: 8/1/18.

CTSU/A031803, “Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.” Drs. D. Tyson and C. Ramamurthy. Activated: 1/6/20.

CTSU/EA8185, “Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in Clinical Stage III, Node Positive Bladder Cancer (INSPIRE).” Drs. T. Mitin and J. Meeks. Activated: 8/25/20.

CTSU/EA8192, “A Phase II/III Trial of MED14736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy” Drs. S. Psutka and A. Tripathi. Activated: 5/6/21.

Closed Studies

S1011, “A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer.” Drs. S. Lerner, A. Alva, and T. Koppie, et al. Activated: 8/1/11; Permanently Closed: 4/15/17. Listed as FDAAA/IRB Completed on 1/8/25.

S1602, “A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG Naïve High-Grade Non-Muscle Invasive Bladder Cancer.” Drs. R. Svatek, A. Alva, and S. Lerner. Activated: 2/7/17; Permanently Closed: 12/15/20.

S1605, “Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.” Drs. P. Black, P. Singh, and S. Lerner. Activated: 2/7/17; Permanently Closed: 7/5/19.

S2011, “Randomized Phase II Trial of Gemcitabine, Avelumab, and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin Ineligible Muscle-Invasive Urothelial Carcinoma.” Drs. Sonpavde, M. Liss, and S. Lerner, et al. Activated: 10/6/21. Closed to Accrual: 11/15/23.

Diverse Studies of Interest

S1609, “DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors.” Drs. S. Patel, Y. Chae, R. Kurzrock, et al. Activated: 1/13/17; Permanently Closed: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 41, 42, 43, 44, 45, 48, 51, 52, and 53; Temporarily Closed: 38, 40, 46, and 51.

CTSU/A031702, “A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)” Dr. S. Liu. Activated: 4/12/19; Temporarily Closed: Cohort A, B, C, E, F, G, I.

CTSU/EAY 131, “Molecular Analysis for Therapy Choice (MATCH).” Dr. V. Villalobos. Activated: 8/12/15; EAY131 (MATCH) Subprotocol Z1C, EAY131-Z1C, is permanently Closed to Accrual: 5/25/21; EAY131 (MATCH) Subprotocol M, or EAY131-M, is suspended, effective immediately: 8/3/21; AY131 Subprotocols A, C1, C2, E, L, V, Z1E, and Z1G are closed to accrual: 1/31/22; Subprotocol Z1G reactivated: 2/23/22

CTSU/EA8134, “InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study).” Dr. C. Pettaway. Activated: 9/8/17.

Genitourinary Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	S1802	S1806	S1931	S1937	S2200	S2210	S2312	A021804	A031701	A031702	A031704
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	7	-	1	-	-	-	-	-	-	-	-
Banner University Medical Center - Tucson	7	-	1	-	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Cntr	5	8	-	-	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	10	-	-
Cancer Research Consortium of West Michigan NCORP	2	8	1	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	5	-	-	-	-	-	-	-	-	1
Cancer Research of Wisconsin and N Michigan Consortium	2	6	-	1	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Prgrm	1	1	1	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	11	4	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	5	-	3	-	6	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	2	4	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	3	4	-	5	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	5	2	-	-	-	-	-	-	-	-	1
Desert Regional Medical Center	2	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	25	-	-	-	-	3	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	1	-	-	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	5	-	-	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	83	73	2	-	1	1	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	4	-	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	11	8	1	-	3	-	1	-	2	-	-
Henry Ford Health Providence Southfield Hospital	-	-	-	-	-	-	-	-	-	-	3
Henry Ford Hospital	28	4	-	3	-	-	-	-	-	2	6
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia	4	-	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	36	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Prgrm	18	-	2	-	-	-	-	-	-	-	66
Lahey Hospital and Medical Center	-	-	-	-	-	-	-	-	-	7	-
Loyola University Medical Center	9	6	1	2	-	-	-	-	-	1	2
Medical University of S Carolina Minority Underserved NCORP	8	-	-	3	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	1	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	15	20	-	3	2	-	3	-	1	-	-
Montana Cancer Consortium NCORP	5	-	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	11	-	-	-	-	-	-	-	-	-	1
Nevada Cancer Research Foundation NCORP	1	-	-	-	-	-	-	-	-	1	-
New Mexico Minority Underserved NCORP	-	-	1	1	-	-	-	-	-	-	1

Genitourinary Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	S1802	S1806	S1931	S1937	S2200	S2210	S2312	A021804	A031701	A031702	A031704
Northwell Health NCORP	-	3	-	-	-	-	-	-	-	-	1
Northwestern University LAPS	-	8	1	1	1	-	2	-	-	-	2
Ohio State University Comprehensive Cancer Center LAPS	2	3	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	1	2	1	1	1	-	1	-	5	5
Regents of the University of Michigan	2	-	27	-	-	-	-	-	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	2	-	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	9	1	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	3	-	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	3	-	-	-	-	-	-	-
Tulane University School of Medicine	-	-	9	-	-	-	-	-	-	-	1
UC Davis Comprehensive Cancer Center LAPS	14	9	2	4	-	-	-	-	10	-	3
UC Irvine Health/Chao Family Comprehensive Cancer Center	7	6	-	2	-	-	-	-	-	-	-
UC San Diego Moores Cancer Center	5	3	-	-	-	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	3	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	8	3	1	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	8	-	1	15	-	-	-	-	-	5	-
U Alabama at Birmingham / Deep S Research Consortium LAPS	-	-	7	-	-	-	-	-	-	1	-
University of Arkansas for Medical Sciences	9	-	-	-	1	-	1	-	-	-	2
University of Cincinnati Cancer Center-UC Medical Center	8	6	3	-	-	-	-	-	-	-	7
University of Colorado Cancer Center LAPS	10	6	-	8	-	-	-	-	-	-	11
University of Kansas Cancer Center - MCA Rural MU NCORP	7	9	-	2	-	-	-	-	-	1	7
University of Kentucky/Markey Cancer Center	2	3	-	1	-	-	-	-	-	-	-
University of Mississippi Medical Center	1	-	-	1	1	-	-	-	-	1	-
University of Oklahoma Health Sciences Center LAPS	44	15	5	5	3	-	4	-	-	-	-
University of Rochester LAPS	25	-	3	-	-	-	-	-	1	3	9
University of Texas Health Science Center at San Antonio	13	-	6	-	-	-	1	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	86	-	-	-	-	-	7	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	19	-	2	3	3	-	-	-	-	-	-
Upstate Carolina Consortium Comm Oncology Research Prgrm	3	2	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	8	6	-	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	1	-	-	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	2	-	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	14	6	-	1	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	1	6	-	3	-	-	-	-	-	-	1
ALLIANCE	116	34	8	5	2	-	4	-	-	-	-
ECOG-ACRIN	102	44	15	15	6	-	-	-	-	-	-
NRG	113	136	14	2	4	-	-	-	-	-	-
Total	933	485	129	91	34	5	23	1	24	27	130

Genitourinary Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	A031801	A031803	A032001	A032101	A032103	EA8134	EA8171	EA8191	EA8192	EA8212	NRGGU008
Arnot Ogden Medical Center/Falck Cancer Center	-	-	1	-	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	2	-	-	-	-	49	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	-	-	-	-	-	26	-
Banner University Medical Center - Tucson	-	-	-	-	1	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Cntr	-	6	-	-	1	-	-	-	-	28	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	12	-	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin and N Michigan Consortium	-	-	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Prgrm	-	-	-	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	-	33	-	16	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-	1	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	1	16	-	-	-	-	11	-	-	69	6
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	2	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	1	-	1	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-	2	-
Instituto Nacional De Cancerologia	-	-	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-	-	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	-	-	-	-	-	6	-
Medical University of S Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	3	-	17	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	2	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-	-	-	1	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-

Genitourinary Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	A031801	A031803	A032001	A032101	A032103	EA8134	EA8171	EA8191	EA8192	EA8212	NRGGU008
Northwell Health NCORP	-	-	-	-	-	-	-	1	-	-	4
Northwestern University LAPS	-	-	-	1	-	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	-	-	-	7	-	15	18	-	29	-
Regents of the University of Michigan	-	-	-	12	1	-	-	-	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-	-	-
Tulane University School of Medicine	-	-	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	7	5	2	-	1	-	-	-	-	3	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-	-	2
UC San Diego Moores Cancer Center	-	-	-	1	-	-	-	-	-	2	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	-	16	-	-	-	18	-
U Alabama at Birmingham / Deep S Research Consortium LAPS	1	12	-	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	1	2	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	2	-	1	-	-	2	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-	-	-	-	2
University of Kentucky/Markey Cancer Center	-	-	-	-	1	-	-	-	2	15	-
University of Mississippi Medical Center	-	-	-	-	2	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	1	-	-	6	-	7	-
University of Rochester LAPS	-	-	-	-	3	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	6	-	-	-	-	13	2	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	6	-	-	-	-	-	-	-	-	-	-
Upstate Carolina Consortium Comm Oncology Research Prgrm	-	-	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-	9	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-	-
Total	15	47	15	16	21	19	91	65	4	248	14

Genitourinary Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	NRGGU009	NRGGU010	NRGGU011	NRGGU012	NRGGU013
Arnot Ogden Medical Center/Falck Cancer Center	-	4	-	-	-
Audie L Murphy VA Hospital	-	-	-	-	-
Banner MD Anderson Cancer Center	1	3	-	-	-
Banner University Medical Center - Tucson	1	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Cntr	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-
Cancer Research of Wisconsin and N Michigan Consortium	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Prgrm	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	5	-	4
Georgia Cares Minority Underserved NCORP	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-
Gulf South Minority Underserved NCORP	16	6	5	2	-
Hawaii Minority Underserved NCORP	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	-
Medical University of S Carolina Minority Underserved NCORP	-	1	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-

Genitourinary Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	NRGGU009	NRGGU010	NRGGU011	NRGGU012	NRGGU013
Northwell Health NCORP	20	3	-	-	-
Northwestern University LAPS	-	4	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-
Oregon Health and Science University	-	-	6	-	-
Regents of the University of Michigan	-	1	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	3	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-
Sutter Cancer Research Consortium	6	10	1	1	-
The West Clinic - Wolf River	-	-	-	-	-
Tulane University School of Medicine	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	1	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-
UC San Diego Moores Cancer Center	2	2	-	2	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	-
U Alabama at Birmingham / Deep S Research Consortium LAPS	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-
University of Colorado Cancer Center LAPS	17	10	1	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	10	7	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-
University of Mississippi Medical Center	2	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	4	4	-	2	5
University of Rochester LAPS	-	-	-	-	-
University of Texas Health Science Center at San Antonio	1	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-
Upstate Carolina Consortium Comm Oncology Research Prgrm	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-
Virginia Mason Medical Center	4	4	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-
Western States Cancer Research NCORP	2	1	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-
ALLIANCE	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-
NRG	-	-	-	-	-
Total	87	63	18	7	9

Immunotherapeutics Committee

Leadership

Co-Chairs: Siwen Hu-Lieskovan, MD, PhD
 Katerina Politi, PhD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Michael LeBlanc, PhD
 Katie Minichiello, MS
 Matt Chansky, BS

Designates

Data Coordinators: Michele Counts
 Pharmaceutical Science: Jordan P. McPherson, PharmD
 Kimberly McConnell, PharmD
 Sr. Protocol Project Manager: Chris Kippola, BS
 Clinical Trial Program Manager: Sharon Palmer

Time/Location

Friday, September 19, 2025 9:00 a.m. - 11:00 a.m.
 Room: Water Tower (Concourse Level, West Tower)

Agenda

9:00 - 9:05 am	Welcome & Introductions Siwen Hu-Lieskovan & Katerina Politi SWOG Immunotherapeutics Committee Co-Chairs
9:05 – 9:20 am	iMATCH Pilot Update: Stage II Update Paul Swiecicki, Katerina Politi, Siwen Hu-Lieskovan S2101 Study Chairs
9:20 – 9:25 am	Q & A
9:25 – 9:45 am	Personalized Cancer Vaccines for Kidney Cancer David Braun, MD, PhD Assistant Professor of Medicine (Medical Oncology) Louis Goodman and Alfred Gilman Yale Scholar
9:45 – 9:55 am	Q & A
9:55 – 10:10 am	ECOG-ACRIN Immunotherapeutics Update Yana G. Najjar, MD Associate Professor of Medicine, Univ of Pittsburgh Director, Clinical and Translational Research Center
10:10 – 10:20 am	Q & A

10:20 – 10:35 am	Alliance Immunotherapeutics Update David Kozono, MD, PhD Assistant Professor of Radiation Oncology, Harvard Medical School Director, Thoracic Radiation Oncology
10:35 – 10:45 am	Q & A
10:45 – 10:55 am	Final Comments & Closing Remarks Siwen Hu-Lieskovan & Katerina Politi SWOG Immunotherapeutics Committee Co-Chairs

Active Study

S2101, “Biomarker Stratified CaboZantinib (NSC#761968) and Nivolumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study.” Drs. Hu-Lieskovan, Swiecicki and Politi.
 Activation: 10/14/22.

Immunotherapeutics Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	S2101
Essentia Health NCI Community Oncology Research Program	1
Froedtert and the Medical College of Wisconsin LAPS	4
Heartland Cancer Research NCORP	1
Michigan Cancer Research Consortium NCORP	1
New Mexico Minority Underserved NCORP	1
Northwestern University LAPS	1
Pacific Cancer Research Consortium NCORP	1
Regents of the University of Michigan	13
University of Arkansas for Medical Sciences	2
University of Utah - Huntsman Cancer Institute LAPS	10
ALLIANCE	8
ECOG-ACRIN	7
NRG	5
Total	55

Leukemia Committee

Leadership

Chair: Harry P. Erba, MD, PhD
 Vice-Chair: Anjali S. Advani, MD
 Executive Officer: Susan M. O'Brien, MD
 Statisticians: Megan Othus, PhD
 Anna Moseley, MS
 Matt Chansky, BS

Scientific Leadership

Translational Medicine: Jerald P. Radich, MD
 Pathology: David R. Head, MD
 Cytogenetics Liaison: Min Fang, MD, PhD

Designates

Cancer Control: Stephanie B. Tsai, MD
 Veterans Affairs: Tsewang Tashi, MD
 Data Coordinators: Roula Bustami
 Louise Highleyman, BA
 Cassie Villasin
 Oncology Research Professionals:

CRA: TBD

Nurse: TBD

Patient Advocate: Gail Sperling, MPH

Pharmaceutical Science: Holly O. Chan, PharmD

..... Ila M. Saunders, PharmD

Protocol Project Manager: Amy Doyle

Protocol Project Manager: Samantha Bankston (MyeloMATCH)

Clinical Trials Program Manager: Sharon Palmer

Clinical Trials Program Manager: Sarah Cantu (MyeloMATCH)

Time/Location

Friday, September 19, 2025 4:30 p.m. - 6:30 p.m.

Room: Water Tower (Concourse Level, West Tower)

Agenda

1. Updates in Leukemia Translational Medicine
2. Updates in CLL - Deb Stephens
3. Updates in AML/MyeloMATCH - Laura Michaelis
4. Updates in CML - Kendra Sweet
5. Updates in ALL - Kristen O'Dwyer

AML/MDS Studies

Active Studies

CTSU/A041701, "A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy." Dr. L. Liesveld. Activated: 1/16/19. Closed: 9/16/24.

Closed Studies

S1612, "A Randomized Phase II/III Trial of "Novel Therapeutics" Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older." Drs. L. Michaelis, R. Walter, S. Assouline, et al. Activated: 12/22/17; Complete: 6/26/24.

S0919, "A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Poor-Risk Acute Myelogenous Leukemia (AML)." Dr. A. Advani. Re-Activated: 4/1/13; Closed: 9/15/17; Complete: 10/21/21.

S1203, "A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)." Drs. Garcia-Manero and Pagel. Activated: 12/15/12; Closed: 11/4/15; Complete: 03/29/22.

ALL Studies

Active Studies

S1905, "A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) / T-Cell Lymphoblastic Lymphoma (T-LBL)." Drs. A. Advani, N. Papadantonakis, and C. Yeung. Activated: 8/17/20.

CTSU/A041501, "A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL." Dr. A. Advani. Activated: 6/1/17. Temporarily closed to accrual: 05/24/22.

Developing Studies

S2507, "A Phase II Randomized Study of Blinatumomab with or without Revumenib for Patients with KMT2Ar B-ALL with persistent measurable residual disease (MRD)." Drs. I. Aldoss, A. Advani, W. Stock, J. McNeer, and C. Saygin.

Leukemia Committee

Closed Studies

S0333, "A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia with Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy." Drs. Forman and O'Donnell. Activated: 4/15/05; Closed: 11/1/09.

S1312, "A Phase I Study of Inotuzumab Ozogamicin in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's Leukemia)." Drs. A. Advani and Liedtke. Activated: 4/1/14; Closed: 8/2/19.

S1318, "A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients \geq 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphocytic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients \geq 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL and Philadelphia-Chromosome-Like Signature (Ph-like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)." Drs. A. Advani and K. O'Dwyer. Activated: 1/12/15; Closed: 9/29/21.

CLL Studies

Active Studies

S1925, "Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL): EVOLVE CLL/SLL Study." Drs. D. Stephens, B. Hill, J. Pagel, et al. Activated: 12/14/20.

Developing Studies

S2504, "A Randomized Phase II Study of Pirtobrutinib Plus R-CHOP vs. R-CHOP for Patients with Previously Untreated Richter Transformation (RT)." Drs. M. Shadman, D. Stephens, and A. Danilov.

Closed Studies

CTSU/EA9161, "A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)." Dr. M. Shadman. Activated: 1/3/19. Closed: 4/30/21.

CTSU/A041702, "A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (\geq 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)." Dr. B. Hill. Activation: 1/4/19. Closed: 7/15/22.

CML Studies

Closed Studies

S1712, "A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease." Drs. K. Sweet and J. Radich. Activated: 7/20/18. Closed: 10/20/22.

MDS/MPN Studies

Developing Studies

SXXXX "A Phase II/III study of Nuvisertib and Decitabine-Cedazuridine for Myelodysplastic/myeloproliferative neoplasms (MDS/MPNs)." Drs. A. Coltoff, A. Gerds, and F. El Chaer.

MyeloMATCH

Active Studies

MYELOMATCH, "Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials." Drs. J. Radich and S. Jiwani. Activated: 05/16/24.

MM1YA-S01, "A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs. (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger who are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by myeloMATCH; A myeloMATCH Clinical Trial." Drs. P. Shami and T. Lin. Activated: 05/16/24.

MM10A-S03, "A Randomized Phase II trial of C-DEC, Venetoclax, and Enasidenib Compared with Azacitidine and Venetoclax for Newly Diagnosed Older Adults with IDH2 mutant AML: A myeloMATCH Substudy." Drs. E. Huselton and U. Borate. Activated: 04/01/25

Developing Studies

MM10A-S04, "A Phase II Trial of ASTX727 with Standard Duration Versus Shorter Duration of Venetoclax in Genomically Heterogenous AML Among Adults Aged 60 or Older and Less Fit for Intensive Therapy: A myeloMATCH Substudy." Drs. U. Borate and J. Jayanshu.

Leukemia Committee

MM10A-S05, "A RAS-Activated Biomark Driven Phase II Study Evaluating the Addition of Tuspentinib to CPX-351 Induction THERapy in Older Fit Adults with Acute Myeloid Leukemia: A myeloMATCH Substudy." Drs. J. Appelbaum, B. Jonas, and M. Konopleva.

Clinical Trials Partnerships (CTP)

Active Studies

21CTP.LEUK01, "A Phase II Trial of Asciminib, Dasatinib, Prednisone, and Blinatumomab for Participants with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia." Drs. Advani, Liedtke and Radich. Activated: 5/15/25

Leukemia Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	MM10A-S03	MM1YA-S01	MYELOMATCH	S1905	S1925	A041501	A041701	A041703
Banner University Medical Center - Tucson	-	-	2	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	5	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	2	7	4	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	1	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	2	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	1	-	-	-
Cedars-Sinai Medical Center	-	-	2	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	4	2	-	-	-
Duke University - Duke Cancer Institute LAPS	-	3	3	-	1	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	1	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	4	3	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	6	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	1	-	9	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	2	-	-	-	-	-
Henry Ford Hospital	-	-	4	-	3	-	4	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	-	-	2	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	2	-	-	-
Loyola University Medical Center	-	-	4	-	1	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	5	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	5	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	13	-	7	-	-	-
Montana Cancer Consortium NCORP	-	-	1	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	1	12	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	2	-
Northwestern University LAPS	-	2	26	-	1	3	1	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	4	-	-	-	-	-
Oregon Health and Science University	-	1	3	1	-	8	-	-
Pacific Cancer Research Consortium NCORP	-	-	17	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	1	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	2	-	-	-
Stanford Cancer Institute Palo Alto	-	-	-	-	-	8	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	4	2	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	4	3	-	1
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	2	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	1	24	-	-	1	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-	4	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	2	-	-	-	1
University of Kansas Cancer Center - MCA Rural MU NCORP	-	3	30	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	4	-	-	-	-	-
University of Rochester LAPS	-	2	35	3	13	7	27	3
University of Utah - Huntsman Cancer Institute LAPS	-	-	9	-	20	1	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	1	9	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	7	-	-	5	-	-
ALLIANCE	-	2	133	2	38	-	-	-
CCTG	-	-	39	-	12	-	-	-
ECOG-ACRIN	1	6	123	2	18	-	-	-
NRG	-	1	16	-	5	-	-	-
Total	2	23	551	20	152	44	38	5

Leukemia Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	EA042001	EA9152	EA9171	EA9181	EA9213	MM10AEA02	MM1YACTG01
Banner University Medical Center - Tucson	-	-	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	3	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	3	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	4	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	2	-	-	-
Intermountain Medical Center	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	2	-	1	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	-
Northwestern University LAPS	1	-	-	4	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-
Oregon Health and Science University	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-
Stanford Cancer Institute Palo Alto	3	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	12	-	-	-
UC San Diego Moores Cancer Center	-	-	-	1	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	2	-	-	-	-	-	1
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	4	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	2
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-
University of Rochester LAPS	4	-	-	9	-	2	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	3	-	-	-
Western States Cancer Research NCORP	-	-	2	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	2	3	2	1	-	1	-
ALLIANCE	-	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-
Total	12	3	4	45	3	4	3

Lung Committee

Leadership

Chair: Jhanelle E. Gray, MD
 Vice-Chair: Roy S. Herbst, MD, PhD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Mary Redman, PhD
 Yingqi Zhao, PhD
 Mia Hsieh, MS
 Katie Minichiello, MS
 James Moon, MS
 Sara Threlkel, BS
 Scientific Leadership
 Translational Medicine:
 Biology/Pathology: Philip C. Mack, PhD
 Fred R. Hirsch, MD, PhD
 Ignacio I. Wistuba MD
 Imaging: Chadwick L. Wright MD, PhD
 Myrna C. Godoy, MD, PhD
 Radiation Oncology: Henry Park, MD
 Surgery: Wayne L. Hofstetter, MD
 Subcommittee Chairs:
 Early Stage Disease: Raymond Osarogiagbon, MD
 Eric Miguel Toloza, MD, PhD
 Locally Advanced Disease: Mary B. Daly, MD
 Tina Cascone, MD, PhD
 Shirish Gadgeel, MD (Early Therapeutics)
 Metastatic Disease: Rachel E. Sanborn, MD
 Sarah B. Goldberg, MD
 Community Engagement: Paul J. Hesketh, MD
 Suzanne Cole, MD
 Designates
 Cancer Control Liaison: Gary E. Goodman, MD
 Veterans Affairs: Chao H. Huang, MD
 Data Coordinators: Amy Johnson, CCRP
 Kevin Moralda, BS
 Larry Kaye
 Louise Highleyman, BA
 Pasarlai Ahmadzai, MD, MPH
 Clinical Research Project Manager: TBD
 Oncology Research Professionals:
 CRA: TBD
 Nurses: Rosalie Zablocki, RN
 Lisa G. Davis, RN
 Patient Advocate: Judy Johnson, MBA

Pharmaceutical Science: Joyce Lee, PharmD
 Safae Ghouraichi, PharmD
 Protocol Project Managers: Justine Trevino
 Gabe Chadwell (Lung-MAP)
 Sr. Protocol Project Manager: Jennifer Beeler (Lung-MAP)
 Clinical Trials Program Manager: Sarah Cantu
 Crystal Miwa (Lung-MAP)

Time/Location

Friday, September 19, 2025 11:30 a.m. - 1:30 p.m.

Room: Regency A (Ballroom Level, West Tower)

Agenda

11:30 - 11:45 am General Update & Accruals: Jhanelle E. Gray, MD
11:45 - 11:50 am Patient Advocate Update: Judy Johnson, MBA
11:50 - 11:55 am Thoracic Surgery Session: Eric Toloza, MD, PhD
11:55 - 12:00 pm Thoracic Radiation Session: Megan Daly, MD
12:00 - 12:05 pm Translational Medicine Session: Philip C. Mack, PhD
12:05 - 12:10 pm Community Engagement: Paul J. Hesketh, MD & Lucy Gansauer, MSN, RN
12:10 - 12:25 pm Keynote Speaker - Paul Bunn, MD, Distinguished Professor of Medical Oncology, James Dudley Chair of Cancer Research, University of Colorado
12:25 - 12:55 pm Thoracic Medical Oncology: Jhanelle Gray, MD

S2414 "A randomized phase III trial incorporating pathologic response in participants with early stage non-small cell lung cancer to optimize immunotherapy in the adjuvant setting (INSIGHT)". Activated: 3/14/25; Accrual Goal: 306; Accrual: 2. Jeremy Cetnar, MD, MS and Raymond Osarogiagbon, MD

S2409 PRISM: A Multicohort PREcision SCLC Subtype Maintenance Phase II Trial of Durvalumab Versus Biomarker-Directed Novel Agents in Combination with Durvalumab in Extensive Stage Small Cell Lung Cancer (ES-SCLC). Anne Chiang, MD, PhD and Alberto Chiappori

CTIU2317/S2402 "Perioperative versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer (PROSPECT LUNG)". Activated: 12/11/24; Accrual Goal: 1100. Raid Aljumaily, MD and Raymond Osarogiagbon, MD

Lung Committee

S1933, "A Pilot Trial of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Activated: 6/15/20; Accrual Goal: 47; Accrual: 45. Raid Aljumaily, MD

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Activated: 1/10/20; Accrual Goal: 668; Accrual: 286. Chad Rusthoven, MD

LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)." Activated: 1/28/19; Accrual Goal: 6000; Accrual: 3693. Karen Reckamp, MD and David R. Gandara, MD

S1800E, "A Randomized Phase II Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Activated: 4/28/25; Accrual Goal: 378; Accrual: 164. Saiama Waqar, MD, MSCI (NRG) and Dr. Tina Li (SWOG)

S1900J, "A Phase II Study of Amivantamab SC in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with High MET Amplification (Lung-MAP Sub-Study)." Activated: 9/27/24; Accrual goal: 88; Accrual: 12. Shirish Gadgil, MD and Christian Rolfo, MD

S1900G, "A Randomized Phase II Study of Capmatinib plus Osimertinib (Tagrisso) with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung- MAP Sub-Study)." Activated: 4/3/23; Accrual Goal: 66 (60 eligible); Accrual: 31. Sarah Goldberg, MD, MPH and Ross Camidge, MD, PhD

S1900K, "A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Activated: 12/18/2023; Accrual Goal: 56; Accrual: 19. Paul Paik, MD (ECOG-ACRIN) and Xiuning Le, MD, PhD (SWOG)

12:55 - 1:30 pm **Open Discussion**

Active Studies

LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)." Drs. Borghaei, Reckamp, Gandara, et al. Activation: 1/28/19.

S1900G, "A Randomized Phase II Study of INC280 (Capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Goldberg and Camidge. Activation: 4/3/23.

S1900K, "A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Paik and Le. Activation: 12/18/23.

S1900J, "A Phase II Study of Amivantamab SC (subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Rolfo and Gadgil. Activation: 9/27/24.

S1800E, "A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Waqar and Li. Activation: 4/28/25.

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Drs. Rusthoven, Brown, Wefel, et al. Activation: 1/10/20.

S1933, "A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Drs. Aljumaily, Mitin, and Wozniak. Activation: 6/15/20.

S2414, "A Randomized Phase III Trial Incorporating Pathologic Complete Response in Participants with Early Stage Non Small Cell Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting (INSIGHT)." Drs. Cetnar and Osarogiagbon. Activation: 3/14/25.

CTSU/A081801, "Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)." Dr. Gray. Activation: 6/3/20.

CTSU/A151216, "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)." Dr. Gandara. Activation: 8/18/14.

CTSU/EA5182, "Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)." Dr. Goldberg. Activated: 10/22/20.

Lung Committee

CTSU/NRG-LU007, "Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial." Dr. Park. Activated: 8/17/20.

Closed Studies

CTSU/NRG-CC003, "Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer." Dr. Gaspar. Activation: 12/7/15; Temporary closure: 5/28/20; Reactivation: 7/27/20; Permanent closure: 6/21/22.

S1800A, "A Phase II Randomized Study of Ramucirumab Plus Pembrolizumab (MK-3475) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Reckamp and Dragnev. Activation: 5/17/19. Permanently closed: 10/20/20.

S1800D, "A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)." Drs. Wrangle and Husain. Activation: 2/15/22. Permanently closed: 3/10/23.

S1900A, "A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Riess and Wheatley-Price. Activation: 1/28/19. Permanently closed: 2/2/21.

S1900B, "A Phase II Study of Selpercatinib (LOXO-292) in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Elamin and Gray. Activation: 2/10/20. Permanently closed: 5/1/21.

S1900C, "A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)." Drs. Skoulidis and Suga. Activation: 1/16/20. Permanently closed: 12/18/20.

S1900E, "A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)." Drs. Padda and Gerber. Activation: 4/2/21. Permanently closed: 12/27/24.

S1900F, "A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and

Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)." Drs. Gray and Elamin. Activation: 7/25/22. Permanently closed: 6/27/23.

S1929, "Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Drs. Karim, Reckamp, Gay, et al. Activation: 6/15/20; Step 1 Registration Permanently Closed 8/15/22; Step 2 Permanently Closed 10/15/22.

S1934, "NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer." Drs. Osarogiagbon, Huang, Decker, et al. Activation: 9/9/21; Temporary closure: 11/5/21; Reactivation: 2/15/22; Permanently closed 3/1/23.

CTSU/EAS163/S1709, "INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis." Dr. Chiang. Activation: 2/28/19; Closed to accrual: 3/1/24.

S1701, "A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma." Drs. Tsao and Koczywas. Activation: 8/9/18; Closed to accrual: 10/15/22.

S1914, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activation: 3/25/20. Closed to accrual: 9/6/24.

S2302, "PRAGMATICA: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer" Drs. Reckamp and Dragnev. Activation: 3/6/23; Closed to accrual: 12/20/24.

CTSU/E4512, "A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein." Dr. Li. Activation: 8/18/14; Closed to accrual: 5/10/24.

CTSU/EAS181, "Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone

Lung Committee

for Unresectable Stage 3 NSCLC." Dr. Harkenrider. Activation: 4/9/20;
Closed to accrual: 11/20/23.

CTSU/NRG-LU002, "Maintenance Systemic Therapy versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial." Dr. Gomez. Activation: 4/7/17; Temporary closure: 11/12/21; Closed to accrual: 12/06/23.

CTSU/NRG-LU005, "Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab." Dr. Hsu. Activation: 5/28/19; Closed to US and Canadian sites 6/23/22; Closed to accrual: 12/31/23.

CTSU/EA5191, "A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC." Dr. Massarelli. Activated: 5/22/20; Closed to accrual: 10/13/23.

NCI-Approved Concepts

S1900N, "A Randomized Phase II Study of Sacituzumab Govitecan alone, Ivonescimab alone, or Sacituzumab Govitecan and Ivonescimab in Participants with Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Scott and Riess.

S2404, "Accelerating Drug Efficacy Evaluation thru Growth Rate and Overall Survival Correlations" Dr. Lawrence Schwartz and Dr. Karen Reckamp.

Concepts in Development

S1800G, "A Randomized Phase II Study of Casdozokitug with or without Toripalimab in Participants with Previously Treated Relapsed or Refractory Advanced Lung Squamous Cell Carcinoma (NRG Lung-MAP Non-match Sub-Study)." Drs. Henick and Marron.

S1900P, "A Phase II Study of Sapanisertib Plus Serabelisib Plus Paclitaxel Versus Standard of Care Chemotherapy in Participants with NFE2L2, KEAP1 or PI3K Pathway-Positive Stage IV Squamous Cell Lung Cancers (ECOG-ACRIN Lung-MAP Sub-Study)." Drs. Paik and Riano.

S2409, "PRISM: Precision in SCLC via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)" Drs. Chiang, Chiappori, Kim, et al.

Clinical Trials Partnerships (CTP)

Developing Studies

21CTP. HN01, CAPT-HN, "A Phase II Study of Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer." Drs. Swiecicki, Rodriguez, and Brenner

Lung Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	LUNGMAP	S1800E	S1827	S1900E	S1900G	S1900J	S1900K	S1914	S1933	S2302
Arnot Ogden Medical Center/Falck Cancer Center	7	-	-	-	-	-	-	3	-	-
Ascension Via Christi Hospitals Wichita	1	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	1	-	-	-	-	1	-	-
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-	-	2
Baptist Mem Health Care/Mid South Minority Underserved NCORP	37	1	3	2	-	-	-	10	1	16
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	5	-	-	-	-	-	-	-
Boston Medical Center	-	-	7	-	-	-	-	-	-	2
CWRU Case Comprehensive Cancer Center LAPS	11	-	2	2	-	-	-	-	-	18
Cancer Research Consortium of West Michigan NCORP	3	-	-	-	-	-	-	7	-	3
Cancer Research for the Ozarks NCORP	50	-	-	-	-	-	-	9	4	5
Cancer Research of Wisconsin & Northern Michigan Consortium	35	-	6	4	-	-	-	8	-	8
Carle Cancer Center NCI Community Oncology Research Program	3	-	1	1	-	-	-	6	-	8
Cedars-Sinai Medical Center	21	-	-	1	1	-	-	4	-	9
City of Hope Comprehensive Cancer Center	5	-	1	-	-	-	-	-	-	3
Columbia University Minority Underserved NCORP	13	-	-	-	-	-	-	-	1	7
Columbus NCI Community Oncology Research Program	28	-	6	-	-	-	-	-	-	4
CommonSpirit Health Research Institute	39	-	1	-	-	-	-	1	-	1
Corewell Health William Beaumont University Hospital	-	-	-	-	-	-	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	2	-	-	-	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-	-	-	-	-	-	2
Essentia Health NCI Community Oncology Research Program	16	-	-	-	-	-	-	3	-	-
Fred Hutchinson Cancer Research Center LAPS	5	-	-	-	1	-	-	-	-	10
Froedtert and the Medical College of Wisconsin LAPS	2	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	6	-	1	-	-	-	-	2	1	-
Georgia NCI Community Oncology Research Program	67	1	3	1	-	-	-	9	-	18
Grupo Oncologico Cooperativo de Investigacion	-	-	1	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	24	-	2	-	-	-	-	3	-	7
Hartford Hospital	3	-	-	-	-	-	-	-	-	4
Hawaii Minority Underserved NCORP	28	-	2	-	-	-	-	-	-	7
Heartland Cancer Research NCORP	153	-	9	6	-	-	-	40	5	52
Henry Ford Health Providence Southfield Hospital	13	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	7	-	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-	2
Instituto Nacional De Cancerologia	-	-	1	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	8	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	92	-	-	8	-	-	1	3	-	27
Kansas City Veterans Affairs Medical Center	3	-	-	-	-	-	-	-	-	1
Lahey Hospital and Medical Center	33	-	-	-	-	-	-	4	2	12
Loma Linda University Medical Center	6	-	-	-	-	-	-	-	-	-
Loyola University Medical Center	25	-	-	-	-	-	-	1	-	8
Malcom Randall Veterans Administration Medical Center	19	-	-	-	-	-	-	-	-	4
Massachusetts Vets Epidemiology Research and Info Center	65	-	4	1	-	-	-	-	-	9
Medical University of S Carolina Minority Underserved NCORP	25	-	-	2	1	-	-	-	-	19
Mercy Medical Center - Des Moines	8	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	127	-	3	7	2	-	-	12	-	18
Mission Hospital	1	-	-	-	-	-	-	-	-	-

Lung Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	LUNGMAP	S1800E	S1827	S1900E	S1900G	S1900J	S1900K	S1914	S1933	S2302
Moffitt Cancer Center	18	-	1	1	1	-	-	-	-	52
Montana Cancer Consortium NCORP	9	-	1	1	-	-	-	1	1	1
Mount Sinai Hospital	-	-	-	-	-	-	-	9	-	2
MultiCare Tacoma General Hospital	-	-	-	-	-	-	-	-	-	3
NCORP of the Carolinas (Prisma Health NCORP)	20	-	-	1	-	-	-	-	-	-
National Cancer Center-Korea	-	-	1	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	15	-	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	104	-	1	2	-	-	-	8	1	3
Northwell Health NCORP	-	-	-	-	-	-	-	1	-	-
Northwestern University LAPS	27	-	1	-	1	-	-	-	-	18
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	6
Oregon Health and Science University	13	-	-	-	1	-	1	1	-	3
Pacific Cancer Research Consortium NCORP	23	-	-	-	-	-	-	-	-	1
Regents of the University of Michigan	1	-	-	-	-	-	-	-	-	6
Saint Joseph Hospital - Cancer Centers of Colorado	1	-	-	-	-	-	-	1	-	-
Salem Hospital	7	-	-	2	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	52	-	7	1	-	-	-	14	-	7
Sutter Cancer Research Consortium	51	-	-	1	1	-	-	-	-	1
The Don and Sybil Harrington Cancer Center	13	-	-	1	-	-	-	-	-	-
The James Graham Brown Cancer Center at U of Louisville	-	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	43	-	1	2	1	-	-	11	-	15
UC Irvine Health/Chao Family Comprehensive Cancer Center	30	-	1	-	-	-	-	5	-	1
UC San Diego Moores Cancer Center	16	-	-	1	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	86	-	12	7	-	-	-	2	5	10
USC Norris Comprehensive Cancer Center LAPS	-	-	6	-	-	-	-	7	-	3
U of Alabama at Birmingham / Deep South Research Consort LAPS	-	-	-	-	-	-	-	-	-	12
University of Arkansas for Medical Sciences	11	-	-	-	-	-	-	17	-	12
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	15	-	4	-	1	1	1	6	-	3
University of Kansas Cancer Center - MCA Rural MU NCORP	105	-	1	1	-	-	-	-	-	5
University of Kentucky/Markey Cancer Center	55	-	1	-	-	-	-	-	-	9
University of Mississippi Medical Center	1	-	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	33	-	1	-	-	-	-	6	18	10
University of Rochester LAPS	61	-	-	6	-	-	1	-	-	14
University of Texas Health Science Center at San Antonio	-	-	2	-	-	-	-	-	-	22
University of Texas MD Anderson Cancer Center LAPS	3	-	6	-	-	-	-	6	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	4	-	-	-	-	5	-	4
Upstate Carolina Consortium Comm Oncology Research Program	41	-	3	-	-	-	-	3	-	1
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-	10
Wayne State University - Karmanos Cancer Institute LAPS	1	-	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	2	-	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	42	-	4	1	-	-	-	13	-	5
Yale University - Yale Cancer Center LAPS	28	-	5	3	4	-	-	11	-	14
ALLIANCE	884	-	25	21	3	1	3	42	5	154
CCTG	-	-	36	-	-	-	-	-	-	-
ECOG-ACRIN	367	1	11	19	-	-	3	31	-	90
NRG	505	-	83	12	3	-	-	91	1	55
Total	3,666	3	285	118	21	2	10	417	45	838

Lung Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	S2414	A081801	A082002	A151216	E4512	EA5162	EA5163	EA5182	EA5221	NRGLU008	S2402
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	-	-	-	-	-	-	-
Ascension Via Christi Hospitals Wichita	-	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	1	-	1	-	-	-	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	7	2	-	-	-	-	-	-
Baptist Mem Health Care/Mid S Minority Underserved NCORP	1	4	-	26	-	-	1	2	-	2	-
Baylor College of Medicine/Duncan Comprehensive Cancer Cntr	-	-	-	-	-	-	-	-	-	-	-
Boston Medical Center	-	-	-	3	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	16	-	59	-	-	17	1	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	1	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	1	-	-	-	-	-	-	-
Cancer Research of Wisconsin & Northern Michigan Consortium	-	-	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Prgrm	-	-	-	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	5	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	2	-	-	-	-	-	-	-
Corewell Health William Beaumont University Hospital	-	-	-	2	-	-	-	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	-	3	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	1	-	8	-	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	15	-	3	-	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	10	-	-	1	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	1	-	1	-	-	3	-	-	-	-
Hartford Hospital	-	-	-	-	-	-	-	1	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-	-
Henry Ford Health Providence Southfield Hospital	-	-	-	15	2	1	2	-	-	-	-
Henry Ford Hospital	-	2	-	29	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	8	-	-	1	2	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Prgm	-	6	-	208	6	-	8	7	-	-	-
Kansas City Veterans Affairs Medical Center	-	-	-	-	-	-	-	-	1	-	-
Lahey Hospital and Medical Center	1	1	-	30	-	-	2	-	-	-	-
Loma Linda University Medical Center	-	-	-	10	-	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	26	-	-	2	-	-	-	-
Malcom Randall Veterans Administration Medical Center	-	-	-	-	-	-	-	-	-	-	-
Massachusetts Vets Epidemiology Research and Info Center	-	12	-	34	-	-	3	-	-	-	-
Medical University of S Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	11	-	-	-	-	-	-	-
Mission Hospital	-	-	-	-	-	-	-	-	-	-	-

Lung Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	S2414	A081801	A082002	A151216	E4512	EA5162	EA5163	EA5182	EA5221	NRGLU008	S2402
Moffitt Cancer Center	-	27	-	83	1	-	5	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	8	-	-	-
MultiCare Tacoma General Hospital	-	-	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	1	-	-	-	-	-	-	-
National Cancer Center-Korea	-	-	-	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	1	-	3	-	-	-	-	-	-	-
Northwestern University LAPS	-	-	-	-	-	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	8	-	24	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	4	-	-	-	-	-	-	-
Regents of the University of Michigan	-	-	-	51	-	-	-	-	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	1	-	3	-	-	-	-	-	-	-
Salem Hospital	-	-	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	1	11	-	-	-	-	-	1	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	-	-	-	-
The James Graham Brown Cancer Center at U of Louisville	-	-	-	5	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	1	2	46	1	-	6	1	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	15	1	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	5	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	12	-	-	-	-	-	-	-
U of Alabama at Birmingham / D South Research Consort LAPS	-	-	-	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	3	1	-	1	-	1	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	24	1	-	2	1	-	-	-
University of Colorado Cancer Center LAPS	-	2	-	58	2	-	-	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	1	-	31	-	-	7	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	1	5	-	-	-	-	-	-	-
University of Mississippi Medical Center	-	-	-	26	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-	-	-	-	3
University of Rochester LAPS	-	-	-	-	-	-	6	-	-	-	1
University of Texas Health Science Center at San Antonio	-	-	-	-	-	-	2	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	2	1	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	1	-	-	-	-
Upstate Carolina Consort Comm Oncology Research Program	-	-	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	1	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	1	-	-	-	1	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	7	-	57	4	-	14	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-	-
Total	2	92	4	986	22	4	84	24	2	3	4

Lymphoma Committee

Leadership

Chair: Jonathan W. Friedberg, MD
 Vice-Chair: Sonali M. Smith, MD
 Executive Officer: Susan M. O'Brien, MD
 Statisticians: Michael LeBlanc, PhD
 Hongli Li, MS
 Gabby Lopez, MS
 Matt Chansky, BS

Scientific Leadership

Translational Medicine: Alexey Danilov, MD, PhD
 Radiation Oncology: Nicholas Burden Figura, MD
 Imaging: Lawrence H. Schwartz, MD
 Immunotherapeutics: Sweetha Thiruvengadam, MD
 Pathology: Joo Y. Song, MD
 Early Therapeutics: Nasheed Mohammad Hossain, MD

Designates

Cancer Control: TBD
 Veterans Affairs: Helen Ma, MD
 Data Coordinators: Alex Rangel, BS
 Gabi Herbert, MS, BS
 Laura Wells, BA
 Daria Chugina, MD, CCRPS
 Oncology Research Professionals:
 CRA: Erin M. Cebula, MPH
 Jacob Kedroske, BA
 Nurse: TBD
 Patient Advocate: Tricia Hernandez, MS
 Pharmaceutical Science: Dawud Nael Dawud Ellayan, PharmD
 Martina Fraga, PharmD
 Protocol Project Manager: Erin Rogers
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Thursday, September 18, 2025 5:00 p.m. - 7:00 p.m.
 Room: Regency C (Ballroom Level, West Tower)

Agenda

1. **Welcome & Introductions** - Jonathan Friedberg, MD & Sonali Smith, MD

2. **Mini Symposium: Improving CAR-T Therapy**

- Radiation bridging - Nicholas Figura, MD
- Novel targeted approaches - Justin Kline, MD
- Bispecific antibodies and S2114 rationale - Brian Hess, MD
- Discussion and Q&A - Sonali Smith, MD

3. **S1826 Update** - Alex Herrera, MD

4. **New study**

S2506: Marginal zone lymphoma - Dr. Hu

5. **SWOG Trial Updates**

- | | | |
|----|-----------------------------|---|
| a. | S2308 | Nilanjan Ghosh, MD, PhD |
| b. | S2207 | Jennifer Amengual, MD /
Patrick Reagan, MD |
| c. | S1925 CLL | Deborah Stephens, DO |
| d. | S1918 phase 2 result timing | Elizabeth Brem, MD /
Sonali Smith, MD |

6. **Open Studies From Other Groups**

- | | | |
|----|--------------------|-----------------------|
| a. | EA4232 T-cell ASCT | Marc Hoffmann, MD |
| b. | AO51902 T-cell | Jennifer Amengual, MD |
| c. | AO52101 older MCL | Tyler Phillips, MD |
| d. | AHOD2131 HL | Boyu Hu, MD |

Developing Studies

S2506, "MOZART MZL: A Randomized 3-Arm Phase II Study Evaluating Mosunetuzumab Alone and In Combination with Either Zanubrutinib or Polatuzumab Vedotin for The Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma." Drs. B. Hu, B. Hu, and S. Smith.

Active Studies

S1918, "A Phase II/III Randomized Study of R-miniCHOP With or Without CC-486 (Oral Azacytidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. E. Brem and S. Smith. Activated: 3/19/21.

S2114, "A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma." Drs. B. Hess and N. Hossain. Activated: 2/23/23.

S2207, "Randomized phase II study of the addition of Targeted therapeutic agents to tafasitamab-based therapy in non-transplant-eligible patients with Relapsed/refractory Large B-cell Lymphoma." Drs. J. Amengual, P. Reagan, and S. Smith. Activated: 6/30/23

Lymphoma Committee

S2308, "Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma." Drs. N. Ghosh and J. Friedberg. Activated: 8/1/24

CTSU/EA4151, "A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission." Dr. Fenske. SWOG Champion: Dr. B. Till. Activated: 8/29/17.

CTSU/ANHL1931, "A Randomized Phase 3 trial of Nivolumab in Combination with Chemo immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B cell Lymphoma." Dr. Roth. SWOG Champion: Dr. M. Kamdar. Activated 6/7/21.

CTSU/A051902, "A Randomized Phase II Study of CHO(E)P vs Oral Azacitidine-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas." Dr. Mehta-Shah. SWOG Champion: Dr. J. Amengual. Activated 7/30/21.

CTSU/A052101, "A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON)." Dr. Beaven. SWOG Champion: Dr. T. Phillips. Activated 9/8/23.

CTSU/AHOS2131, "A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma." Dr. Henderson. SWOG Champion: Dr. B. Hu. Activated 4/28/23.

Closed Studies

S1608, "Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma." Dr. P. Barr. Activated: 8/10/17. Closed: 7/15/24

CTSU/A051701, "Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas." Dr. Abramson. SWOG Champion: Dr. S. Smith. Activated: 8/7/19. Closed: 12/14/23.

CTSU/EA4181, "A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CA-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients \leq 70 years Old with Untreated Mantle Cell Lymphoma." Dr. Wagner-Johnson. SWOG Champion: Dr. S. Spurgeon. Activated: 10/3/19. Closed: 4/7/23

Open Leukemia Studies

S1905, "A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)." Drs. Advani, N. Papadantonakis, and C. Yueng. Activated: 8/17/20.

S1925, "A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study." Dr. D. Stephens. Activated: 12/14/20.

Developing Leukemia Studies

S2504, "A Randomized Phase II Study of Pirtobrutinib Plus R-CHOP vs. R-CHOP for Patients with Previously Untreated Richter Transformation (RT)." Drs. M. Shadman, D. Stephens, and A. Danilov.

Closed Cancer Care Delivery Study

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Dr. V. Shankaran. Activated 7/26/21. Closed 12/16/24.

Lymphoma Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	S1608	S1918	S2114	S2207	S2308	A051902	A052101	AH0D2131
Banner University Medical Center - Tucson	2	-	1	-	1	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	1	2	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	4	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	3	-	5	-	-	-	-	4
Cancer Research for the Ozarks NCORP	1	1	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	2	-	3	-	-	-	-
Cedars-Sinai Medical Center	-	1	-	4	-	-	-	3
City of Hope Comprehensive Cancer Center	8	11	-	-	5	-	-	16
Columbia University Minority Underserved NCORP	-	6	5	1	-	3	-	1
Columbus NCI Community Oncology Research Program	1	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	7	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	4	-	4	-	-	-
Georgia Cares Minority Underserved NCORP	-	2	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	2	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	1	-	-	-	-	-	-
Heartland Cancer Research NCORP	1	-	-	-	1	-	-	-
Henry Ford Hospital	-	-	-	-	-	-	-	1
Kaiser Permanente NCI Community Oncology Research Program	3	3	-	-	-	-	-	7
Loyola University Medical Center	-	-	2	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	2	3	20	-	4	-	-	1
Michigan Cancer Research Consortium NCORP	1	8	-	1	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	1	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-
Northwestern University LAPS	1	-	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	2	-	-	4	-	-	-
Oregon Health and Science University	-	-	4	-	3	-	-	4
Pacific Cancer Research Consortium NCORP	-	-	9	1	-	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	1	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	2	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	7	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-	4	-	-	-
University of Arkansas for Medical Sciences	-	-	8	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	1	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	4	-	11	-	4	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	1	-	-	-	-	-
University of Rochester LAPS	16	-	9	7	10	6	13	18
University of Texas Health Science Center at San Antonio	-	-	13	1	10	-	-	1
University of Texas MD Anderson Cancer Center LAPS	3	-	-	-	8	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	1	12	-	-	4	-	-	6
Upstate Carolina Consortium Community Oncology Research Program	1	1	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	4	-	1	-	1	-
Wisconsin NCI Community Oncology Research Program	-	2	-	-	1	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	1	-
ALLIANCE	17	42	36	5	34	-	-	-
ECOG-ACRIN	5	17	10	-	15	-	-	-
NRG	11	7	5	4	4	-	-	-
Total	78	136	143	27	126	17	19	62

Lymphoma Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	ANHL1931	E4412	EA4151
Banner University Medical Center - Tucson	-	-	1
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	23
Cancer Research Consortium of West Michigan NCORP	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-
Cedars-Sinai Medical Center	1	-	-
City of Hope Comprehensive Cancer Center	15	-	18
Columbia University Minority Underserved NCORP	3	1	-
Columbus NCI Community Oncology Research Program	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	15
Froedtert and the Medical College of Wisconsin LAPS	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-
Gulf South Minority Underserved NCORP	-	-	-
Hawaii Minority Underserved NCORP	-	-	-
Heartland Cancer Research NCORP	-	-	-
Henry Ford Hospital	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	11	-
Loyola University Medical Center	-	-	5
Medical University of South Carolina Minority Underserved NCORP	-	-	2
Michigan Cancer Research Consortium NCORP	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	1	-	2
Nevada Cancer Research Foundation NCORP	-	1	-
Northwestern University LAPS	1	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-
Oregon Health and Science University	-	-	7
Pacific Cancer Research Consortium NCORP	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	2	-	-
UC San Diego Moores Cancer Center	-	-	1
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	7	5
University of Arkansas for Medical Sciences	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	2
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-
University of Kentucky/Markey Cancer Center	-	-	3
University of Oklahoma Health Sciences Center LAPS	-	-	-
University of Rochester LAPS	10	-	11
University of Texas Health Science Center at San Antonio	-	-	14
University of Texas MD Anderson Cancer Center LAPS	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	20
Upstate Carolina Consortium Community Oncology Research Program	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	1
Wisconsin NCI Community Oncology Research Program	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	5
ALLIANCE	-	-	-
ECOG-ACRIN	-	-	-
NRG	-	-	-
Total	33	20	135

Melanoma Committee

Leadership

Chair: Sapna P. Patel, MD
 Vice-Chair: Roger S. Lo, MD, PhD
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Michael Wu, PhD
 James Moon, MS
 Gabby Lopez, MS
 Matt Chansky, BS

Scientific Leadership

Translational Medicine: William E. Carson, III, MD
 Radiation Oncology: TBD
 Surgery: John Robert Hyngstrom, MD
 Dermatology: TBD
 Imaging: TBD
 Medical Oncology: TBD
 Pathology: TBD
 Non-Melanoma Skin Cancer: Nikhil I. Khushalani, MD
 Early Therapeutics: TBD
 SWOG's ECOG Liaisons: Thach-Giao Truong, MD
 ECOG's SWOG Liaisons: David H. Lawson, MD
 Michael Lowe, MD

Designates

Prevention: Sancy Leachman, MD, PhD
 Data Coordinator: Michele Counts, BS
 Tonya Johnson, BS

Oncology Research Professionals:

CRA: Kathryn Allen, BA, CCRP
 Nurse: TBD
 Patient Advocate: Sara Selig
 Pharmaceutical Science: Sun "Coco" Yang, PharmD, PhD
 Kimberly McConnell, PharmD
 Protocol Project Manager: Catrina De Los Santos-Mireles
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Saturday, September 20, 2025 11:30 a.m. - 1:30 p.m.
 Room: Regency D (Ballroom Level, West Tower)

Keynote Speaker: Inside Out - Gut Check with Monty Pal

Monty Pal, MD, FASCO
 Professor & Vice Chair of Academic Affairs
 Department of Medical Oncology & Experimental Therapeutics
 City of Hope Comprehensive Cancer Center

Active Studies

S2015, "Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma." Dr. Mammen. Activated: 4/8/22.

CTSU/EA6141, "Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma." SWOG Champion: Dr. K. Kim. Activated: 9/10/15.

CTSU/EA6192, "The BMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma with Elevated LDH." SWOG Champion: Dr. Truong. Activated: 10/23/20.

A091903, "A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma." SWOG Champion: K. Tsai, MD (SWOG) Activated 6/1/22. Temporarily Closed to Accrual as of 10/10/23

Studies in Development

S2431, "Randomized, open-label, phase III study of anti-PD-1, anti-CTLA-4, and anti-LAG-3 antibodies in patients with previously untreated unresectable or metastatic melanoma." Dr. Chandra

Closed Studies

CTSU/EA6174, "STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial." SWOG Champion: Dr. Hsu. Activated: 10/1/18. Closed to Accrual as of 7/1/24.

S2000, "A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases." Dr. Eroglu. Activated: 9/23/20. Closed: 6/18/24

S1801, "A Phase II Randomized Study of Adjuvant Versus Neoadjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High Risk Melanoma." Dr. Patel. Activated: 12/6/18. Closed: 5/5/22.

Melanoma Committee

S1512, “A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM).” Drs. Kendra and Hu-Lieskovan. Activated: 10/20/16. Closed: 6/4/21.

S1607, “A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) in Patients with Advanced Melanoma who have Progressed on Anti-PD1/L1 Based Therapy.” Dr. Hu-Lieskovan. Activated: 10/2/17. Closed: 11/1/20.

S1616, “A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent.” Dr. VanderWalde. Activated: 7/17/17. Closed: 7/15/20.

S1404, “A Phase III Randomized Study of MK3475 versus High-Dose Interferon a-2b for Resected High-Risk Melanoma.” Dr. Patel. Activated: 10/15/15. Closed: 11/2/17.

CTSU/EA6134, “DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial.” SWOG Champion: Dr. Chmielowski. Activated: 7/13/15. Closed: 9/30/21.

CTSU/EA6183, “A Phase II Neoadjuvant Study of Encorafenib with Binimetinib in Patients with Resectable Locoregional Metastases from Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D).” SWOG Champion: C. D. Lao, MD, MPh Activated: 2/18/20. Closed: 9/23/22.

Melanoma Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	S2000	S2015	A091903	EA6141	EA6174	EA6192	EA6194
Banner MD Anderson Cancer Center	-	37	-	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-	3	1	1
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	16	-	-
Cancer Research Consortium of West Michigan NCORP	-	105	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	-	-	1	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	29	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	3	-	-	-
Columbia University Minority Underserved NCORP	-	7	-	-	-	-	-
Dayton NCI Community Oncology Research Program	1	-	-	2	-	-	-
Duke University - Duke Cancer Institute LAPS	-	19	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	1	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	14	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	11	-	-	-	-	-
Intermountain Medical Center	-	44	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	5	-	30	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	18	-	-	-	-	-
Moffitt Cancer Center	20	56	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	1	-	-
New Mexico Minority Underserved NCORP	-	4	-	-	-	-	-
Northwell Health NCORP	-	10	-	-	-	-	-
Northwestern University LAPS	-	40	-	1	1	5	-
Ohio State University Comprehensive Cancer Center LAPS	3	33	-	-	3	3	-
Regents of the University of Michigan	2	24	-	1	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	-	-	1	-	-
Sutter Cancer Research Consortium	-	-	-	7	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	17	-	4	8	-	3
UPMC Hillman Cancer Center LAPS	1	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	3	1	-	3	-	-
University of Arkansas for Medical Sciences	-	6	-	-	-	1	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	2	4	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	46	-	3	1	-	-
University of Kentucky/Markey Cancer Center	-	13	-	-	-	-	-
University of Nebraska Medical Center	-	3	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	1	-	-	-	-	-
University of Rochester LAPS	-	6	-	9	1	-	-
University of Texas Health Science Center at San Antonio	-	3	-	1	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	19	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	32	-	-	8	-	-
Western States Cancer Research NCORP	-	-	-	1	-	-	-
Wisconsin NCI Community Oncology Research Program	-	15	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	28	-	8	1	-	-
ALLIANCE	1	120	-	-	-	-	-
ECOG-ACRIN	6	220	-	-	-	-	-
NRG	1	98	-	-	-	-	-
Total	37	1,086	1	73	53	10	4

Radiation Oncology Committee

Leadership

Chair: Chul Ha, MD
 Vice-Chair: Lisa Kachnic, MD
 Executive Officer: Lisa Kachnic, MD
 Statisticians: Sam Callis, MS

Designates

Breast Committee Liaison: Reshma Jagsi, MD, DPhil
 BMT Committee Liaison: Austin Sim, MD
 Cancer Care Delivery Committee Liaison: Eileen Connolly, MD
 Prevention, Screening, & Surveillance
 Committee Liaison: Eileen Connolly, MD
 CNS Working Group Liaison: Tony Wang, MD
 Genitourinary Committee Liaison: James Yu, MD
 Gastrointestinal Committee Liaison: Lisa A. Kachnic, MD
 Immunotherapeutics Committee Liaison: Robert Samstein, MD, PhD
 Lung Committee Liaison: Henry Park, MD
 Lymphoma Committee Liaison: Nicholas B. Figura, MD
 Melanoma Committee Liaison: TBD
 Myeloma Committee Liaison: Chelsea Pinnix, MD, PhD
 Sarcoma Working Group Liaison: Jeremy Harris, MD
 Symptom Management & Survivorship
 Committee liaison: Erin Gillespie, MD, MPH
 Kiri A. Cook, MD
 Theranostics Subcommittee Chair Jeffrey Wong, MD
 Theranostics Subcommittee Vice-Chairs Jeremie Calais, MD, PhD
 Tanya Dorff, MD
 Data Coordinator: Larry Kaye

4:40 - 5:00 pm SLOW ROLL: SaLvage radiation Or Watchful waiting,
Reimaging upOn eLevated Labs with delayed salvage -
 Martin Ma, MD, PhD

5:00 - 5:20 pm Combining immunotherapy and radiation therapy
 to help patients avoid bladder removal after treatment
 shrinks muscle invasive bladder cancer, BRIGHT Trial -
 Leslie Ballas, MD

5:20 - 5:40 pm An esophageal cancer concept under development -
 Russell Palm, MD

5:40 - 6:00 pm Combination prostate directed EBRT plus metastasis
 directed RPT - Ravi Patel, MD, PhD

6:00 pm Closing Remarks - Chul S. Ha, MD

Time/Location

Thursday, September 18, 2025 4:00 p.m. - 6:00 p.m.

Room: Comiskey (Concourse Level, West Tower)

Agenda

4:00 - 4:05 pm Welcome - Chul S. Ha, MD

4:05 - 4:10 pm Report from Executive Officer - Lisa Kachnic, MD

4:10 - 4:15 pm Update from IROC - TBD

4:15 - 4:20 pm Update from NCI - Jacek Capala, PhD, DSc

4:20 - 4:40 pm High Risk DCIS:DCISionRT SWOG Trial Concept -
 Eileen Connolly, MD

Publication List by Committee

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Spring 2025 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts

ADOLESCENT AND YOUNG ADULT (AYA) COMMITTEE

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

None this cycle

BARLOGIE-SALMON MYELOMA COMMITTEE

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

S1702 Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial. Parker T, Rosenthal A, Sancherawala V, Landau H, Campagnaro E, Kapoor P, Neparidze N, Girnius S, Hagen P, Scott E, Hoering A, Durie B, Orlowski R. (SWOG S1702). Submitted 2025.

BREAST COMMITTEE

Published/Accepted Manuscripts

S1007 Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive BC in the Phase III RxPONDER Trial (SWOG S1007). Abdou Y, Barlow W, Gralow J, Meric-Bernstam F, Albain K, Hayes D, Lin N, Perez E, Goldstein L, Chia S, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott A, Shak S, Sharma P, Lew D, Miao J, Unger J, Tripathy D, Pusztai L, Hortobagyi G, Kalinsky K. *Journal of the National Cancer Institute* May 1;117(5):889-897, 2025.
<https://pubmed.ncbi.nlm.nih.gov/39656951/>

Submitted Manuscripts

S1007 Ovarian Reserve as a Measure of Adjuvant Chemotherapy Benefit in Women with Hormone Receptor Positive (HR+), HER2-negative, Node-positive Breast Cancer in SWOG S1007 (RxPONDER). Kalinsky K, Barlow W, Puri R, Mitra A, Home T, Gralow J, Albain K, Hayes D, Delaloge S, Lin N, Perez E, Goldstein L, Chia S, Rastogi P, Schott A, Shak S, Tripathy D, Hortobagyi G, Meric-Bernstein F, Sharma P, Pusztai L, Thompson A, Pathak H, Godwin A. Submitted, 2025.

CANCER CONTROL AND PREVENTION

CANCER CARE DELIVERY COMMITTEE

Published/Accepted Manuscripts

S1912CD Addressing Challenges in Research Aimed at Reducing Financial Toxicity Among Cancer Patients and Caregivers: An Example From the CREDIT Study (SWOG S1912CD). Bell-Brown A, Tawfik B, Segarra-Vazquez B, Hopkins T, Watabayashi K, O'Kane P, Carlos R, Langer S, Unger J, Darke A, Hershman D, Ramsey S, Shankaran V. *Cancer Control* Jan-Dec;32:10732748251344469, 2025.
<https://pubmed.ncbi.nlm.nih.gov/40384469/>

Multiple Studies Cancer in rural America: Improving access to clinical trials and quality of oncologic care. Unger J, McAneny B, Osarogiagbon R. CA: *A Cancer Journal for Clinicians* Jul-Aug;75(4):341-361, 2025.
<https://pmc.ncbi.nlm.nih.gov/articles/PMC12223359/>

Multiple Studies Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Treatment Trials: A Meta-Analysis of Industry and National Cancer Institute Studies. Unger J, Andrews H, Levit L, McKelvey B, Stewart M, Canin B, Flaherty K, Kimball D, Miller T, Onitilo A, Bruinooge S, Garrett-Mayer E, Schenkel C. *JCO Oncology Advances* Jun 13;2(1):e2500021, 2025.
<https://pubmed.ncbi.nlm.nih.gov/40546794/>

Multiple Studies Automating Data Entry from Electronic Health Record to Electronic Data Capture Using Trusted Cloud-based Application in Multi-site Cancer Clinical Trials. Goodman K, Cook C, Weatherbee D, Yadav S, Mudaranthakam D, Sexton R, Mahaffey N, Garcia L, Ta T, Cebula E, Smart J, Goudeau T, Annis A, Gilmore A, Chugina D, Ahmadzai P, Hoering A, LeBlanc M. *Journal of the Society for Clinical Data Management* Winter;5(1):1-16, 2025.
<https://pubmed.ncbi.nlm.nih.gov/40510739/>

Submitted Manuscripts

None this cycle

Publication List by Committee

PALLIATIVE CARE COMMITTEE

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

S1316 Optimizing Palliative Cancer Surgery Trial Completion: Lessons Learned from S1316 –Comparative Effectiveness Trial for Malignant Bowel Obstruction. Farooq F, Amini N, Sun V, Deutsch G, Deneve J, Grant M, Arnold K, Alvarez Secord A, Krouse R. Submitted, 2025.

PREVENTION, SCREENING, AND SURVEILLANCE COMMITTEE

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

None this cycle

SYMPTOM MANAGEMENT AND SURVIVORSHIP COMMITTEE

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

S1714 A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Patients with Cancer: SWOG S1714. Trivedi M, Unger J, Darke A, Hertz D, Brannagan T, Smith S, Hershman D, Henry NL, Fisch M. Submitted, 2025.

DIGITAL ENGAGEMENT COMMITTEE

Published/Accepted Manuscripts

N/A Likes and Hashtags: The Impact of Social Media Use on the Emotional Wellbeing of Oncology Professionals. Moerdler S, Yan Y, Chrysanthopoulou S, Barry M, Henry E, Lucas T, Marshall A, Dizon D. *Pediatric Blood & Cancer*, Apr;72(4):e31568, 2025. <https://pubmed.ncbi.nlm.nih.gov/39865348/>

Submitted Manuscripts

None this cycle

EARLY THERAPEUTICS AND RARE CANCERS COMMITTEE

Published/Accepted Manuscripts

S1609 A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Pancreatic Neuroendocrine Neoplasm (PNEN) Cohort. Patel S, Fisher J, Chae Y, Soto

L, Kasi A, Konda B, Walshauser M, Parra E, Zhang J, Duault C, Gonzalez-Kozlova E, Manyam G, Holmes T, Zhang J, Chen H, Duose D, Laberiano Fernandez C, Luthra R, Al-Atrash G, Kim-Schulze S, Maecker H, Wistuba I, Gnjjatic S, Lee J, Zhang J, Magner C, Chen H, Sharon E, Othus M, Ryan C, Blanke C, Haymaker C, Kurzrock R. *Journal of Immunotherapy of Cancer* Jun 30;13(6):e011760, 2025. <https://pubmed.ncbi.nlm.nih.gov/40588371/>

S1609 A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort. Chae YK, Othus M, Patel SP, Aljumaily R, Win K, Pejovic T, Thomas S, Robinson W, Kim H, Chung L, McLeod C, Chen H, Sharon E, Streicher H, Ryan C, Blanke C, Kurzrock R. Accepted.

Submitted Manuscripts

S1609 A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Salivary Gland Tumor Cohort. Chae Y, Sun R, Patel S, Giles F, Ohr J, Worden F, Suga J, Naing A, Cohen E, Wallace J, Fenton S, Il-Young Chung L, Kang H, McLeod C, Chen H, Sharon E, Streicher H, Ryan C, Othus M, Blanke CD, Kurzrock R. Submitted, 2025.

S1609 DART/SWOG/NCI Phase II Anti-CTLA-4/PD-1 Trial: Clear Cell Carcinomas of Ovary, Endometrium, Cervix. Chae Y, Othus M, Patel S, Backes F, O'Malley D, Cristea M, Naing A, Kurnit K, Eskander R, Goodrich S, Robinson W, Kim H, Il-Young Chung L, McLeod C, Chen H, Sharon E, Streicher H, Ryan C, Blanke CD, Kurzrock R. Submitted, 2025.

GASTROINTESTINAL COMMITTEE

Published/Accepted Manuscripts

S2303 S2303: Phase II/III Trial of Nivolumab + Paclitaxel + Ramucirumab in Gastric and Esophageal Adenocarcinoma (PARAMUNE). Saeed A, Colby S, Oberstein P, Duda D, Park R, Agarwal R, Figueroa Moseley C, Vaidya R, Unger J, Guthrie K, Rocha F, Senthil M, Safyan R, Wainberg Z, Iqbal S, Chiorean EG, Philip P. *Future Oncology* May;21(11):1325?1331, 2025. <https://pubmed.ncbi.nlm.nih.gov/40155326/>

Submitted Manuscripts

None this cycle

Publication List by Committee

GENITOURINARY COMMITTEE

Note: All PCPT and SELECT publications are listed under Cancer Control & Prevention Committees

Published/Accepted Manuscripts

S1314 Predicting Clinical Outcomes in the S1314-COXEN Trial Using a Multimodal Deep Learning Model Integrating Histopathology, Cell Types, and Gene Expression. Bai Z, Brendel M, Osman M, Tangen C, Flaig T, Thompson I, Plets M, Lucia MS, Theodorescu D, Gustafson D, Daneshmand S, Meeks J, Choi W, Dinney C, Elemento O, Lerner S, McConkey D, Faltas B, Wang F. *NPJ Digital Medicine* Mar 22;8(1):174, 2025. <https://pubmed.ncbi.nlm.nih.gov/40121304/>

S1314 Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning framework. Bai Z, Osman M, Brendel M, Tangen C, Flaig T, Thompson I, Plets M, Lucia MS, Theodorescu D, Guftason D, Daneshmand S, Meeks J, Choi W, Dinney C, Elemento O, Lerner S, McConkey D, Faltas B, Wang F. *Digital Medicine* Mar 22;8(1):174, 2025. <https://pubmed.ncbi.nlm.nih.gov/40121304/>

S1605 Urine tumor DNA detection predicts response to atezolizumab in BCG-unresponsive non-muscle-invasive bladder cancer. St-Laurent M, Singh P, McConkey D, Lucia MS, Koshkin V, Stratton K, Bivalacqua T, Kassouf W, Porten S, Bangs R, Plets M, Thompson I, Meeks J, Caruso V, Ward C, Mazzearella B, Phillips K, Bicocca V, Levin T, Lerner S, Black P. *European Urology* May 21:S0302-2838(25)00217-9, 2025. <https://pubmed.ncbi.nlm.nih.gov/40404526/>

C90601 Relationship among DNA damage response gene alterations, molecular subtypes, and survival outcomes in patients with metastatic bladder cancer treated on CALGB 90601. Iyer G, Choi W, Luo B, Carvalho F, Hanlon T, Reis H, Guerico B, Fong M, Mountain J, Feng M, Regazzi A, McCart A, Wen Y, Al-Ahmadie H, Mouw K, Van Allen E, Bellmunt J, Dreicer R, Flaig T, Halabi S, McConkey D, Rosenberg J. *JCO Precision Oncology* Jul;9:e2400938 2025. <https://pubmed.ncbi.nlm.nih.gov/40591902/>

Submitted Manuscripts

S1216 Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216). Ingles S, Pinski J, Manojlovic Z, Xiong S, Weisenberger D, Goldkorn A, Tangen C, McConkey D, Lara P, Hussain M, Quinn D, Thompson I, Lerner S, Dorff T, Agarwal N. Submitted, 2025.

IMMUNOTHERAPEUTICS COMMITTEE

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

None this cycle

LEUKEMIA COMMITTEE

Published/Accepted Manuscripts

Multiple Studies Guideline-Concordant Treatment among Adolescents and Young Adults (AYAs) with Acute Lymphoblastic Leukemia (ALL). Wolfson J, Grimes A, Nuno M, Ramakrishnan S, Dickens D, Roth M, Woods W, Barnett K, Alabi T, Beauchemin M, Levine J, Scialla M, Boayue K, Kerber C, Ponce O, Vargas S, Chang G, Stock W, Hershman D, Curran E, Advani A, O'Dwyer K, Luger S, Liu J, Freyer D, Sung L, Parsons S. *Journal of Clinical Oncology* Apr 30;9(3):pkaf033, 2025. <https://pubmed.ncbi.nlm.nih.gov/40238217/>

Multiple Studies Influence of Nucleophosmin (NPM1) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration. Tregnago C, Benetton M, Ries RE, Peplinski JH, Alonzo TA, Stirewalt D, Othus M, Duployez N, Sonneveld E, Abrahamsson J, Fogelstrand L, von Neuhoff N, Hasle H, Reinhardt D, Meshinchi S, Locatelli F, Pigazzi M. *Journal of Clinical Oncology* Mar 10;43(8):972-984, 2025. <https://pubmed.ncbi.nlm.nih.gov/39621969/>

N/A Biobanking and consent to future biospecimen use among adults enrolled in SWOG trials from 2000 to 2024. Olivieri DJ, Berridge-Green A, Othus M, Radich JP, Advani AS, Erba HP, Walter RB. *Blood Cancer Journal* May 3;15(1):85, 2025. <https://pubmed.ncbi.nlm.nih.gov/40319052/>

Submitted Manuscripts

None this cycle

Publication List by Committee

LUNG COMMITTEE

Published/Accepted Manuscripts

Lung-MAP Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study. Mack PC, Redman MW, Tukachinsky H, Kozono DE, Minichiello K, Dragnev KH, Tolba KA, Neal JW, Madison RW, Waqar SN, Aggarwal C, Hirsch FR, Patel JD, Herbst RS, Chiang AC, Reckamp KL, Kelly K, Borghaei H, Gray JE, Gandara DR. *Clinical Cancer Research* Jun 4. doi: 10.1158/1078-0432.CCR-24-3658. Online ahead of print. <https://pubmed.ncbi.nlm.nih.gov/40465842/>

Submitted Manuscripts

S1900A S1900A: SQUAMOUS: A phase II study of rucaparib in patients with LOH-positive stage IV NSCLC (Lung-MAP Biomarker-driven sub-study). Homologous Recombination Deficiency (HRD) Phenotypes of non-small cell lung cancer (NSCLC) that are potentially actionable to PARP inhibition identified in Lung-MAP substudy S1900A. Riess J, Miao J, Wheatley-Price P, Reckamp K, Redman M, Kozono D, Edelman M; Faller B, Villaruz L, Corum L, Gowda A, Srkalovic G, Osarogiagbon R, Baumgart M, Sokol E, Schrock A, Madison R, Jin D, Wang S, Waqar S, Stinchcombe T, Borghaei H, Gray J, Herbst R, Gandara D, Kelly K. Submitted, 2025.

S0819 External validation of a novel computed tomography-based prognostic radiomic signature in patients with metastatic non-small cell lung cancer:correlative analysis of SWOG S0819 phase III randomized trial. Dercle L, Gomez D, Zhao B, Hama J, Kelly K, Redman M, Gandara D, Schwartz L, Gray JE. Submitted.

LYMPHOMA COMMITTEE

Published/Accepted Manuscripts

S0016 Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on SWOG S0016. Danilov A, Li H, Shadman M, Rimsza L, Zebari A, Smith S, LeBlanc M, Friedberg J, Carlson C, Song J. *Haematologica*, Jul 3. doi: 10.3324/haematol.2025.288057. Online ahead of print. 2025. <https://pubmed.ncbi.nlm.nih.gov/40605713/>

S1826 Nivolumab-AVD versus brentuximab vedotin-AVD in older patients with advanced stage classic Hodgkin lymphoma. Rutherford S, Li H, Herrera A, LeBlanc M, Ahmed S, Davison K, Parsons S, Unger J, Perry A, Casulo C, Bartlett N, Tusciano J, Hess B, Torka P, Kumar P, Jacobs R, Song J, Castellino S, Kahl B, Leonard J, Smith S, Friedberg J, Evens A. *Journal of Clinical Oncology* Jun 16;JCO2500204, 2025. <https://pubmed.ncbi.nlm.nih.gov/40523203/>

S2308 Ghosh N, Bellasea S, Li H, Olszewski A, Bryan L, Danilov A, Smith S, LeBlanc M, Friedberg JW. SWOG 2308: Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma. *JCO Oncology Advances* Apr;2(1):e2500037, 2025. <https://pubmed.ncbi.nlm.nih.gov/40264918/>

A051301 Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201. Andreadis C, Bobek O, Hsi ED, Fenske TS, Stiff PJ, Hill BT, Geyer SM, Horwitz M, Khimani F, Little RF, Dinner SN, Friedberg JW, Kahl BS, Perales MA, Devine SM, Leonard JP, Bartlett NL. *Leukemia & Lymphoma* Jul 9:1-10, 2025. <https://pubmed.ncbi.nlm.nih.gov/40632607/>

Submitted Manuscripts

S0816 Advanced Stage classical Hodgkin Lymphoma Patients with a Positive Interim-PET (PET-2) Deauville Score 5 After 2 ABVD Cycles: Viviani S, Pavoni S, Barrington S, Guerra L, Schoder H, Johnson P, Kirkwood A, Stephens D, Friedberg J, Chauvie S, Knopp M, Luminari S, Molin D, Corradini P, Gallamini A, Rambaldi A, Tarella C. A Pooled Analysis of Three Multicenter Trials. Submitted, 2025.

S1826 Castellino S, Li H, Herrera A, Punnett A, LeBlanc M, Parsons S, Hodgson D, Keller F, Drachtman R, Lambie A, Forlenza C, Doan A, Rutherford S, Evens A, Little R, Smith M, Hoppe B, Song J, Smith S, Friedberg J, Kelly K. Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Adolescent Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL). Submitted, 2025.

MELANOMA COMMITTEE

Published/Accepted Manuscripts

S1801 Design considerations for randomized comparisons of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy when tumor measurement schedules do not align (SWOG S1801). Othus M, Sharon E, Wu M, Sondak V, Ribas A, Patel S. *Clinical Trials*, Mar 18:17407745251321371, 2025. <https://pubmed.ncbi.nlm.nih.gov/40099861/>

Submitted Manuscripts

S1512 Neoadjuvant PD-1 blockade in patients with surgically resectable desmoplastic 3 melanoma (SWOG S1512 cohort A).. Kendra K, Bellasea S, Eroglu Z, Hu-Lieskovan S, Campbell K, Carson W, Wada D, Plaza J, In G, Ikeguchi A, Hyngstrom J, Brohl A, Bartosz Chmielowski, Nikhil I. Khushalani, Joseph Markowitz, Marcus Monroe, Carlo Contreras,

Publication List by Committee

Egmidio Medina , Gonzalez C, Baselga-Carretero I, Garcilazo I , Vega-Crespo A , Chen J, Al-Deen N , Patel S , Grossmann K, Sondak V , Sharon E , Moon J, Wu M, Ribas A.. Submitted, 2025.

S1512 High response rate with single agent anti-PD-1 therapy in patients with unresectable desmoplastic melanoma (SWOG S1512 cohort B). Kendra K, Bellasea S, Eroglu Z, Hu-Lieskovan S, Campbell K, Carson W, Wada D, Plaza J, Sosman J, In G, Ikeguchi A, Hyngstrom J, Brohl A, Khushalani N, Markowitz J, Negrea G, Kasbari S, Doolittle G, Swami U, Roberts T, Medina E, Baselga-Carretero I, Gonzalez C, Garcilazo I, Vega-Crespo A, JChen J, Al-Deen N, Patel S, Sharon E, Moon J, Wu M, Ribas A. Submitted, 2025.

PHARMACEUTICAL SCIENCES COMMITTEE

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

None this cycle

